Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(496 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
'''Abbreviations'''


{{CMG}}; {{AE}} {{HMHJ}}
ACTH: Adrenocorticotropic hormone, ARR: Aldosterone-renin ratio, CAM: Cellular adhesion molecules, ERCP: Endoscopic retrograde cholangiopancreatography, ESR: Erythrocyte sedimentation rate, CT: Computerized tomography, Fluorescence in situ hybridization, FDG: Fluorodeoxyglucose, FSH: Follicle stimulating hormone, GI: Gastrointestinal, H&E stain: Hematoxylin and eosin stain, LCA: Leukocyte common antigen, LDH: Lactate dehydrogenase, LH: Luteinizing hormone, MEN: Multiple endocrine neoplasia, MRCP: Magnetic resonance cholangiopancreatography, MRI: Magnetic resonance imaging, N/A: Not applicable/Not available, N/L: Normal, PAS stain: Periodic acid–Schiff stain, PET: Position emission tomography, PGP: Protein gene product 9.5, TB: Tuberculosis, U/S: Ultrasound, ZF: Zona fasciculata, ZG: Zona granulosa, ZR: Zona reticularis.
 
==Overview==
{| class="wikitable"
{| class="wikitable"
|+
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Adrenal Cortex
! colspan="5" |Vascular Anomalies
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
|-
!Vascular Tumors
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
! colspan="4" |Vascular Malformations
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|-
|-
| rowspan="2" |Benign
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |Adrenal [[Adrenal adenoma|Adenoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Aldosterone]]<br><ref name="pmid26867466">{{cite journal |vauthors=Park JJ, Park BK, Kim CK |title=Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses |journal=Br J Radiol |volume=89 |issue=1062 |pages=20151018 |date=June 2016 |pmid=26867466 |pmc=5258164 |doi=10.1259/bjr.20151018 |url=}}</ref><ref name="pmid25958045">{{cite journal |vauthors=Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P |title=Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas |journal=Mol. Cell. Endocrinol. |volume=411 |issue= |pages=146–54 |date=August 2015 |pmid=25958045 |pmc=4474471 |doi=10.1016/j.mce.2015.04.022 |url=}}</ref><ref name="pmid20498828">{{cite journal |vauthors=Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD |title=Laboratory investigation of primary aldosteronism |journal=Clin Biochem Rev |volume=31 |issue=2 |pages=39–56 |date=May 2010 |pmid=20498828 |pmc=2874431 |doi= |url=}}</ref><ref name="pmid24605256">{{cite journal |vauthors=Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C |title=Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging |journal=J Clin Imaging Sci |volume=3 |issue= |pages=61 |date=2013 |pmid=24605256 |pmc=3935261 |doi=10.4103/2156-7514.124088 |url=}}</ref>
|
* [[Headache]]
* [[Vision]] problems
* [[Muscle]] [[cramps]]
* [[Muscle]] weakness & [[cramps]]
* [[Numbness]]
* Temporary [[paralysis]]
* [[Polyuria]] and [[polydipsia]]
|
* [[Hypertension]]
* [[Refractory hypertension]]
|
* [[Hypokalemia]]
* [[Alkalosis]]
* ↑ [[Plasma]] [[aldosterone]]
* ↓ [[Plasma]] [[Renin]]
* ↑ ARR
|
* Single or multiple [[nodules]]
* Encapsulated
* Abundant clear [[cytoplasm]]
* Uniforming [[nuclei]]
* [[Histopathology]] may resemble:
** [[Zona fasciculata|ZF]] (large, [[lipid]]-laden clear [[cells]])
** [[Zona fasciculata|ZG]] (small, compact [[cells]] with moderate amount of [[lipid]])
** [[Zona reticularis|ZR]] (lipid-sparse [[cytoplasm]])
|
* [[Fludrocortisone]] suppression testing (Gold standard)
* Oral [[Sodium]] loading
* [[Saline]] infusion testing
* [[Captopril]] test
* [[Adrenal venous sampling]]
* Posture test
* [[Genetic testing]]
* [[Immunohistochemical staining]]
*
|
* [[Adrenal]] [[mass]] or [[nodule]]
|
* [[nodule|Adrenal]] [[mass]] or nodule
* [[nodule|Unilateral or bilateral]] [[adrenal]] [[atrophy]]
* [[nodule|Hypodense]] [[mass]]
|
* Iso and low [[FDG]] uptake compared with [[liver]]
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* [[Glucocorticoid]]-Remediable [[Aldosteronism]] responds to [[glucocorticoids]]
* Higher [[cardiovascular]] and [[cerebrovascular]] [[morbidity]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cortisol]]<br><ref name="pmid26867466">{{cite journal |vauthors=Park JJ, Park BK, Kim CK |title=Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses |journal=Br J Radiol |volume=89 |issue=1062 |pages=20151018 |date=June 2016 |pmid=26867466 |pmc=5258164 |doi=10.1259/bjr.20151018 |url=}}</ref><ref name="pmid18493137">{{cite journal |vauthors=Stratakis CA |title=Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome) |journal=Endocr Dev |volume=13 |issue= |pages=117–32 |date=2008 |pmid=18493137 |pmc=3132884 |doi=10.1159/000134829 |url=}}</ref><ref name="pmid25871963">{{cite journal |vauthors=Zilbermint M, Stratakis CA |title=Protein kinase A defects and cortisol-producing adrenal tumors |journal=Curr Opin Endocrinol Diabetes Obes |volume=22 |issue=3 |pages=157–62 |date=June 2015 |pmid=25871963 |pmc=4560837 |doi=10.1097/MED.0000000000000149 |url=}}</ref><ref name="pmid29685132">{{cite journal |vauthors=Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J |title=ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures |journal=BMC Endocr Disord |volume=18 |issue=1 |pages=22 |date=April 2018 |pmid=29685132 |pmc=5913873 |doi=10.1186/s12902-018-0250-6 |url=}}</ref>
|
* [[Weight]] gain
* [[Growth retardation]]
* [[Headache]]
* [[Amenorrhea]]
* [[Virilization]] (rare)
* [[Acne]]
* Violaceous [[striae]]
* [[Acanthosis nigricans]]
* [[Sleep]] disruption
* [[Mental]] changes
* [[Muscular]] weakneness
|
* [[Hypertension]]
* [[Hirsutism]]
* [[Hypogonadism]]
* [[Growth retardation]]
* [[Facial]] plethora
* [[Acne]]
* [[Striae]]
* [[Bruising]]
* [[Acanthosis nigricans]]
* [[Mental]] changes
* [[Muscular]] weakneness
|
* ↑ [[Plasma]] [[cortisol]]
* ↑ 24 Hour [[urinary]] [[cortisol]]
* ↓ or inappropriately normal [[plasma]] [[ACTH]]
* ↑ [[Blood]] [[glucose]]
|
* Yellow [[fat]]
* Brown [[discoloration]]
* Large [[cells]] with increased [[lipid]] contetnt (''[[zona fasciculata]])''
* May contain [[pigment]] ([[lipofuscin]])
* Adjacent [[Atrophy|atrophied]] [[cells]]
* [[Hemorrhage]] and [[calcification]] (Pre-[[malignant]] [[lesions]])
|
* Diurnal [[plasma]] [[cortisol]] variation
* Low dose and high dose [[dexamethasone suppression test]]
* [[Dexamethasone]]-[[CRH]] test
* Adrenal venous sampling
* [[Genetic testing]]
* [[Immunohistochemical staining]]
* [[Dual energy X-ray absorptiometry|Dual-energy X-ray absorptiometry]]
|
* [[Adrenal]] [[mass]] or [[nodule]]
* ↑ [[Fat]]
|
* [[Adrenal]] [[mass]] or [[nodule]]
* Unilateral or bilateral [[adrenal]] [[atrophy]]
* ↑ [[Fat]]
* Hypodense [[mass]]
|
* Iso and low [[FDG]] uptake compared with [[liver]]
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* Associated with [[Carney complex]]
* Associated with [[Multiple endocrine neoplasia type 1|MEN-1]]
* [[Plasma]] levels of [[cortisol]] and [[ACTH]] may show false positive and false negative results due to normal diurnal [[hormonal]] variation
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Androgens]]<br><ref name="pmid24605256">{{cite journal |vauthors=Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C |title=Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging |journal=J Clin Imaging Sci |volume=3 |issue= |pages=61 |date=2013 |pmid=24605256 |pmc=3935261 |doi=10.4103/2156-7514.124088 |url=}}</ref><ref name="pmid16278716">{{cite journal |vauthors=Arnold DT, Reed JB, Burt K |title=Evaluation and management of the incidental adrenal mass |journal=Proc (Bayl Univ Med Cent) |volume=16 |issue=1 |pages=7–12 |date=January 2003 |pmid=16278716 |pmc=1200803 |doi= |url=}}</ref><ref name="pmid23819074">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J |title=Pure androgen-secreting adrenal adenoma associated with resistant hypertension |journal=Case Rep Endocrinol |volume=2013 |issue= |pages=356086 |date=2013 |pmid=23819074 |pmc=3681270 |doi=10.1155/2013/356086 |url=}}</ref><ref name="pmid30674304">{{cite journal |vauthors=Zhou WB, Chen N, Li CJ |title=A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman |journal=BMC Endocr Disord |volume=19 |issue=1 |pages=14 |date=January 2019 |pmid=30674304 |pmc=6343319 |doi=10.1186/s12902-019-0342-y |url=}}</ref>
|
* [[Hirsutism]]
* [[Virilization]]
* [[Amenorrhea]]
* [[Precocious puberty]]
* [[Testicular]] [[atrophy]] & diminished [[libido]] ([[male]])
|
* [[Clitorimegaly]]
* [[Male]] pattern [[baldness]]
* [[Resistant hypertension]]
* [[Gynecomastia]]
|
* ↑ [[Serum]] [[testosterone]]
* ↑ [[Serum]] [[androstenedione]]
* ↑ [[Serum]] [[dehydroepiandrosterone sulfate]] ([[DHEA-S]])
* ↑ [[Urine]] 17-ketosteroids
* ↑ [[Plasma]] and [[urine]] [[estrogens]]


Locally aggressive or  
*
|
* Pale tan to brown
* Pseudocapsule or the [[fibrous]] [[capsule]]
* Nesting, alveolar, cords, [[trabeculae]]
* [[Eosinophilic]] [[cytoplasm]]
* May see clear, vacuolated [[cytoplasm]]


Borderline
*
 
|
Malignant
* [[FSH]], [[LH]], [[prolactin]] levels
|Simple
* [[Cortisol]] levels
|Combined°
* [[FDG]] [[PET]]/[[CT]]
|of major named vessels
* [[Pelvic]] [[Ultrasound]]
|associated with other anomalies
* [[Adrenal Venous sampling]]
|
* Well-defined
* Solid [[mass]]
|
* Homogeneous enhancement ([[CT]] [[contrast]])
|
* N/A
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* Extremely rare
* Most [[androgen]] secreting [[adenomas]] are mixed [[tumors]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Non-functional<br><ref name="pmid26867466">{{cite journal |vauthors=Park JJ, Park BK, Kim CK |title=Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses |journal=Br J Radiol |volume=89 |issue=1062 |pages=20151018 |date=June 2016 |pmid=26867466 |doi=10.1259/bjr.20151018 |url=}}</ref><ref name="pmid27479926">{{cite journal |vauthors=Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A |title="Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study |journal=Ann. Intern. Med. |volume=165 |issue=8 |pages=533–542 |date=October 2016 |pmid=27479926 |pmc=5453639 |doi=10.7326/M16-0547 |url=}}</ref><ref name="pmid20823463">{{cite journal |vauthors=Nieman LK |title=Approach to the patient with an adrenal incidentaloma |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4106–13 |date=September 2010 |pmid=20823463 |pmc=2936073 |doi=10.1210/jc.2010-0457 |url=}}</ref><ref name="pmid23255953">{{cite journal |vauthors=Li B, Guo Q, Yang H, Guan J |title=Giant non-functional adrenal adenoma: A case report |journal=Oncol Lett |volume=5 |issue=1 |pages=378–380 |date=January 2013 |pmid=23255953 |pmc=3525484 |doi=10.3892/ol.2012.978 |url=}}</ref>
|
* Asymptomatic
* [[Abdominal]] [[pain]]
* [[Abdominal]] distenstion
* [[Nausea]]/[[vomiting]]
* Sub-clinical [[Cushing syndrome]]
* Sub-clinical [[hyperaldosteronism]]
|
* Asymptomatic
* [[Abdominal]] asymmetry
* [[Abdominal]] [[mass]]
* Sub-clinical [[Cushing syndrome]]
* Sub-clinical [[hyperaldosteronism]]
|
* N/L
* ↓ [[Adrenal]] [[hormones]]
* ↑ [[Serum]] [[cortisol]] (sub-clinical)
* ↑ [[Serum]] [[aldosterone]](sub-clinical)
* ↑ [[Serum]] [[androgens]] (sub-clinical)
|
* Well-defined margins
* Large monomorphic [[cells]]
* Abundant/foamy [[cytoplasm]]
* Typically resemble normal [[adrenal]] [[histology]]
* May see [[hemorrhage]] & [[necrosis]]
|
* [[Adrenal]] [[hormones]] levels
* [[Blood]] [[glucose]] level
* [[Plasma]] [[catecholamines]] and [[urinary]] [[metanephrines]]
* ARR
* [[Immunohistochemical staining]]
|
* Solid, well defined [[mass]]
|
* High [[lipid]] content and adjacent compression
|
* N/A
|
* Hyperintense on in-phase and hypointense on oppose-phase
|
* 2-fold increased risk for [[Diabetes mellitus]] in some studies
* Work up must exclude [[Cushing syndrome]], [[pheochromocytoma]] and [[adrenal carcinoma]]
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Adrenal [[Adrenal cancer|Carcinoma]]<br><ref name="pmid20823463">{{cite journal |vauthors=Nieman LK |title=Approach to the patient with an adrenal incidentaloma |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4106–13 |date=September 2010 |pmid=20823463 |pmc=2936073 |doi=10.1210/jc.2010-0457 |url=}}</ref><ref name="pmid26191527">{{cite journal |vauthors=Libé R |title=Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment |journal=Front Cell Dev Biol |volume=3 |issue= |pages=45 |date=2015 |pmid=26191527 |pmc=4490795 |doi=10.3389/fcell.2015.00045 |url=}}</ref><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid24423978">{{cite journal |vauthors=Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD |title=Adrenocortical carcinoma |journal=Endocr. Rev. |volume=35 |issue=2 |pages=282–326 |date=April 2014 |pmid=24423978 |pmc=3963263 |doi=10.1210/er.2013-1029 |url=}}</ref><ref name="pmid24102952">{{cite journal |vauthors=Wang C, Sun Y, Wu H, Zhao D, Chen J |title=Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers |journal=Histopathology |volume=64 |issue=4 |pages=567–76 |date=March 2014 |pmid=24102952 |pmc=4282325 |doi=10.1111/his.12283 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Cortisol]]
* [[Aldosterone]]
* [[Androgens]]
* Non-functional
* [[Erythropoietin]]
|
* Symptoms of [[adrenal]] [[hormones]] excess as mentioned in [[adrenal adenoma]]
* Constitutional [[symptoms]] such as [[cachexia]], [[night sweats]], [[fever]]
* Localized [[symptoms]] such as [[abdominal]] [[pain]], [[mass]], fullness, early [[satiety]]
|
* [[Hypertension]]
* Signs of [[Adrenal gland|adrenal hormones]] excess as mentioned in [[adrenal adenoma]]
* Constitutional
* Localized [[signs]] such as [[abdominal]] [[mass]],[[abdominal]] [[distension]]
|
* N/L
* ↑ [[Serum]] [[cortisol]]
* ↑ [[Serum]] [[aldosterone]]
* ↑ [[Serum]] [[androgens]] 
* [[Hypokalemia]] 
* [[Alkalosis]]
* ↑ ARR
* ↑ [[Blood]] [[glucose]]
|
* Brown to orange to yellow
* [[Necrosis]] & [[mitosis]]
* [[Hypercellular]] & [[solid]] and/or diffuse [[growth]] pattern
* Low to high [[lipid]] content
* [[Nuclear]] [[pleomorphism]]
* Lymphovascular [[invasion]]
|
* [[Serum]] [[ACTH]]
* Low dose and high dose [[dexamethasone suppression test]]
* [[Urinary]] [[adrenal]] [[metabolites]]
* [[Spectroscopy|Proton MR spectroscopy]]
* [<sup>11</sup>C]MTO [[PET]]
* [[Immunohistochemical staining]]
|
* N/A
|
* Heterogeneous enhancement
|
* Heterogeneous mass with intense [[FDG]] uptake greater than [[liver]]
|
* Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted)
|
* May cause [[hypoglycemia]] (Anderson's syndrome}
* May be associated with:
** [[Hyperreninemic hypoaldosteronism|Hyperreninemic]]
** [[Hyperaldosteronism]]
** [[Erythropoietin]]-associated [[polycythemia]]
** [[Leukocytosis]]
|-
|-
|Capillary malformations
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Adrenal [[Adrenal hyperplasia|Hyperplasia]]<br><ref name="pmid25958045">{{cite journal |vauthors=Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P |title=Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas |journal=Mol. Cell. Endocrinol. |volume=411 |issue= |pages=146–54 |date=August 2015 |pmid=25958045 |pmc=4474471 |doi=10.1016/j.mce.2015.04.022 |url=}}</ref><ref name="pmid18493137">{{cite journal |vauthors=Stratakis CA |title=Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome) |journal=Endocr Dev |volume=13 |issue= |pages=117–32 |date=2008 |pmid=18493137 |pmc=3132884 |doi=10.1159/000134829 |url=}}</ref><ref name="pmid24605256">{{cite journal |vauthors=Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C |title=Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging |journal=J Clin Imaging Sci |volume=3 |issue= |pages=61 |date=2013 |pmid=24605256 |pmc=3935261 |doi=10.4103/2156-7514.124088 |url=}}</ref><ref name="pmid16278716">{{cite journal |vauthors=Arnold DT, Reed JB, Burt K |title=Evaluation and management of the incidental adrenal mass |journal=Proc (Bayl Univ Med Cent) |volume=16 |issue=1 |pages=7–12 |date=January 2003 |pmid=16278716 |pmc=1200803 |doi= |url=}}</ref><ref name="pmid23819074">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J |title=Pure androgen-secreting adrenal adenoma associated with resistant hypertension |journal=Case Rep Endocrinol |volume=2013 |issue= |pages=356086 |date=2013 |pmid=23819074 |pmc=3681270 |doi=10.1155/2013/356086 |url=}}</ref><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid28707538">{{cite journal |vauthors=Michelle M A, Jensen CT, Habra MA, Menias CO, Shaaban AM, Wagner-Bartak NA, Roman-Colon AM, Elsayes KM |title=Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics |journal=Br J Radiol |volume=90 |issue=1079 |pages=20170330 |date=November 2017 |pmid=28707538 |pmc=5963387 |doi=10.1259/bjr.20170330 |url=}}</ref><ref name="pmid26770569">{{cite journal |vauthors=Zhang Y, Li H |title=Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease |journal=Int J Clin Exp Med |volume=8 |issue=10 |pages=19311–7 |date=2015 |pmid=26770569 |pmc=4694469 |doi= |url=}}</ref>
Lymphatic malformations
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Cortisol]] (most common)
* [[Aldosterone]]
* [[Androgens]]
* Non-functional
|
* Depending on the product secreted, may present as:
** [[Cushing syndrome]]
** [[Hyperaldosteronism]]
** [[Virilization]]
** [[Hirsutism]]
** [[Menstrual irregularities]]
** [[Testicular]] [[atrophy]]
** Diminished [[libido]]
* Localized [[symptoms]] such as [[abdominal]] [[pain]], [[mass]], [[fullness]], early [[satiety]]
|
* Depending on the product secreted, may present as:
** [[Cushing syndrome]]
** [[Hyperaldosteronism]]
** [[Virilization]]
** [[Hirsutism]]
** [[Menstrual irregularities]]
** [[Testicular]] [[atrophy]]
** [[Gynecomastia]]
* Localized [[symptoms]] such as [[abdominal]] [[pain]], [[mass]], [[fullness]], early [[satiety]]
|
* ↑ [[Serum]] [[cortisol]]
* ↑ [[Serum]] [[aldosterone]]
* ↑ [[Serum]] [[androgens]] 
* [[Hypokalemia]] 
* [[Alkalosis]]
* ↑ ARR
* ↑ [[Blood]] [[glucose]]
* ↑ [[Serum]] [[testosterone]]
* ↑ [[Serum]] [[androstenedione]]
* ↑ [[Serum]] [[dehydroepiandrosterone sulfate]] ([[DHEA-S]])
* ↑ [[Plasma]] and [[urine]] [[estrogens]]
|


Venous malformations
* Diffuse or [[nodular]] enlargement


Arteriovenous malformations*
* Increased thickness of [[zona reticularis]] and [[zona fasciculata]]
 
* Large polygonal [[cells]] with/without [[lipid]] depletion
Arteriovenous fistula*
* May contain [[pigment]] ([[lipofuscin]])
|Capillary venous malformation , Capillary lymphatic malformation
* [[endocrine]] [[atypia]]
Lymphatic venous malformation, Capillary lymphatic venous malformation
* Small [[nodules]]
 
|
Capillary arteriovenous malformation
* [[Adrenal venous sampling]]
 
* [[Pelvic]] & [[pituitary]] [[imaging]]
Capillary lymphatic arteriovenous malformation
* [[Genetic testing]]
 
* [[Fludrocortisone]] suppression testing
others
* [[Saline]] infusion testing
|See details
* Diurnal [[plasma]] [[cortisol]] variation
|See list
* Low dose and high dose [[dexamethasone suppression test]]
|}
* [[FSH]], [[LH]], [[prolactin]] levels
 
* [[Cortisol]] levels
° defined as two or more vascular malformations found in one lesion
|
 
* [[Adrenal]] [[mass]]
<nowiki>*</nowiki> high flow lesions
* Unilateral or bilateral [[adrenal]] enlargement or thickening
 
|
==Classification==
* Unilateral or bilateral [[adrenal]] enlargement or thickening
 
* [[Density]] is same as that of normal [[adrenal gland]]
===Classification of Vascular Malformations===
|
{{Family tree/start}}
* N/A
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | | A01 | | | | | | | | | | | | | | | | | | | | | |A01= Vascular malformations}}
|
{{Family tree | | | | | | | | |,|-|-|-|-|-|-|-|-|-|v|-|-|-|-|-|^|-|-|-|-|-|v|-|-|-|-|-|-|-|-|-|.| | | | | | |}}
* Unilateral or bilateral [[adrenal]] enlargement or thickening
{{Family tree | | | | | | | | B01 | | | | | | | | B02 | | | | | | | | | | B03 | | | | | | | | B04 | | | | | |B01=Simple|B02=Combined|B03=of major named vessels|B04=asscoiated with other anomalies}}
* Signaling is same as that of normal [[adrenal gland]]
{{Family tree | | | | | | | | |!| | | | | | | | | |!| | | | | | | | | | | |!| | | | | | | | | |!| | | | | | |}}
|
{{Family tree | | | | | | | | |!| | | | | | | | | I02 | | | | | | | | | | I03 | | | | | | | | I04 | | | | | | |I02=Combined vascular malformations*
* [[Congenital adrenal hyperplasia]] presents in [[children]]/young adults
<table class="wikitable">
* Associated with [[Carney complex]]
<tr><td>'''CM + VM'''</td><td>Capillary-venous malformation</td><td>CVM</td></tr>
* [[Plasma]] levels of [[cortisol]] and [[ACTH]] may show false positive and false negative results due to normal diurnal [[hormonal]] variation
<tr><td>'''CM + LM'''</td><td>Capillary-lymphatic malformation</td><td>CLM</td></tr>
<tr><td>'''CM + AVM'''</td><td>Capillary-arteriovenous malformation</td><td>CAVM</td></tr>
<tr><td>'''LM + VM'''</td><td>Lymphatic-venous malformation</td><td>LVM</td></tr>
<tr><td>'''CM + LM + VM'''</td><td>Capillary-lymphatic-venous malformation</td><td>CLVM</td></tr>
<tr><td>'''CM + LM + AVM'''</td><td>Capillary-lymphatic-arteriovenous malformation</td><td>CLVM</td></tr>
<tr><td>'''CM + VM + AVM'''</td><td>Capillary-venous-arteriovenous malformation</td><td>CVAVM</td></tr>
<tr><td>'''CM + LM + VM + AVM'''</td><td>Capillary-lymphatic-venous-arteriovenous malformation</td><td>CLVAVM</td></tr>
</table>
|I03='''Anomalies of major named vessels'''<br>(also known as "channel type" or "truncal" vascular malformations)
|I04=Vascular malformations associated with other anomalies
<table class="wikitable">
<tr><td>'''Klippel-Trenaunay syndrome'''</td><td>CM + VM +/-LM + limb overgrowth</td></tr>
<tr><td>'''Parke's Weber syndrome'''</td><td>CM + AVF + limb overgrowth</td></tr>
<tr><td>'''Servelle-Martorell syndrome'''</td><td>Limb VM + bone undergrowth</td></tr>
<tr><td>'''Sturge-Weber syndrome'''</td><td>Facial + leptomeningeal CM + eye anomalies
+/-bone and/or soft tissue overgrowth</td></tr>
<tr><td>'''Maffucci syndrome'''</td><td>VM +/-spindle-cell hemangioma + enchondroma</td></tr>
<tr><td>'''CLOVES syndrome'''</td><td>LM + VM + CM +/-AVM+ lipomatous overgrowth</td></tr>
<tr><td>'''Proteus syndrome'''</td><td>CM, VM and/or LM + asymmetrical somatic overgrowth</td></tr>
<tr><td>'''Bannayan-Riley-Ruvalcaba sd'''</td><td>lower lip CM + face and neck LM + asymmetry and partial/generalized overgrowth</td></tr>
<tr><td>'''Limb CM + congenital non-progressive limb overgrowth'''</td><td></td></tr>
<tr><td>'''Macrocephaly-CM (M-CM / MCAP)'''</td><td></td></tr>
<tr><td>'''Microcephaly-CM (MICCAP)'''</td><td></td></tr>
</table>
|}}
{{Family tree | | | |,|-|-|-|-|+|-|-|-|-|v|-|-|-|-|v|-|-|-|-|.| | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | | C01 | | | C02 | | | C03 | | | C04 | | | C05 | | | | | | | | | | | | | | | | | | | | | | |C01=Capillary malformations|C02=Lymphatic malformations|C03=Venous malformations|C04=Arteriovenous malformations|C05=Arteriovenous fistula}}
{{Family tree | | |!| | | | |!| | | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |)| D01 | |)| E01 | |)| F01 | |)| G01 | |)| H01 | | | | | | | | | | | | | | | | | | | | | |D01=Nevus simplex / salmon patch, “angel kiss”, “stork bite”|E01=Common (cystic) LM <br>Macrocystic  LM <br>Microcystic  LM <br>Mixed cystic LM|F01=Common VM|G01=Sporadic|H01=Sporadic}}
{{Family tree | | |!| | | | |!| | | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |)| D02 | |)| E02 | |)| F02 | |)| G02 | |)| H02 | | | | | | | | | | | | | | | | | | | | | |D02=Cutaneous and/or mucosal CM (also known as “port-wine” stain) <br>Nonsyndromic CM <br>CM with CNS and/or ocular anomalies (Sturge-Weber syndrome) <br>CM with bone and/or soft tissues overgrowth <br>Diffuse CM with overgrowth (DCMO)|E02=Generalized lymphatic anomaly (GLA) <br>Kaposiform lymphangiomatosis (KLA)|F02=Familial VM cutaneo-mucosal (VMCM)|G02=In HHT|H02=In HHT|}}
{{Family tree | | |!| | | | |!| | | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |)| D03 | |)| E03 | |)| F03 | |)| G03 | |)| H03 | | | | | | | | | | | | | | | | | | | | | |D03=Reticulate CM <br>CM of MIC-CAP (microcephaly-capillary malformation) <br>CM of MCAP (megalencephaly-capillary malformation-polymicrogyria)|E03=LM in Gorham-Stout disease|F03=Blue rubber bleb nevus (Bean) syndrome VM|G03=In CM-AVM|H03=In CM-AVM|}}
{{Family tree | | |!| | | | |!| | | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |)| D04 | |)| E04 | |)| F04 | |`| G04 | |`| H04 | | | | | | | | | | | | | | | | | | | | | |D04=CM of CM-AVM|E04=Channel type LM|F04=Glomuvenous malformation (GVM)|G04=Others|H04=Others|}}
{{Family tree | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |)| D05 | |)| E05 | |)| F05 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |D05=Cutis marmorata telangiectatica congenita (CMTC)|E05=“Acquired” progressive lymphatic anomaly (so called acquired progressive "lymphangioma")|F05=Cerebral cavernous malformation (CCM) |}}
{{Family tree | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |)| D06 | |)| E06 | |)| F06 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |D06=Others|E06=Primary lymphedema |F06=Familial intraosseous vascular malformation (VMOS)|}}
{{Family tree | | |!| | | | |!| | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | |`| D07 | |`| E07 | |)| F07 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |D07=Telangiectasia <br>Hereditary hemorrhagic telangiectasia (HHT) <br>Others|E07=Others|F07=Verrucous venous malformation (formerly verrucous hemangioma)|}}
{{Family tree | | | | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | | | | | | | | | | | |`| F08 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |F08=Others|}}
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |}}
{{Family tree/end}}
 
===Tables===
{| class="wikitable" style="text-align:left"
|+
|+
!Anomalies of major named vessels
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Medulla
(also known as "channel type" or "truncal" vascular malformations)
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
|-
|Affect
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
  lymphatics
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
  veins
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
  arteries
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
 
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
Anomalies of
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
  origin
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
  course
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
  number
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
  length
  diameter (aplasia, hypoplasia, stenosis, ectasia / aneurysm)
  valves
  communication (AVF)
  persistence (of embryonal vessel)
|}
 
{|class="wikitable"
! colspan="3" |Combined vascular malformations*
|-
|-
|CM + VM
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Pheochromocytoma]]<br><ref name="pmid24636754">{{cite journal |vauthors=Martucci VL, Pacak K |title=Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment |journal=Curr Probl Cancer |volume=38 |issue=1 |pages=7–41 |date=2014 |pmid=24636754 |pmc=3992879 |doi=10.1016/j.currproblcancer.2014.01.001 |url=}}</ref><ref name="pmid20541673">{{cite journal |vauthors=Kantorovich V, Pacak K |title=Pheochromocytoma and paraganglioma |journal=Prog. Brain Res. |volume=182 |issue= |pages=343–73 |date=2010 |pmid=20541673 |pmc=4714594 |doi=10.1016/S0079-6123(10)82015-1 |url=}}</ref><ref name="pmid19605896">{{cite journal |vauthors=Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV |title=Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus) |journal=Vet. Pathol. |volume=46 |issue=6 |pages=1221–9 |date=November 2009 |pmid=19605896 |doi=10.1354/vp.09-VP-0022-M-FL |url=}}</ref><ref name="pmid19120142">{{cite journal |vauthors=Kantorovich V, Eisenhofer G, Pacak K |title=Pheochromocytoma: an endocrine stress mimicking disorder |journal=Ann. N. Y. Acad. Sci. |volume=1148 |issue= |pages=462–8 |date=December 2008 |pmid=19120142 |pmc=2693284 |doi=10.1196/annals.1410.081 |url=}}</ref><ref name="pmid25332315">{{cite journal |vauthors=Eisenhofer G, Peitzsch M |title=Laboratory evaluation of pheochromocytoma and paraganglioma |journal=Clin. Chem. |volume=60 |issue=12 |pages=1486–99 |date=December 2014 |pmid=25332315 |doi=10.1373/clinchem.2014.224832 |url=}}</ref>
|capillary-venous malformation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
|CVM
* [[Catecholamines]]
|
*[[Headaches]]
*[[Palpitations]]
*Excessive [[sweating]]
*[[Anxiety]]
*[[Pallor]]
*Pain in [[chest]]/[[abdomen]]
*[[Weakness]], [[fatigue]]
*[[Nausea]]/[[vomiting]]
*[[Dizziness]]
*[[Paresthesias]]
*[[Constipation]] (rarely [[diarrhea]])
*[[Visual disturbance]]
|
*[[Hypertension]]
*Postural [[hypotension]]
*[[Tachycardia]] or reflex [[bradycardia]]
*Tremulousness
*[[Pallor]]
*[[Flushing]] (rare)
*[[Weight]] loss
*Fasting [[hyperglycaemia]]
*Decreased [[GI]] [[motility]]
*[[Pallor]]
*↑ [[Respiratory rate]]
*[[Psychosis]]
|
* ↑ [[Plasma]] and [[urine]] [[catecholamines]] (Gold standard)
* ↑ [[Plasma]] and [[urine]] [[metanephrines]] (Gold standard)
* ↑ [[Chromogranin A]]
* ↑ [[Plasma]] [[methoxytyramine]]
|
*Loosely cohesive clusters
*Scattered [[tumor]] [[cells]] with prominent anisokaryosis, abundant [[eosinophilic]] granular [[cytoplasm]] and indistinct [[cell]] borders
*Occasional bi-nucleate [[cells]]
|
*Genetic testing
*Provacative [[glucagon]] test
*[[Clonidine]] suppression test
*Metaiodobenzyl-guanidine [[scintigraphy]]
*[[PET]] scan
*[[Octereoscan]]
|
*[[Cystic]] or solid with [[necrotic]] areas or [[hemorrhages]]
|
* Heterogeneous appearance, often with some [[cystic]] areas.
* [[Calcification]] or [[hemorrhage]] may also be present
|
* N/A
|
* T2-bright lesions, with/without [[cystic]] or [[necrotic]] components
|
*May mimic [[panic attack]]
*May be associated with  [[Von Hippel-Lindau disease]],  [[MEN type 2]] and [[neurofibromatosis type 1]].
*Arise from the [[chromaffin cells]]
*[[Stain|Stains]] positive for
** [[Chromogranin A]] (CGA)
** Protein gene product (PGP) 9.5
** [[Synaptophysin]] (SYN)
** [[CD56]] ([[CAM|N-CAM]])
** [[Glial fibrillary acidic protein]] ([[GFAP]])
|-
|-
|CM + LM
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Neuroblastoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid25154816">{{cite journal |vauthors=Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG |title=Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project |journal=J. Clin. Oncol. |volume=32 |issue=28 |pages=3169–76 |date=October 2014 |pmid=25154816 |pmc=4171360 |doi=10.1200/JCO.2014.56.1621 |url=}}</ref><ref name="pmid25254086">{{cite journal |vauthors=Bordbar M, Tasbihi M, Kamfiroozi R, Haghpanah S |title=Epidemiological and clinical characteristics of neuroblastoma in southern iran |journal=Iran J Ped Hematol Oncol |volume=4 |issue=3 |pages=89–96 |date=2014 |pmid=25254086 |pmc=4173027 |doi= |url=}}</ref><ref name="pmid24563879">{{cite journal |vauthors=Skoura E, Oikonomopoulos G, Vasileiou S, Kyprianou D, Koumakis G, Datseris IE |title=(18)F-FDG-PET/CT, (123)I-MIBG and (99m)Tc-MDP whole-body scans, in detecting recurrence of an adult adrenal neuroblastoma |journal=Hell J Nucl Med |volume=17 |issue=1 |pages=58–61 |date=2014 |pmid=24563879 |doi=10.1967/s002449910116 |url=}}</ref>
|capillary-lymphatic malformation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
|CLM
* [[Catecholamines]]
|
* Constitutional
* Failure to thrive
* [[Abdominal]] [[pain]]
* [[Diarrhea]]
* [[Constipation]]
* [[Dyspnea]]
* Prolonged [[cough]]
* [[Strabismus]]
* [[Proptosis]]
|
* [[Abdominal]] [[mass]]
* [[Pallor]]
* [[Tachycardia]]
* [[Hypertension]]
* Failure to thrive
* [[Strabismus]]
* [[Proptosis]]
|
* N/L
* Slight elevation in [[catecholamines]]
* ↑ [[Urinary]] [[metanephrines]]
* [[Anemia]]
* ↑ [[Ferritin]]
* ↑ [[LDH]]
* [[Thrombocytosis]]
|
* Pathological examinations are gold standard.
* Cells may show:
** Undifferentiation
** Poor differentiation
** Differentiating [[neuroblasts]]
* [[Necrosis]]
* Salt and pepper [[chromatin]]
* [[Spindle]]-like [[fibers]]
|
* [[Immunohistochemical staining]]
* [[PET]] scan
*[[Octereoscan]]
*<sup>131</sup>I-metaiodobenzylguanidine (MIBG) [[scintigraphy]]
*[[FISH]]
*[[Genetic testing]]
|
* Large mass
* May cross midline
|
* Large mass extending across the midline
* Heterogeneous enhancement
* [[Calcification]] & [[hemorrhage]]
|
* N/A
|
* [[Calcification]] & [[hemorrhage]]
* Non-homogeneous and hyperintense
* Hypointense (T1-weighted)
|[[Stain|Stains]] positive for:
* [[Chromogranin A]] (CGA)
* Protein gene product (PGP) 9.5
* [[Neuron-specific enolase]]
* [[Synaptophysin]] ([[Synaptophysin|SYN]])
* [[CD56]] & [[CD57]]
* [[Glial fibrillary acidic protein]] ([[GFAP]])
 
*
|-
|-
|CM + AVM
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ganglioneuroma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid29085827">{{cite journal |vauthors=Mylonas KS, Schizas D, Economopoulos KP |title=Adrenal ganglioneuroma: What you need to know |journal=World J Clin Cases |volume=5 |issue=10 |pages=373–377 |date=October 2017 |pmid=29085827 |pmc=5648998 |doi=10.12998/wjcc.v5.i10.373 |url=}}</ref><ref name="pmid24779851">{{cite journal |vauthors=Adas M, Koc B, Adas G, Ozulker F, Aydin T |title=Ganglioneuroma presenting as an adrenal incidentaloma: a case report |journal=J Med Case Rep |volume=8 |issue= |pages=131 |date=April 2014 |pmid=24779851 |pmc=4031973 |doi=10.1186/1752-1947-8-131 |url=}}</ref><ref name="pmid23661526">{{cite journal |vauthors=Li J, Yang CH, Li LM |title=Diagnosis and treatment of 29 cases of adrenal ganglioneuroma |journal=Eur Rev Med Pharmacol Sci |volume=17 |issue=8 |pages=1110–3 |date=April 2013 |pmid=23661526 |doi= |url=}}</ref>
|capillary-arteriovenous malformation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
|CAVM
* [[Catecholamines]]
* [[VIP]]
* [[Cortisol]]
* [[Androgens]]
|
* Asymptomatic
* [[Abdominal]] [[pain]]
* [[Diarrhea]]
|
* N/L
* [[Abdominal]] [[mass]]
* [[Hypertension]]
|
* N/L
* ↑ [[Plasma]] and [[urinary]] [[catecholamine]]
* ↑ [[VIP]]
* ↑ [[Cortisol]] and [[testosterone]]
|
* Pathological examinations are gold standard.
* Mature type: mature [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]]
* Maturing type: [[Schwann cells]], [[ganglion cells]] and peri-[[neural]] [[cells]] with varying [[maturation]]
|
* Pathological examinations are gold standard.
* [[Ultrasound]]
* [[Immunohistochemical staining]]
* <sup>18</sup>F-2-fluoro-deoxy-D-glucose-[[positron emission tomography]] ([[PET]])
|
* N/A
|
* Well-defined, Homogeneous
* Punctate or discrete [[calcification]]
|
* N/A
|
* Hypointense (T1-weighted)
* Varied signal (T2-weighted)
|
[[Stain|Stains]] positive for:
* [[S-100|S100]]
* [[Synaptophysin]]
* [[Neurofilament]] ([[NF]]) [[protein]]
* [[Chromogranin A]]
* [[Glial fibrillary acidic protein]]
* PGP 9.5
* [[Type IV collagen]]
* [[VIP]]
|+
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Stroma
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
|-
|LM + VM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
|lymphatic-venous malformation
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
|LVM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|+
|-
|-
|CM + LM + VM
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lipoma]]/[[Myolipoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid11533079">{{cite journal |vauthors=Lam KY, Lo CY |title=Adrenal lipomatous tumours: a 30 year clinicopathological experience at a single institution |journal=J. Clin. Pathol. |volume=54 |issue=9 |pages=707–12 |date=September 2001 |pmid=11533079 |pmc=1731508 |doi= |url=}}</ref><ref name="pmid24328509">{{cite journal |vauthors=Gershuni VM, Bittner JG, Moley JF, Brunt LM |title=Adrenal myelolipoma: operative indications and outcomes |journal=J Laparoendosc Adv Surg Tech A |volume=24 |issue=1 |pages=8–12 |date=January 2014 |pmid=24328509 |pmc=3931430 |doi=10.1089/lap.2013.0411 |url=}}</ref><ref name="pmid26464739">{{cite journal |vauthors=Luo J, Chen L, Wen Q, Xu L, Chu S, Wang W, Alnemah MM, Fan S |title=Lipoadenoma of the adrenal gland: report of a rare entity and review of literature |journal=Int J Clin Exp Pathol |volume=8 |issue=8 |pages=9693–7 |date=2015 |pmid=26464739 |pmc=4583971 |doi= |url=}}</ref>
|capillary-lymphatic-venous malformation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
|CLVM
* N/A
|
* Asymptomatic
* [[Abdominal]] [[pain]]
* Back [[pain]]
* [[Fever]]
|
* N/L
* [[Abdominal]] [[mass]]
* [[Fever]]
|
* N/L
|
* Pathological examinations are gold standard.
* Yellow [[adipose tissue]]
* [[Hemorrhagic]] foci
* Islands of [[Hematopoiesis lineages|hematopoietic cells]] ([[myolipoma]]) and mature [[fat cells]] ([[Lipoma]])
|
* [[Renal function tests|RFTs]]
* [[LFTs]]
* [[Urinalysis|Urine analysis]]
* [[Ultrasound]]
|
* Heterogeneous [[mass]]
|
* [[Retro-peritoneal]] [[mass]]
* Well-defined heterogenous enhancement
|
* N/A
|
* High signal
|
* [[Myolipoma]]: mature [[adipose tissue]] and [[haematopoietic]]  elements
* [[Lipoma]]: mature [[fat cells]]
|+
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Product
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical manifestations
! colspan="7" style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnosis
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Other features
|-
|-
|CM + LM + AVM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptoms
|capillary-lymphatic-arteriovenous malformation
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Signs
|CLAVM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Blood & Urine
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Histopathological
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Others
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Ultrasound
! style="background:#4479BA; color: #FFFFFF;" align="center" + |CT scan
! style="background:#4479BA; color: #FFFFFF;" align="center" + |FDG PET/CT
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MRI
|-
|-
|CM + VM + AVM
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tuberculosis]]<br><ref name="pmid27006656">{{cite journal |vauthors=Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG |title=Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test |journal=Int J Endocrinol |volume=2016 |issue= |pages=9051865 |date=2016 |pmid=27006656 |pmc=4781954 |doi=10.1155/2016/9051865 |url=}}</ref><ref name="pmid15451821">{{cite journal |vauthors=Haddara WM, van Uum SH |title=TB and adrenal insufficiency |journal=CMAJ |volume=171 |issue=7 |pages=710; author reply 710–1 |date=September 2004 |pmid=15451821 |pmc=517840 |doi=10.1503/cmaj.1041046 |url=}}</ref><ref name="pmid26516430">{{cite journal |vauthors=Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW |title=Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status |journal=World J Radiol |volume=7 |issue=10 |pages=336–42 |date=October 2015 |pmid=26516430 |pmc=4620114 |doi=10.4329/wjr.v7.i10.336 |url=}}</ref><ref name="pmid28233510">{{cite journal |vauthors=Vinnard C, Blumberg EA |title=Endocrine and Metabolic Aspects of Tuberculosis |journal=Microbiol Spectr |volume=5 |issue=1 |pages= |date=January 2017 |pmid=28233510 |doi=10.1128/microbiolspec.TNMI7-0035-2016 |url=}}</ref><ref name="pmid23687365">{{cite journal |vauthors=Rajasekharan C, Ajithkumar S, Anto V, Parvathy R |title=Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine |journal=BMJ Case Rep |volume=2013 |issue= |pages= |date=May 2013 |pmid=23687365 |doi=10.1136/bcr-2012-008011 |url=}}</ref>
|capillary-venous-arteriovenous malformation
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
|CVAVM
* N/A
|
* [[Weakness]]
* [[Malaise]]
* [[Nausea]]
* [[Fatigue]]
* [[Anorexia]]
* [[Abdominal]] [[pain]]
* [[Orthostatic hypotension]]
* [[Constipation]]
* [[Salt]] craving
* [[Adrenal crisis]]
* [[Symptoms]] of [[pulmonary]] [[TB]]
|
* [[Weight loss]]
* [[Hyperpigmentation]] of the [[skin]]
* [[Fever]]
* [[Hypotension]]
* [[Adrenal crisis]]
* [[Signs]] of [[pulmonary tuberculosis]]
|
* [[Anemia]]
* [[Leukocytosis]]
* [[Hyponatremia]]
* [[Hyperkalemia]]
* [[Hypoglycemia]]
* Low early morning [[serum]] [[cortisol]] levels
* Low basal [[urinary]] [[cortisol]]
* ↑ [[ACTH]]
* ↓ [[Aldosterone]]
* ↑ [[Plasma]] [[renin]]
|
* Enlarged, [[necrotic]] [[adrenal glands]]
* Central [[caseous necrosis]]
* Rim of [[granulomatous]] [[inflammatory cells]] ([[Langerhans giant cells]] and [[lymphocytes]])
* Identifiable [[Acid fast|acid-fast stain]]-positive [[bacteria]] with [[Ziehl-Neelsen stain|Ziehl-Neelsen]] or [[Immunofluorescence|fluorescent stains]]
|
* [[Laparoscopic]] [[adrenalectomy]]
* [[Chest X-ray]]
* [[Chest]] [[CT scan]]
* [[Tuberculin test]]
* [[ACTH]] stimulation test
* [[Insulin]] induced [[hypoglycemia]]
* [[Metyrapone]] stimulation tests
|
* Variable
|
* [[Calcification]]
* Hypodense areas
* Rim enhancement
|
* High [[FDG]] uptake by [[adrenal glands]]
|
* [[Calcification]]
* Variable signals
|
* Majority of the cases are secondary to:
** [[Pulmonary TB]]
** [[Genitourinary]] [[TB]]
** [[HIV]] [[infection]]
* May present with [[shock]] with severe [[hypotension]] and [[hypoglycemia]] due to [[glucocorticoid]] insufficiency
|-
|-
|CM + LM + VM + AVM
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Histoplasmosis]]<br><ref name="pmid27995051">{{cite journal |vauthors=Rog CJ, Rosen DG, Gannon FH |title=Bilateral adrenal histoplasmosis in an immunocompetent man from Texas |journal=Med Mycol Case Rep |volume=14 |issue= |pages=4–7 |date=December 2016 |pmid=27995051 |pmc=5154969 |doi=10.1016/j.mmcr.2016.11.006 |url=}}</ref><ref name="pmid27047312">{{cite journal |vauthors=Wahab NA, Mohd R, Zainudin S, Kamaruddin NA |title=Adrenal involvement in histoplasmosis |journal=EXCLI J |volume=12 |issue= |pages=1–4 |date=2013 |pmid=27047312 |pmc=4817423 |doi= |url=}}</ref><ref name="pmid29888193">{{cite journal |vauthors=May D, Khaled D, Gills J |title=Unilateral adrenal histoplasmosis |journal=Urol Case Rep |volume=19 |issue= |pages=54–56 |date=July 2018 |pmid=29888193 |pmc=5991316 |doi=10.1016/j.eucr.2018.03.010 |url=}}</ref><ref name="pmid29643659">{{cite journal |vauthors=Gupta RK, Majumdar K, Srivastava S, Varakanahalli S, Saran RK |title=Endoscopic Ultrasound-guided Cytodiagnosis of Adrenal Histoplasmosis with Reversible CD4 T-Lymphocytopenia and Jejunal Lymphangiectasia |journal=J Cytol |volume=35 |issue=2 |pages=110–113 |date=2018 |pmid=29643659 |pmc=5885598 |doi=10.4103/JOC.JOC_234_15 |url=}}</ref><ref name="pmid25027093">{{cite journal |vauthors=Padma S, Sreehar S |title=18F FDG PET/CT identifies unsuspected bilateral adrenal histoplasmosis in an elderly immuno compromised patient |journal=Indian J. Med. Res. |volume=139 |issue=5 |pages=786–7 |date=May 2014 |pmid=25027093 |pmc=4140048 |doi= |url=}}</ref>
|capillary-lymphatic-venous-arteriovenous m.
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
|CLVAVM
* N/A
|}
|
* No [[adrenal]] s[[ymptoms]]
* [[Adrenal insufficiency]]:
** [[Weakness]] & [[malaise]]
** [[Nausea]], [[fatigue]] and [[anorexia]]
** [[Abdominal]] [[pain]]
** [[Orthostatic hypotension]]
** [[Constipation]]
** [[Salt]] craving
* [[Symptoms]] of [[pulmonary]]/[[skin]]/[[bone]] [[histoplasmosis]]
|
* [[Weight loss]]
* [[Hyperpigmentation]] of the [[skin]]
* [[Fever]]
* [[Hypotension]]
* [[Adrenal crisis]]
* [[Signs]] of [[pulmonary]]/[[skin]]/[[bone]] [[histoplasmosis]]
|
* [[Anemia]]
* [[Leukocytosis]]
* [[Hyponatremia]]
* [[Hyperkalemia]]
* [[Hypoglycemia]]


 
* Low early morning [[serum]] [[cortisol]] levels
{| class="wikitable" style="text-align:center"
* Low basal [[urinary]] [[cortisol]]
! colspan="3" |Vascular malformations associated with other anomalies
* ↑ [[ACTH]]
* ↓ [[Aldosterone]]
* ↑ [[Plasma]] [[renin]]
|
* [[Necrotizing]] [[granulomatous]] [[inflammation]] similar to [[tuberculosis]]
* [[Capsulated]] [[yeast]] forms of ''[[Histoplasma]]'' ([[Giemsa stain]])
* ''[[Histoplasma]]'' identification ([[H&E stain]])
* Focal ovoid bodies with a clear halo ([[PAS stain]])
|
* [[Ultrasound]]-guided [[fine needle aspiration]] [[cytology]] ([[Ultrasound|USG]]-[[FNA|FNAC]]) is gold standard.
* [[Laparoscopic]] [[adrenalectomy]]
* [[Endoscopic ultrasound]]
* [[Ultrasound|Abdominal ultrasound]]
* [[Chest X-ray]]
* [[ACTH]] stimulation test
* [[Metyrapone]] stimulation tests
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
* Heterogeneous enhancement
|
* Abnormal [[FDG]] uptake by [[adrenal glands]]
|
* Enlarged [[adrenal glands]]
* [[Calcification]]
* Isointense [[adrenal]] [[mass]] ([[MRI]])
|
* [[Patient]] may exhibit no [[clinical manifestations]] of [[adrenal]] involvement
* Majority of the cases are secondary to:
** [[Pulmonary]] [[histoplasmosis]]
** [[HIV]] [[infection]]
* May present with [[shock]] with severe [[hypotension]] and [[hypoglycemia]] due to [[glucocorticoid]] insufficiency
|-
|-
| colspan="2" |Klippel-Trenaunay syndrome *
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cysts]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid28246490">{{cite journal |vauthors=Carsote M, Ghemigian A, Terzea D, Gheorghisan-Galateanu AA, Valea A |title=Cystic adrenal lesions: focus on pediatric population (a review) |journal=Clujul Med |volume=90 |issue=1 |pages=5–12 |date=2017 |pmid=28246490 |doi=10.15386/cjmed-677 |url=}}</ref><ref name="pmid26807295">{{cite journal |vauthors=Słapa RZ, Jakubowski WS, Dobruch-Sobczak K, Kasperlik-Załuska AA |title=Standards of ultrasound imaging of the adrenal glands |journal=J Ultrason |volume=15 |issue=63 |pages=377–87 |date=December 2015 |pmid=26807295 |pmc=4710689 |doi=10.15557/JoU.2015.0035 |url=}}</ref><ref name="pmid29881567">{{cite journal |vauthors=Olaoye IO, Adesina MD, Afolayan EA |title=A giant adrenal cyst with an uncertain preoperative diagnosis causing a dilemma in management |journal=Clin Case Rep |volume=6 |issue=6 |pages=1074–1076 |date=June 2018 |pmid=29881567 |pmc=5986023 |doi=10.1002/ccr3.1519 |url=}}</ref>
|CM + VM +/-LM + limb overgrowth
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* [[Abdominal]] [[pain]]
* [[Abdominal Aortic Aneurysm|Abdominal]] [[mass]]
* [[Abdominal]] fullness
* [[Hematuria]]
* [[Infection]]
* [[Symptoms]] of [[malignancy]] ([[Cystic]] part of other [[tumors]])
|
* [[Abdominal]] [[mass]] & assymetry
* [[Fever]]
* [[Hypertension]] ([[Renal]] compression)
* [[Hypotension]] ([[Hemorrhage]] into [[cyst]])
* [[Signs]] of [[malignancy]] ([[Cystic]] part of other [[tumors]])
|
* N/L
* [[Anemia]]
* [[Leukocytosis]]
|
* [[Vascular]] or [[endothelial]] [[cyst]]: lined by flattened [[endothelial cells]]
* [[Epithelial]]: lined by [[epithelium]]
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* [[Hydatid cyst]]: 3 layers (germinal layer, laminated [[membrane]] and dense [[fibrovascular tissue]])
|
* Complete [[endocrine]] panel
* [<sup>18</sup>F][[FDG]] [[PET]]/[[CT]] (if [[malignancy]] is suspected)
* [[Biopsy]] (if [[malignancy]] is suspected)
* [[ACTH]] stimulation test
|
* Gold standard
* Circumscribed anechoic or hypoechoic mass
|
* Homogeneous [[mass]]
* No enhancement
* [[Calcification]]
* Low density
|
* N/A
|
* High signal
|
* 3 major subtypes
** Pure [[cysts]] ([[vascular]] or [[endothelial]] [[cyst]], [[pseudocyst]] and 'true' [[epithelial]] [[cysts]])
** [[Parasitic cysts]]
** [[Cystic]] part of an otherwise solid [[tumor]]
|-
|-
| colspan="2" |Parkes Weber syndrome
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hematoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid14747454">{{cite journal |vauthors=Hamilton D, Harris MD, Foweraker J, Gresham GA |title=Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection |journal=J. Clin. Pathol. |volume=57 |issue=2 |pages=208–9 |date=February 2004 |pmid=14747454 |pmc=1770213 |doi= |url=}}</ref><ref name="pmid28828107">{{cite journal |vauthors=Di Serafino M, Severino R, Coppola V, Gioioso M, Rocca R, Lisanti F, Scarano E |title=Nontraumatic adrenal hemorrhage: the adrenal stress |journal=Radiol Case Rep |volume=12 |issue=3 |pages=483–487 |date=September 2017 |pmid=28828107 |pmc=5551907 |doi=10.1016/j.radcr.2017.03.020 |url=}}</ref><ref name="pmid29770310">{{cite journal |vauthors=Ierardi AM, Petrillo M, Patella F, Biondetti P, Fumarola EM, Angileri SA, Pesapane F, Pinto A, Dionigi G, Carrafiello G |title=Interventional radiology of the adrenal glands: current status |journal=Gland Surg |volume=7 |issue=2 |pages=147–165 |date=April 2018 |pmid=29770310 |pmc=5938278 |doi=10.21037/gs.2018.01.04 |url=}}</ref>
|CM + AVF + limb overgrowth
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* [[Flank]]/back [[pain]]
* [[Weakness]]
* [[Hypovolemic shock]]
* [[Adrenal crisis]] (massive [[hemorrhage]])
* [[Adrenal insufficiency]]
* [[Symptoms]] of underlying [[cause]]
|
* [[Hypotension]]
* [[Abdominal]]/[[flank]] [[mass]]
* [[Hypovolemic shock]]
* [[Adrenal crisis]] (massive [[hemorrhage]])
* [[Adrenal insufficiency]]
* [[Signs]] of underlying cause
|
* [[Anemia]]
* ↓ [[Serum]] and [[urinary]] [[Adrenal Gland|adrenal hormones]] and [[metabolites]]
* Findings related to underlying cause
|
* [[Pseudocyst]]: lined by [[fibrous tissue]]
* Findings related to underlying cause
|
* [[Adrenal]] [[ultrasound]]
* [[ACTH]] stimulation test
* Tests related to underlying cause
|
* Variable
|
* High density (acute [[hemorrhage]])
|
* N/A
|
* Isointense and low signal (Early [[hemorrhage]])
* Hypointense (Late [[hemorrhage]])
|
* Majority of the cases in [[neonantal]] peiod
* Majority of the cases caused by [[trauma]]
|-
|-
| colspan="2" |Servelle-Martorell syndrome
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemangioma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid22701011">{{cite journal |vauthors=Alhajri K, Alhasan I, Alzerwi N, Abudaff N |title=Adrenal haemangioma |journal=BMJ Case Rep |volume=2011 |issue= |pages= |date=April 2011 |pmid=22701011 |pmc=3079485 |doi=10.1136/bcr.12.2010.3604 |url=}}</ref><ref name="pmid29560018">{{cite journal |vauthors=Iwamoto G, Shimokihara K, Kawahara T, Takamoto D, Yao M, Teranishi JI, Otani M, Uemura H |title=Adrenal Hemangioma: A Case of Retroperitoneal Tumor |journal=Case Rep Med |volume=2018 |issue= |pages=8796327 |date=2018 |pmid=29560018 |pmc=5836307 |doi=10.1155/2018/8796327 |url=}}</ref><ref name="pmid26600897">{{cite journal |vauthors=Tarchouli M, Boudhas A, Ratbi MB, Essarghini M, Njoumi N, Sair K, Zentar A |title=Giant adrenal hemangioma: Unusual cause of huge abdominal mass |journal=Can Urol Assoc J |volume=9 |issue=11-12 |pages=E834–6 |date=2015 |pmid=26600897 |pmc=4639440 |doi=10.5489/cuaj.2967 |url=}}</ref>
|limb VM + bone undergrowth
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* [[Cortisol]] (rare)
* [[Aldosterone]] (rare)
* [[Androgens]] (rare)
|
* [[Abdominal]] [[mass]] & discomfort
* [[Nausea]] & [[vomiting]]
* Back [[pain]]
* [[Hypovolemic shock]] ([[hemorrhage]])
* [[Symptoms]] of [[hormonal]] excess (very rare)
|
* [[Abdominal]] [[mass]]
* [[Hypovolemic shock]] ([[hemorrhage]])
* [[Symptoms]] of [[hormonal]] excess (very rare)
|
* N/L
* [[Anemia]] ([[hemorrhage]])
* ↑ [[Serum]] and [[urinary]] [[Adrenal gland|adrenal hormones]] and [[metabolites]] (very rare)
|
* [[Histopathology]] is gold standard
* Most often [[cavernous]]
* Peripheral dilated [[vascular]] spaces
* Monostromatic [[endothelium]]
* Absence of [[atypia]]
* Central [[necrosis]]
* [[Calcification]]
* [[Hemorrhage]]
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[FDG]]-[[PET]] scan
* [[Endoscopic ultrasound]]
* Post-[[resection]] [[biopsy]] (if [[malignancy]] is suspected)
|
* [[Calcification]]
* [[Phleboliths]]
|
* [[Calcification]]
* [[Phleboliths]]
* Irregular peripheral enhancement
|
* N/A
|
* Hyperintensity (T2) hypointensity (T1)
* Peripheral spotty and centripetal enhancement
|
* Majority of the cases diagnosed incidentally
* Majority of the [[lesions]] are non-functional with [[female]] pre-dominance
|-
|-
| colspan="2" |Sturge-Weber syndrome
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid28794358">{{cite journal |vauthors=Harada K, Kimura K, Iwamuro M, Terasaka T, Hanayama Y, Kondo E, Hayashi E, Yoshino T, Otsuka F |title=The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency |journal=Intern. Med. |volume=56 |issue=17 |pages=2261–2269 |date=September 2017 |pmid=28794358 |pmc=5635296 |doi=10.2169/internalmedicine.8216-16 |url=}}</ref><ref name="pmid27795295">{{cite journal |vauthors=Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM |title=Adrenal lymphoma: presentation, management and prognosis |journal=QJM |volume=110 |issue=2 |pages=103–109 |date=February 2017 |pmid=27795295 |doi=10.1093/qjmed/hcw174 |url=}}</ref><ref name="pmid29344029">{{cite journal |vauthors=Karimi F |title=Primary Adrenal Lymphoma Presenting with Adrenal Failure: A Case Report and Review of the Literature |journal=Int J Endocrinol Metab |volume=15 |issue=4 |pages=e12014 |date=October 2017 |pmid=29344029 |pmc=5750783 |doi=10.5812/ijem.12014 |url=}}</ref>
|facial + leptomeningeal CM + eye anomalies
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
+/-bone and/or soft tissue overgrowth
* N/A
|
* [[Fatigue]]
* Loss of [[appetite]]
* [[Weight loss]]
* [[Pigmentation]] of [[skin]]
* [[Flank]]/[[abdominal]] [[pain]]
* [[Fever]]
* [[Nausea]] & [[vomiting]]
|
* [[Hypotension]]
* [[Altered mental status]]
* [[Abdominal]]/[[flank]] [[mass]]
* [[Fever]]
* [[Weight loss]]
|
* ↑ [[ESR]]
* ↑ [[LDH]]
* ↑ [[Serum]] [[ACTH]]
* ↓ [[Hyponatremia]]
* Low early morning [[serum]] [[cortisol]] levels
* Low basal [[urinary]] [[cortisol]]
* ↓ [[Aldosterone]]
|
* [[Histopathology]] is gold standard
* Diffuse growth pattern with large [[cells]] ( 5× normal [[lymphocytes]]) resembling [[immunoblasts]]
* Extensive [[necrosis]]
* May resemble [[anaplastic]] large [[cell]] [[lymphoma]] or [[metastatic]] [[carcinoma]]
* Abundant [[T-cells]]
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[ACTH]] stimulation test
* [[CT]]-guided needle [[biopsy]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
* Heterogeneous [[mass]]
* [[Hemorrhages]]
|
* Heterogeneous [[mass]]
* [[Hemorrhages]]
* [[Necrosis]]
|
* N/A
|
* Enlarged [[retroperitoneal]] [[lymph nodes]]
* Low intensity (T1)
* High intensity (T2)
|
* May stain positive for:
** [[CD3]], [[CD19]], [[CD20]], [[CD22]]
** [[BCL6]] / [[CD10]]
** [[CD43]], [[CD45]]
** [[Immunoglobulin A|Surface Ig]]
** [[CD68]]
** [[CD79a]]
** [[LCA]]
** [[Pax genes|Pax 5]]
|-
|-
| colspan="2" |Limb CM + congenital non-progressive limb overgrowth
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystic Lymphangioma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid27011561">{{cite journal |vauthors=Michalopoulos N, Laskou S, Karayannopoulou G, Pavlidis L, Kanellos I |title=Adrenal Gland Lymphangiomas |journal=Indian J Surg |volume=77 |issue=Suppl 3 |pages=1334–42 |date=December 2015 |pmid=27011561 |pmc=4775622 |doi=10.1007/s12262-015-1206-y |url=}}</ref><ref name="pmid25197378">{{cite journal |vauthors=Zhao M, Gu Q, Li C, Yu J, Qi H |title=Cystic lymphangioma of adrenal gland: a clinicopathological study of 3 cases and review of literature |journal=Int J Clin Exp Pathol |volume=7 |issue=8 |pages=5051–6 |date=2014 |pmid=25197378 |pmc=4152068 |doi= |url=}}</ref><ref name="pmid25889625">{{cite journal |vauthors=Joliat GR, Melloul E, Djafarrian R, Schmidt S, Fontanella S, Yan P, Demartines N, Halkic N |title=Cystic lymphangioma of the adrenal gland: report of a case and review of the literature |journal=World J Surg Oncol |volume=13 |issue= |pages=58 |date=February 2015 |pmid=25889625 |pmc=4335415 |doi=10.1186/s12957-015-0490-0 |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* Asymptomatic
* [[Flank]]/back/[[abdominal]] [[pain]]
* [[Abdominal]]/[[flank]] [[mass]]
* [[GI]] obstruction
|
* N/L
* Palpable [[mass]]
* [[Hypertension]]
* [[Fever]]
|
* N/L
|
* [[Histopathology]] is gold standard
* Cystic channels and spaces
* Flat [[endothelial cells]]
* Mature [[lymphoid]] aggregates
|
* Complete [[endocrine]] panel
* [[Ultrasound]]
* [[FDG]]-[[PET]] scan
* [[Aspiration]] & [[biopsy]]
|
* Well-demarcated
* [[Calcification]]
|
* Well-demarcated
* Low-density
* [[Calcification]]
|
* N/A
|
* T1 hypointense & T2 hyperintense
|
|
* Associated with [[Gorlin-Goltz syndrome]]
* Stains positive for [[CD31]], [[CD34]], and D2-40 and negative for [[cytokeratin]]
|-
|-
| colspan="2" |Maffucci syndrome
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Teratoma]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid29067922">{{cite journal |vauthors=Ramakant P, Rana C, Singh KR, Mishra A |title=Primary adrenal teratoma: An unusual tumor - Challenges in diagnosis and surgical management |journal=J Postgrad Med |volume=64 |issue=2 |pages=112–114 |date=2018 |pmid=29067922 |pmc=5954807 |doi=10.4103/jpgm.JPGM_588_16 |url=}}</ref><ref name="pmid26722254">{{cite journal |vauthors=Li S, Li H, Ji Z, Yan W, Zhang Y |title=Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults |journal=Oncol Lett |volume=10 |issue=5 |pages=2865–2870 |date=November 2015 |pmid=26722254 |pmc=4665718 |doi=10.3892/ol.2015.3701 |url=}}</ref><ref name="pmid30214733">{{cite journal |vauthors=Zhou L, Pan X, He T, Lai Y, Li W, Hu Y, Ni L, Yang S, Chen Y, Lai Y |title=Primary adrenal teratoma: A case series and review of the literature |journal=Mol Clin Oncol |volume=9 |issue=4 |pages=437–442 |date=October 2018 |pmid=30214733 |pmc=6125700 |doi=10.3892/mco.2018.1687 |url=}}</ref>
|VM +/-spindle-cell hemangioma + enchondroma
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* N/A
|
* Asymptomatic
* [[Abdominal]]/back discomfort & [[pain]]
* [[Abdominal]] distension
* [[Lumbago]]
* [[Nausea]] & [[vomiting]]
* Local obstructive [[symptoms]]
|
* N/L
* [[Abdominal]] distension
* [[Abdominal]] [[mass]]
* [[Weight loss]]
* [[Urinary]] retention
* Lower extremity [[edema]]
* [[Peritoneal]] [[effusion]] or [[peritonitis]] (rupture)
|
* N/L
|
* [[Fibrous tissue]], [[adipose tissue]] and [[muscle fibers]]
* [[Stratified squamous epithelium]], [[hair]] shafts, [[fat cells]], [[GI]] and [[respiratory]] [[epithelium]]
* [[Necrosis]]
* [[Calcification]]
|
* Complete [[endocrine]] panel
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
* Post-resection [[biopsy]] (if [[malignancy]] is suspected)
|
* Heterogeneous
* Mixed echo ([[Ultrasonogram|U/S]])
|
* Heterogeneous
* Mixed density elements
* Egg-shell [[calcification]]
* Mild enhancement
|
* N/A
|
* Mild enhancement
* Mixed signals ([[MRI]])
|
* Derived from [[germ layers]]
* Majority are [[benign]], but about one forth of [[adrenal]] [[teratoma]] are [[malignant]] [[lesions]]
|-
|-
| colspan="2" |Macrocephaly-CM (M-CM / MCAP) *
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Metastases]]<br><ref name="pmid30306064">{{cite journal |vauthors=Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T |title=CT and MRI of adrenal gland pathologies |journal=Quant Imaging Med Surg |volume=8 |issue=8 |pages=853–875 |date=September 2018 |pmid=30306064 |pmc=6177362 |doi=10.21037/qims.2018.09.13 |url=}}</ref><ref name="pmid15541184">{{cite journal |vauthors=Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K |title=Large bilateral adrenal metastases in non-small cell lung cancer |journal=World J Surg Oncol |volume=2 |issue= |pages=37 |date=November 2004 |pmid=15541184 |pmc=535544 |doi=10.1186/1477-7819-2-37 |url=}}</ref><ref name="pmid15405683">{{cite journal |vauthors=ABRAMS HL, SPIRO R, GOLDSTEIN N |title=Metastases in carcinoma; analysis of 1000 autopsied cases |journal=Cancer |volume=3 |issue=1 |pages=74–85 |date=January 1950 |pmid=15405683 |doi= |url=}}</ref><ref name="pmid15554272">{{cite journal |vauthors=Gerber E, Dinlenc C, Wagner JR |title=Laparoscopic adrenalectomy for isolated adrenal metastasis |journal=JSLS |volume=8 |issue=4 |pages=314–9 |date=2004 |pmid=15554272 |pmc=3016821 |doi= |url=}}</ref><ref name="pmid9781426">{{cite journal |vauthors=Vaughan ED |title=Diagnosis and management of surgical adrenal disorders |journal=Int. J. Urol. |volume=5 |issue=5 |pages=401–17 |date=September 1998 |pmid=9781426 |doi= |url=}}</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |
* Related to the primary [[tumor]]
|
* Asymptomatic
* [[Adrenal insufficiency]]
* [[Abdominal]] [[mass]] & discomfort
* [[Symptoms]] due to primary [[tumor]] that may include:
** [[Lung cancer]]
** [[Breast cancer]]
** [[Gastric cancer]]
** [[Liver cancer]]
** [[Pancreatic cancer]]
** [[Renal cell carcinoma]]
** [[Melanoma]]
** [[Lymphoma]]
|
* Asymptomatic
* [[Adrenal insufficiency]]
* [[Abdominal]] [[mass]]
* [[Signs]] due to primary [[tumor]] that may include
** [[Lung cancer]]
** [[Breast cancer]]
** [[Gastric cancer]]
** [[Liver cancer]]
** [[Pancreatic cancer]]
** [[Renal cell carcinoma]]
** [[Melanoma]]
** [[Lymphoma]]
|
* Varies depending on the primary [[tumor]]
* N/L
* If [[adrenal insufficiency]]:
** [[Hyponatremia]]
** [[Hyperkalemia]]
** [[Hypoglycemia]]
** Low early morning [[serum]] [[cortisol]] levels
** Low basal [[urinary]] [[cortisol]]
** ↑ [[ACTH]]
** ↓ [[Aldosterone]]
** ↑ [[Plasma]] [[renin]]
|
* Single or multiple firm [[masses]]
* [[Hemorrhage]]
* [[Necrosis]]
 
* [[Morphology]] similar to the primary [[tumor]]
* Compression and [[atrophy]] of adjacent [[adrenal]] [[tissue]]
|
* [[Blood]] and [[urine]] lab testing
* Complete [[endocrine]] panel
* [[Imaging]] of [[chest]], [[abdomen]], and [[pelvis]]
* [[Immunohistochemistry]]
* [[Endoscopy]]
* [[MRCP]] & [[ERCP]]
* <sup>18</sup>F-fluorodeoxyglucose ([[FDG]]) [[positron emission tomography]] [[PET]]/[[CT]]
|
* [[Calcification]]
* [[Hemorrhage]]
|
* [[Calcification]]
* [[Hemorrhage]]
* Irregular peripheral enhancement
|
* N/A
|
|
|-
* Low signal on T1-weighed [[MRI]] and high signal on T2-weighed [[MRI]]
| colspan="2" |Microcephaly-CM (MICCAP)
OR
* Isointense on T1- and T2-weighed [[MRI]]
|
|
|-
* [[Metastases]] more common than primary [[adrenal tumors]]
| colspan="2" |CLOVES syndrome *
* [[Adrenal]] [[hemorrhage]] is the most serious [[complication]] and may present as [[adrenal crisis]] and/or [[shock]]
|LM + VM + CM +/-AVM+ lipomatous overgrowth
|-
| colspan="2" |Proteus syndrome
|CM, VM and/or LM + asymmetrical somatic overgrowth
|-
|Bannayan-Riley-Ruvalcaba sd
| colspan="2" |lower lip CM + face and neck LM + asymmetry and partial/generalized overgrowth
|}
|}
==Vascular malformations==
===Simple vascular malformations===
====Capillary malformations (CM)====
=====Nevus simplex=====
* Also called "salmon patch" , “angel kiss”, “stork bite”, this common anomaly presents as single or multiple blanchable, pink-red patches with poorly defined borders in newborn infants. It may affect up to 60% of new born infants.<ref name="pmid20728246">{{cite journal |vauthors=Juern AM, Glick ZR, Drolet BA, Frieden IJ |title=Nevus simplex: a reconsideration of nomenclature, sites of involvement, and disease associations |journal=J. Am. Acad. Dermatol. |volume=63 |issue=5 |pages=805–14 |date=November 2010 |pmid=20728246 |doi=10.1016/j.jaad.2009.08.066 |url=}}</ref>
* Typically are found at the nape of the neck , on the forehead between the eyebrows or on the eyelids. Although asymptomatic, they often become more noticeable during crying or temperature changes.
* Fades within one to two years, though some lesions can persist on the back of the neck.<ref name="pmid3562091">{{cite journal |vauthors=Cohen BA |title=Hemangiomas in infancy and childhood |journal=Pediatr Ann |volume=16 |issue=1 |pages=17–26 |date=January 1987 |pmid=3562091 |doi= |url=}}</ref> No treatment is needed except when asked by the patient.
* Imaging studies are recommended to evaluate for underlying spinal dysraphism if lumbosacral nevus simplex is present with another lumbosacral abnormality such as dermal sinus or pit, lipoma, patch of hypertrichosis, or deviated gluteal cleft.<ref name="pmid20728246">{{cite journal |vauthors=Juern AM, Glick ZR, Drolet BA, Frieden IJ |title=Nevus simplex: a reconsideration of nomenclature, sites of involvement, and disease associations |journal=J. Am. Acad. Dermatol. |volume=63 |issue=5 |pages=805–14 |date=November 2010 |pmid=20728246 |doi=10.1016/j.jaad.2009.08.066 |url=}}</ref>
=====Cutaneous and/or mucosal CM (“port-wine” stain)=====
* "A vascular malformation of developmental origin characterized pathologically by ectasia of superficial dermal capillaries, and clinically by persistent macular erythema." They occur on face for majority of times and may vary from pale pink to deep red or purple, ranging from few millimeters to centimeters in diameter.<ref name="urlPort-Wine Stain - MeSH - NCBI">{{cite web |url=https://www.ncbi.nlm.nih.gov/mesh/68019339 |title=Port-Wine Stain - MeSH - NCBI |format= |work= |accessdate=}}</ref> Lesions are usually flat, are not painful and do not regress spontaneously.
* Can be classified as follows:
** Nonsyndromic CM
** CM with CNS and/or ocular anomalies (Sturge-Weber syndrome)
** CM with bone and/or soft tissues overgrowth
** Diffuse CM with overgrowth (DCMO)
* Usually occur as sporadic isolated lesions, following the embryonic vasculature of the face.<ref name="pmid26192947">{{cite journal |vauthors=Frigerio A, Wright K, Wooderchak-Donahue W, Tan OT, Margraf R, Stevenson DA, Grimmer JF, Bayrak-Toydemir P |title=Genetic Variants Associated with Port-Wine Stains |journal=PLoS ONE |volume=10 |issue=7 |pages=e0133158 |date=2015 |pmid=26192947 |pmc=4508108 |doi=10.1371/journal.pone.0133158 |url=}}</ref> Majority of lesions are caused by somatic mutations in GNAQ (Guanine nucleotide-binding protein G(q) subunit alpha) and its paralogue GNA 11. Somatic activating mutation in  GNAQ c.548G>A, p.Arg183Gln has been demonstrated in majority of lesions. A novel GNAQ, c.547C>G, p.Arg183Gly variant has also been found to be associated with some lesions.<ref name="pmid26192947">{{cite journal |vauthors=Frigerio A, Wright K, Wooderchak-Donahue W, Tan OT, Margraf R, Stevenson DA, Grimmer JF, Bayrak-Toydemir P |title=Genetic Variants Associated with Port-Wine Stains |journal=PLoS ONE |volume=10 |issue=7 |pages=e0133158 |date=2015 |pmid=26192947 |pmc=4508108 |doi=10.1371/journal.pone.0133158 |url=}}</ref>
* May be associated with other abnormalities including glaucoma, and soft tissue and bone overgrowth and with various syndromes including Sturge-Weber syndrome, Klippel-Trenaunay syndrome, Parkes-Weber syndrome, Servelle-Martorell syndrome, Proteus syndrome, CLOVES syndrome, Bannayan-Riley-Ruvalcaba syndrome, Capillary malformation-arteriovenous malformation syndrome, Macrocephaly-capillary malformation syndrome, Microcephaly-capillary malformation syndrome, Beckwith-Wiedemann syndrome.
* Diagnosis is mainly clinical depending upon history and examination. New born screening for other congenital and genetic anomalies may be indicated including urgent ophthalmology review and a brain MRI.<ref name="pmid24976116">{{cite journal |vauthors=Waelchli R, Aylett SE, Robinson K, Chong WK, Martinez AE, Kinsler VA |title=New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk |journal=Br. J. Dermatol. |volume=171 |issue=4 |pages=861–7 |date=October 2014 |pmid=24976116 |pmc=4284033 |doi=10.1111/bjd.13203 |url=}}</ref>
* The pulsed dye laser (PDL) treatment is considered to be the gold standard. Surgery is considered when PWS is associated with bone and soft tissues overgrowth.<ref name="pmid29217063">{{cite journal |vauthors=Lee JW, Chung HY |title=Capillary Malformations (Portwine Stains) of the Head and Neck: Natural History, , Laser, and Surgical Management |journal=Otolaryngol. Clin. North Am. |volume=51 |issue=1 |pages=197–211 |date=FebInvestigationsruary 2018 |pmid=29217063 |doi=10.1016/j.otc.2017.09.004 |url=}}</ref>
* To learn more about PWS click here.
=====Reticulate CM=====
* Cutaneous capillary malformations which are reticulated, widespread on body ranging from few to hundreds of oval/circular macules or patches varying in size from few mm to several cm. These anomalies are found in two syndromes:
** CM of MIC-CAP (microcephaly-capillary malformation)
** CM of MCAP (megalencephaly-capillary malformation-polymicrogyria)
=====CM of CM-AVM=====
* Usually multiple, these malformations can be round to oval, can vary from pink-red to tan,and are found in patches of 1 to 2 cm in size. These patches are scattered throughout the body and new ones may continue to appear throughout childhood. Sometimes a high flow murmur can be heard using Doppler device.<ref name="pmid18446851">{{cite journal |vauthors=Revencu N, Boon LM, Mulliken JB, Enjolras O, Cordisco MR, Burrows PE, Clapuyt P, Hammer F, Dubois J, Baselga E, Brancati F, Carder R, Quintal JM, Dallapiccola B, Fischer G, Frieden IJ, Garzon M, Harper J, Johnson-Patel J, Labrèze C, Martorell L, Paltiel HJ, Pohl A, Prendiville J, Quere I, Siegel DH, Valente EM, Van Hagen A, Van Hest L, Vaux KK, Vicente A, Weibel L, Chitayat D, Vikkula M |title=Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations |journal=Hum. Mutat. |volume=29 |issue=7 |pages=959–65 |date=July 2008 |pmid=18446851 |doi=10.1002/humu.20746 |url=}}</ref>
* These are found in Capillary malformation-arteriovenous malformation syndrome, an autosomal dominant syndrome associated with mutations in RASA1.<ref name="pmid20007727">{{cite journal |vauthors=Thiex R, Mulliken JB, Revencu N, Boon LM, Burrows PE, Cordisco M, Dwight Y, Smith ER, Vikkula M, Orbach DB |title=A novel association between RASA1 mutations and spinal arteriovenous anomalies |journal=AJNR Am J Neuroradiol |volume=31 |issue=4 |pages=775–9 |date=April 2010 |pmid=20007727 |doi=10.3174/ajnr.A1907 |url=}}</ref>
=====Cutis marmorata telangiectatica congenita (CMTC)=====
* A congenital, vascular malformation consisting of capillary and venous sized vessels. Presentation is similar to physiologic cutis marmorata with a fixed reticulate erythema but unlike physiologic cutis marmorata, the erythema does not resolve with warming and may be associated with skin ulceration, atrophy of the skin, and undergrowth of the involved extremity. <ref name="pmid10792796">{{cite journal |vauthors=Amitai DB, Fichman S, Merlob P, Morad Y, Lapidoth M, Metzker A |title=Cutis marmorata telangiectatica congenita: clinical findings in 85 patients |journal=Pediatr Dermatol |volume=17 |issue=2 |pages=100–4 |date=2000 |pmid=10792796 |doi= |url=}}</ref> <ref>Ponnurangam VN, Paramasivam V. Cutis marmorata telangiectatica congenita. Indian Dermatol Online J [serial online] 2014 [cited 2018 Sep 25];5:80-2. Available from: http://www.idoj.in/text.asp?2014/5/1/80/126042</ref>
* Findings may include prominent veins, telangiectasias, cutaneous atrophy, ulceration, and hyperkeratosis. May have localized or generalized appearance. In localized pattern, the lesions are confined to one side of the body, not crossing midline with or without sharp demarcation. <ref>Ponnurangam VN, Paramasivam V. Cutis marmorata telangiectatica congenita. Indian Dermatol Online J [serial online] 2014 [cited 2018 Sep 25];5:80-2. Available from: http://www.idoj.in/text.asp?2014/5/1/80/126042</ref>
* May be associated with a number of other abnormalities, of which limb asymmetry is the most common. Others may include glaucoma, port wine stains, angiokeratomas, hemangiomas. It may also be associated with Sturge-Weber syndrome.<ref>Ponnurangam VN, Paramasivam V. Cutis marmorata telangiectatica congenita. Indian Dermatol Online J [serial online] 2014 [cited 2018 Sep 25];5:80-2. Available from: http://www.idoj.in/text.asp?2014/5/1/80/126042</ref> Most cases tend be sporadic but autosomal recessive pattern has been observed in familial cases.<ref name="urlCutis marmorata telangiectatica congenita - MeSH - NCBI">{{cite web |url=https://www.ncbi.nlm.nih.gov/mesh/?term=C536226 |title=Cutis marmorata telangiectatica congenita - MeSH - NCBI |format= |work= |accessdate=}}</ref>
* Diagnosis is clinical and depends on history and examination. Management depends on the systemic involvement. Skin lesions tend to improve spontaneously.<ref name="pmid19196300">{{cite journal |vauthors=Kienast AK, Hoeger PH |title=Cutis marmorata telangiectatica congenita: a prospective study of 27 cases and review of the literature with proposal of diagnostic criteria |journal=Clin. Exp. Dermatol. |volume=34 |issue=3 |pages=319–23 |date=April 2009 |pmid=19196300 |doi=10.1111/j.1365-2230.2008.03074.x |url=}}</ref><ref name="pmid10943257">{{cite journal |vauthors=Dohil MA, Baugh WP, Eichenfield LF |title=Vascular and pigmented birthmarks |journal=Pediatr. Clin. North Am. |volume=47 |issue=4 |pages=783–812, v–vi |date=August 2000 |pmid=10943257 |doi= |url=}}</ref>
=====Telangiectasia=====
* "Permanent dilation of preexisting blood vessels creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders."<ref name="urlTelangiectasis - MeSH - NCBI">{{cite web |url=+++++https://www.ncbi.nlm.nih.gov/mesh/?term=D013684 |title=Telangiectasis - MeSH - NCBI |format= |work= |accessdate=}}</ref> To learn about Hereditary hemorrhagic telangiectasia (HHT) click here.
====Lymphatic malformations (LM)====
=====Common (cystic) LM=====
* benign lesions consisting of dilated lymphatic channels or cysts lined by cells of endothelial origin with lymphatic differentiation.<ref name="pmid26055853">{{cite journal |vauthors=Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, Burrows P, Frieden IJ, Garzon MC, Lopez-Gutierrez JC, Lord DJ, Mitchel S, Powell J, Prendiville J, Vikkula M |title=Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies |journal=Pediatrics |volume=136 |issue=1 |pages=e203–14 |date=July 2015 |pmid=26055853 |doi=10.1542/peds.2014-3673 |url=}}</ref> If these lesions are associated with overgrowth then some of these lesions belong to the PIK3CA-related overgrowth spectrum. <ref>http://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf</ref>
* These are classified as follows:
** Macrocystic  LM
** Microcystic  LM
** Mixed cystic LM
*# '''Macrocystic  LM'''
*#* Also called cystic hygroma, and cystic lymphangioma. A cystic growth consisting of large, interconnected lymphatic cysts lined by a thin endothelium. Usually found in neck, axilla and groin. Presents as a large, poorly delineated, translucent, soft cystic mass covered by normal skin.
*#* May be associated with chromosomal abnormalities such as Down syndrome, Turner syndrome. To learn more click here.
*# '''Microcystic  LM'''
*#* Also known as 'lymphangioma circumscriptum', these lymphatic anomalies may be present at birth or may develop in first few years of life. Usual presentation is as a cluster of clear, translucent or hemorrhagic vesicles that may cause pressure symptoms as they grow in size.
*#* Usually affect deep seated structures and frequent locations are proximal extremities, trunk, axilla, and the oral cavity.
*#* Diagnosis is clinical and treatment options include surgery, sclerotherapy, radiotherapy, and laser therapy. Recently topical sirolimus has also been used.<ref name="pmid30133999">{{cite journal |vauthors=Çalışkan E, Altunel CT, Özkan CK, Tunca M |title=A case of microcystic lymphatic malformation successfully treated with topical sirolimus |journal=Dermatol Ther |volume= |issue= |pages=e12673 |date=August 2018 |pmid=30133999 |doi=10.1111/dth.12673 |url=}}</ref> To learn more click here.
=====Generalized lymphatic anomaly (GLA)=====
* Diffuse or multicentric proliferation of dilated lymphatic vessels that may involve skin, bones, and internal organs. The proliferating vessels resemble common lymphatic malformations but the disease involvement is multi-system.<ref name="pmid29871646">{{cite journal |vauthors=Du H, Xiong M, Liao H, Luo Y, Shi H, Xie C |title=Chylothorax and constrictive pericarditis in a woman due to generalized lymphatic anomaly: a case report |journal=J Cardiothorac Surg |volume=13 |issue=1 |pages=59 |date=June 2018 |pmid=29871646 |pmc=5989411 |doi=10.1186/s13019-018-0752-3 |url=}}</ref><ref name="pmid29397482">{{cite journal |vauthors=Manevitz-Mendelson E, Leichner GS, Barel O, Davidi-Avrahami I, Ziv-Strasser L, Eyal E, Pessach I, Rimon U, Barzilai A, Hirshberg A, Chechekes K, Amariglio N, Rechavi G, Yaniv K, Greenberger S |title=Somatic NRAS mutation in patient with generalized lymphatic anomaly |journal=Angiogenesis |volume=21 |issue=2 |pages=287–298 |date=May 2018 |pmid=29397482 |doi=10.1007/s10456-018-9595-8 |url=}}</ref> Lungs, bones and mediastinum are most commonly affected but skin, liver and spleen are commonly affected as well. Liver, spleen, and thoracic duct involvement typically indicates worse prognosis.<ref name="pmid2709285">{{cite journal |vauthors=Levine C |title=Primary disorders of the lymphatic vessels--a unified concept |journal=J. Pediatr. Surg. |volume=24 |issue=3 |pages=233–40 |date=March 1989 |pmid=2709285 |doi= |url=}}</ref>
* Considered to b sporadic and non-hereditary, it may present in childhood or can be diagnosed later in life.<ref name="pmid10712360">{{cite journal |vauthors=Faul JL, Berry GJ, Colby TV, Ruoss SJ, Walter MB, Rosen GD, Raffin TA |title=Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome |journal=Am. J. Respir. Crit. Care Med. |volume=161 |issue=3 Pt 1 |pages=1037–46 |date=March 2000 |pmid=10712360 |doi=10.1164/ajrccm.161.3.9904056 |url=}}</ref><ref name="pmid23457676">{{cite journal |vauthors=Kadakia KC, Patel SM, Yi ES, Limper AH |title=Diffuse pulmonary lymphangiomatosis |journal=Can. Respir. J. |volume=20 |issue=1 |pages=52–4 |date=2013 |pmid=23457676 |pmc=3628648 |doi=10.1155/2013/971350 |url=}}</ref> Etiology is unknown but high levels of VEGFR-3 have been reported in patient population.
* Chylothorax due to leakage of lymphtic fluid is commonly encountered and is difficult to treat.<ref name="pmid29906363">{{cite journal |vauthors=Ludwig KF, Slone T, Cederberg KB, Silva AT, Dellinger M |title=A New Case and Review of Chylothorax in Generalized Lymphatic Anomaly and Gorham-Stout Disease |journal=Lymphology |volume=49 |issue=2 |pages=73–84 |date=June 2016 |pmid=29906363 |doi= |url=}}</ref> Patient may present with respiratory symptoms such as chest pain, wheezing, SOB, cough, repeated infections or symptoms due to involvement of other organs such as bone pain, pathological fractures, pelvic or abdominal pain, swelling, fever, internal bleeding, skin lesions.<ref name="pmid29871646">{{cite journal |vauthors=Du H, Xiong M, Liao H, Luo Y, Shi H, Xie C |title=Chylothorax and constrictive pericarditis in a woman due to generalized lymphatic anomaly: a case report |journal=J Cardiothorac Surg |volume=13 |issue=1 |pages=59 |date=June 2018 |pmid=29871646 |pmc=5989411 |doi=10.1186/s13019-018-0752-3 |url=}}</ref><ref name="pmid11247693">{{cite journal |vauthors=Aviv RI, McHugh K, Hunt J |title=Angiomatosis of bone and soft tissue: a spectrum of disease from diffuse lymphangiomatosis to vanishing bone disease in young patients |journal=Clin Radiol |volume=56 |issue=3 |pages=184–90 |date=March 2001 |pmid=11247693 |doi=10.1053/crad.2000.0606 |url=}}</ref><ref name="pmid22196284">{{cite journal |vauthors=Satria MN, Pacheco-Rodriguez G, Moss J |title=Pulmonary lymphangiomatosis |journal=Lymphat Res Biol |volume=9 |issue=4 |pages=191–3 |date=2011 |pmid=22196284 |pmc=3246407 |doi=10.1089/lrb.2011.0023 |url=}}</ref><ref name="pmid23457676">{{cite journal |vauthors=Kadakia KC, Patel SM, Yi ES, Limper AH |title=Diffuse pulmonary lymphangiomatosis |journal=Can. Respir. J. |volume=20 |issue=1 |pages=52–4 |date=2013 |pmid=23457676 |pmc=3628648 |doi=10.1155/2013/971350 |url=}}</ref>
* Diagnosis of GLA is very challenging and requires multidisciplinary input. It depends on history, examination, imaging studies such as MRI, contrast ultrasound, magnetic resonance lymphangiogram, CXR,near-infrared fluorescence lymphatic imaging, nanotechnology-based MRI agents and biopsy.<ref name="pmid29871646">{{cite journal |vauthors=Du H, Xiong M, Liao H, Luo Y, Shi H, Xie C |title=Chylothorax and constrictive pericarditis in a woman due to generalized lymphatic anomaly: a case report |journal=J Cardiothorac Surg |volume=13 |issue=1 |pages=59 |date=June 2018 |pmid=29871646 |pmc=5989411 |doi=10.1186/s13019-018-0752-3 |url=}}</ref><ref name="pmid24590275">{{cite journal |vauthors=Sevick-Muraca EM, Kwon S, Rasmussen JC |title=Emerging lymphatic imaging technologies for mouse and man |journal=J. Clin. Invest. |volume=124 |issue=3 |pages=905–14 |date=March 2014 |pmid=24590275 |pmc=3938259 |doi=10.1172/JCI71612 |url=}}</ref><ref name="pmid19913379">{{cite journal |vauthors=Lohrmann C, Foeldi E, Langer M |title=Assessment of the lymphatic system in patients with diffuse lymphangiomatosis by magnetic resonance imaging |journal=Eur J Radiol |volume=80 |issue=2 |pages=576–81 |date=November 2011 |pmid=19913379 |doi=10.1016/j.ejrad.2009.10.021 |url=}}</ref> Sometimes surgery is required that can be both diagnostic and therapeutic.<ref name="pmid29871646">{{cite journal |vauthors=Du H, Xiong M, Liao H, Luo Y, Shi H, Xie C |title=Chylothorax and constrictive pericarditis in a woman due to generalized lymphatic anomaly: a case report |journal=J Cardiothorac Surg |volume=13 |issue=1 |pages=59 |date=June 2018 |pmid=29871646 |pmc=5989411 |doi=10.1186/s13019-018-0752-3 |url=}}</ref>
* Management is usually focused on symptomatic improvement. Options include chest drainage, open thorax surgery, sclerotherapy, surgical removal (debulking), lymphatic anastomosis and medical therapies such as sirolimus and interferon.<ref name="pmid29871646">{{cite journal |vauthors=Du H, Xiong M, Liao H, Luo Y, Shi H, Xie C |title=Chylothorax and constrictive pericarditis in a woman due to generalized lymphatic anomaly: a case report |journal=J Cardiothorac Surg |volume=13 |issue=1 |pages=59 |date=June 2018 |pmid=29871646 |pmc=5989411 |doi=10.1186/s13019-018-0752-3 |url=}}</ref>
*# '''Kaposiform lymphangiomatosis (KLA)'''
*#* A rare subtype with worse pronosis.<ref name="pmid25598153">{{cite journal |vauthors=Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S |title=Successful treatment of kaposiform lymphangiomatosis with sirolimus |journal=Pediatr Blood Cancer |volume=62 |issue=7 |pages=1291–3 |date=July 2015 |pmid=25598153 |doi=10.1002/pbc.25422 |url=}}</ref> Malformed vessels occur with cluster and sheets of spindle lymphatic endothelial cells.<ref name="pmid24252784">{{cite journal |vauthors=Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G, Mulliken JB, Trenor CC |title=Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly |journal=J. Pediatr. |volume=164 |issue=2 |pages=383–8 |date=February 2014 |pmid=24252784 |pmc=3946828 |doi=10.1016/j.jpeds.2013.10.013 |url=}}</ref> Consumptive coagulopathy is also a feature.<ref name="pmid25307772">{{cite journal |vauthors=Fernandes VM, Fargo JH, Saini S, Guerrera MF, Marcus L, Luchtman-Jones L, Adams D, Meier ER |title=Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder |journal=Pediatr Blood Cancer |volume=62 |issue=5 |pages=901–4 |date=May 2015 |pmid=25307772 |doi=10.1002/pbc.25278 |url=}}</ref>
*#* Intra-thoracic component is often the cause of mortality.<ref name="pmid24252784">{{cite journal |vauthors=Croteau SE, Kozakewich HP, Perez-Atayde AR, Fishman SJ, Alomari AI, Chaudry G, Mulliken JB, Trenor CC |title=Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly |journal=J. Pediatr. |volume=164 |issue=2 |pages=383–8 |date=February 2014 |pmid=24252784 |pmc=3946828 |doi=10.1016/j.jpeds.2013.10.013 |url=}}</ref> Currently there are no treatment guidelines.<ref name="pmid25598153">{{cite journal |vauthors=Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S |title=Successful treatment of kaposiform lymphangiomatosis with sirolimus |journal=Pediatr Blood Cancer |volume=62 |issue=7 |pages=1291–3 |date=July 2015 |pmid=25598153 |doi=10.1002/pbc.25422 |url=}}</ref>
=====LM in Gorham-Stout disease=====
* Lymphatic malformation in Gorham-Stout disease affect a single or multiple bones and adjacent soft tissues, leading to progressive osteolysis and invasion of the bone cortex.<ref name="pmid8961021">{{cite journal |vauthors=Klein M, Metelmann HR, Gross U |title=Massive osteolysis (Gorham-Stout syndrome) in the maxillofacial region: an unusual manifestation |journal=Int J Oral Maxillofac Surg |volume=25 |issue=5 |pages=376–8 |date=October 1996 |pmid=8961021 |doi= |url=}}</ref><ref name="pmid18519969">{{cite journal |vauthors=Radhakrishnan K, Rockson SG |title=The clinical spectrum of lymphatic disease |journal=Ann. N. Y. Acad. Sci. |volume=1131 |issue= |pages=155–84 |date=2008 |pmid=18519969 |doi=10.1196/annals.1413.015 |url=}}</ref><ref name="pmid23371338">{{cite journal |vauthors=Lala S, Mulliken JB, Alomari AI, Fishman SJ, Kozakewich HP, Chaudry G |title=Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation |journal=Skeletal Radiol. |volume=42 |issue=7 |pages=917–24 |date=July 2013 |pmid=23371338 |doi=10.1007/s00256-012-1565-4 |url=}}</ref> Was originally described as disappearing or vanishing bone disease. GSD progression often leads to visceral, abdominal and thoracic involvement that may cause effusion and ascites<ref name="pmid23371338">{{cite journal |vauthors=Lala S, Mulliken JB, Alomari AI, Fishman SJ, Kozakewich HP, Chaudry G |title=Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation |journal=Skeletal Radiol. |volume=42 |issue=7 |pages=917–24 |date=July 2013 |pmid=23371338 |doi=10.1007/s00256-012-1565-4 |url=}}</ref> The osteolysis is progressive in GSD as compared to non-progressive osteolysis in GLA.<ref name="pmid23371338">{{cite journal |vauthors=Lala S, Mulliken JB, Alomari AI, Fishman SJ, Kozakewich HP, Chaudry G |title=Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation |journal=Skeletal Radiol. |volume=42 |issue=7 |pages=917–24 |date=July 2013 |pmid=23371338 |doi=10.1007/s00256-012-1565-4 |url=}}</ref>
* There are two distinct forms of GSD. Primary form involves multiple bones and tissues with multi-focal lesions as described above versus trauma induced GSD that typically involves one or closely adjacent one and is usually self limited.<ref name="pmid30248728">{{cite journal |vauthors=Tanoue N, Moedano L, Witte M, Montague M, Lukefahr A, Bernas M |title=Primary versus trauma-induced Gorham-Stout disease |journal=Lymphology |volume=51 |issue=1 |pages=18–27 |date=2018 |pmid=30248728 |doi= |url=}}</ref>
* The etiology has not been established and gender, genetic inheritance, or race seem to play no role but inflammation, trauma and puberty have been thought to pay a role. Activation of platelet derived growth factor pathway and up regulation of lymphangiogenesis stimulating pathways may play a role in pathogenesis.<ref name="pmid16816171">{{cite journal |vauthors=Meijer-Jorna LB, van der Loos CM, de Boer OJ, van der Horst CM, van der Wal AC |title=Microvascular proliferation in congenital vascular malformations of skin and soft tissue |journal=J. Clin. Pathol. |volume=60 |issue=7 |pages=798–803 |date=July 2007 |pmid=16816171 |pmc=1995770 |doi=10.1136/jcp.2006.038885 |url=}}</ref><ref name="pmid18519972">{{cite journal |vauthors=Radhakrishnan K, Rockson SG |title=Gorham's disease: an osseous disease of lymphangiogenesis? |journal=Ann. N. Y. Acad. Sci. |volume=1131 |issue= |pages=203–5 |date=2008 |pmid=18519972 |doi=10.1196/annals.1413.022 |url=}}</ref><ref name="pmid17139320">{{cite journal |vauthors=Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH |title=Platelet-derived growth factor receptor-beta in Gorham's disease |journal=Nat Clin Pract Oncol |volume=3 |issue=12 |pages=693–7 |date=December 2006 |pmid=17139320 |pmc=2693369 |doi=10.1038/ncponc0660 |url=}}</ref> IL-6 has been found to be elevated in some patients.<ref name="pmid8626854">{{cite journal |vauthors=Devlin RD, Bone HG, Roodman GD |title=Interleukin-6: a potential mediator of the massive osteolysis in patients with Gorham-Stout disease |journal=J. Clin. Endocrinol. Metab. |volume=81 |issue=5 |pages=1893–7 |date=May 1996 |pmid=8626854 |doi=10.1210/jcem.81.5.8626854 |url=}}</ref>
* Symptoms depend on the bone involved and extent of involvement. Patient can experience chest pain, dyspnea, tachypnea, wheezing, SOB, dull ache, back pain, paralysis, loose teeth and facial deformation.<ref name="pmid22937447">{{cite journal |vauthors=Garbers E, Reuther F, Delling G |title=Report of a rare case of gorham-stout disease of both shoulders: bisphosphonate treatment and shoulder replacement |journal=Case Rep Rheumatol |volume=2011 |issue= |pages=565142 |date=2011 |pmid=22937447 |pmc=3420766 |doi=10.1155/2011/565142 |url=}}</ref><ref name="pmid16012125">{{cite journal |vauthors=Duffy BM, Manon R, Patel RR, Welsh JS |title=A case of Gorham's disease with chylothorax treated curatively with radiation therapy |journal=Clin Med Res |volume=3 |issue=2 |pages=83–6 |date=May 2005 |pmid=16012125 |pmc=1183437 |doi= |url=}}</ref> The involvement of thorax and development of chylothorax indicate poor prognosis.<ref name="pmid16012125">{{cite journal |vauthors=Duffy BM, Manon R, Patel RR, Welsh JS |title=A case of Gorham's disease with chylothorax treated curatively with radiation therapy |journal=Clin Med Res |volume=3 |issue=2 |pages=83–6 |date=May 2005 |pmid=16012125 |pmc=1183437 |doi= |url=}}</ref>
* Diagnosis often requires clinical, radiological and histopathological evidence. Imaging studies including MRI and CT scan are often crucial. Management is often symptomatic and encompasses anti-osteoclastic medication and radiotherapy.<ref name="pmid16012125">{{cite journal |vauthors=Duffy BM, Manon R, Patel RR, Welsh JS |title=A case of Gorham's disease with chylothorax treated curatively with radiation therapy |journal=Clin Med Res |volume=3 |issue=2 |pages=83–6 |date=May 2005 |pmid=16012125 |pmc=1183437 |doi= |url=}}</ref><ref name="pmid14528108">{{cite journal |vauthors=Fontanesi J |title=Radiation therapy in the treatment of Gorham disease |journal=J. Pediatr. Hematol. Oncol. |volume=25 |issue=10 |pages=816–7 |date=October 2003 |pmid=14528108 |doi= |url=}}</ref> If disease affects neuro-vascular structures then surgery is indicated.<ref name="pmid29363434">{{cite journal |vauthors=Mulvihill D, Kumar RS, Muzaffar J, Irving R |title=Gorham-Stout disease of the temporal bone involving the temporomandibular joint |journal=J Laryngol Otol |volume=132 |issue=3 |pages=279–281 |date=March 2018 |pmid=29363434 |doi=10.1017/S0022215118000099 |url=}}</ref><ref name="pmid22865280">{{cite journal |vauthors=Noda M, Endo C, Hoshikawa Y, Ishibashi N, Suzuki T, Okada Y, Kondo T |title=Successful management of intractable chylothorax in Gorham-Stout disease by awake thoracoscopic surgery |journal=Gen Thorac Cardiovasc Surg |volume=61 |issue=6 |pages=356–8 |date=June 2013 |pmid=22865280 |doi=10.1007/s11748-012-0130-3 |url=}}</ref>
=====“Acquired” progressive lymphatic anomaly=====
* Also called  acquired progressive lymphangioma, this vascular anomaly usually presents as asymptomatic, slow growing, reddish brown or violaceous papule, plaque, macule or erythema. Histological studies show numerous, dilated, thin-walled vessels that are lined by flat endothelial cells and are proliferating. No nuclear atypia has been demonstrated in this locally aggressive tumor. The cells appear to dissect between the collagen fibers.<ref name="pmid25246470">{{cite journal |vauthors=Alkhalili E, Ayoubieh H, O'Brien W, Billings SD |title=Acquired progressive lymphangioma of the nipple |journal=BMJ Case Rep |volume=2014 |issue= |pages= |date=September 2014 |pmid=25246470 |pmc=4173197 |doi=10.1136/bcr-2014-205966 |url=}}</ref><ref name="pmid21034710">{{cite journal |vauthors=Messeguer F, Sanmartín O, Martorell-Calatayud A, Nagore E, Requena C, Guillén-Barona C |title=[Acquired progressive lymphangioma (benign lymphangioendothelioma)] |language=Spanish; Castilian |journal=Actas Dermosifiliogr |volume=101 |issue=9 |pages=792–7 |date=November 2010 |pmid=21034710 |doi= |url=}}</ref><ref name="pmid7999605">{{cite journal |vauthors=Meunier L, Barneon G, Meynadier J |title=Acquired progressive lymphangioma |journal=Br. J. Dermatol. |volume=131 |issue=5 |pages=706–8 |date=November 1994 |pmid=7999605 |doi= |url=}}</ref><ref name="pmid12601956">{{cite journal |vauthors=Paredes Esteban RM, Velasco Sánchez B, Martínez-Victoria Muñoz JM, Cuevas C, García Ruiz M |title=[Progressive acquired lymphangioma: report of a case and review of the literature] |language=Spanish; Castilian |journal=Cir Pediatr |volume=13 |issue=4 |pages=170–1 |date=October 2000 |pmid=12601956 |doi= |url=}}</ref>
* Excision is usually the treatment of choice but some other therapies such as Imiquimod 5% cream have been tried.<ref name="pmid29633311">{{cite journal |vauthors=Larkin SC, Wentworth AB, Lehman JS, Tollefson MM |title=A case of extensive acquired progressive lymphangioma |journal=Pediatr Dermatol |volume=35 |issue=4 |pages=486–489 |date=July 2018 |pmid=29633311 |doi=10.1111/pde.13486 |url=}}</ref><ref name="pmid28940760">{{cite journal |vauthors=Salman A, Sarac G, Can Kuru B, Cinel L, Yucelten AD, Ergun T |title=Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream |journal=Pediatr Dermatol |volume=34 |issue=6 |pages=e302–e304 |date=November 2017 |pmid=28940760 |doi=10.1111/pde.13283 |url=}}</ref>
=====Primary lymphedema=====
* Edema due to obstruction or disorder of lymphatic vessels and lymph nodes. Can present at any stage of life but majority of he cases present at puberty.<ref name="pmid9796078">{{cite journal |vauthors=Szuba A, Rockson SG |title=Lymphedema: classification, diagnosis and therapy |journal=Vasc Med |volume=3 |issue=2 |pages=145–56 |date=1998 |pmid=9796078 |doi=10.1177/1358836X9800300209 |url=}}</ref>
* Treatment is usually conservative by compression therapy that may include complex physical therapy, pneumatic pumps and compressive garments. Some cases may require volume reducing surgery. Lymphatic microsurgery is being tried in some experimental studies.<ref name="pmid9796078">{{cite journal |vauthors=Szuba A, Rockson SG |title=Lymphedema: classification, diagnosis and therapy |journal=Vasc Med |volume=3 |issue=2 |pages=145–56 |date=1998 |pmid=9796078 |doi=10.1177/1358836X9800300209 |url=}}</ref>
*# '''Nonne-Milroy syndrome'''
*#* A hereditary disorder that usually presents as bilateral edema of lower limbs that may involve the whole extremity or may be limited to legs, feet or toes. This may or may not be accompanied by toenail changes such as upslanting toenails and deep creases in the toes, papillomatosis, hydrocele, hydrothorax, lung hypoplasia and prominent leg veins. A case of unilateral phenotype have also been reported. Swellings may be complicated by recurrent episodes of cellulitis.<ref name="pmid12528167">{{cite journal |vauthors=Lev-Sagie A, Hamani Y, Raas-Rothschild A, Yagel S, Anteby EY |title=Prenatal ultrasonographic diagnosis of atypical Nonne-Milroy lymphedema |journal=Ultrasound Obstet Gynecol |volume=21 |issue=1 |pages=72–4 |date=January 2003 |pmid=12528167 |doi=10.1002/uog.16 |url=}}</ref><ref name="pmid2075326">{{cite journal |vauthors=Zbranca V, Aramă A, Mihăescu T, Covic M |title=[Hereditary lymphedema (Nonne-Milroy-Meige syndrome) associated with chylothorax. Comments on 2 cases] |language=Romanian |journal=Rev Med Chir Soc Med Nat Iasi |volume=94 |issue=1 |pages=189–92 |date=1990 |pmid=2075326 |doi= |url=}}</ref><ref name="urlMilroy disease - Genetics Home Reference - NIH">{{cite web |url=https://ghr.nlm.nih.gov/condition/milroy-disease#inheritance |title=Milroy disease - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref><ref name="pmid16924388">{{cite journal |vauthors=Spiegel R, Ghalamkarpour A, Daniel-Spiegel E, Vikkula M, Shalev SA |title=Wide clinical spectrum in a family with hereditary lymphedema type I due to a novel missense mutation in VEGFR3 |journal=J. Hum. Genet. |volume=51 |issue=10 |pages=846–50 |date=2006 |pmid=16924388 |doi=10.1007/s10038-006-0031-3 |url=}}</ref>
*#* The disease typically follows autosomal-dominant pattern though cases of autosomal-recessive inheritance and variable expression has also been reported. The defect thought to be responsible has been located on VEGFR3 (FLT4) gene that codes for vascular endothelial growth factor receptor 3 (VEGFR3).<ref name="urlMilroy disease - Genetics Home Reference - NIH">{{cite web |url=+https://ghr.nlm.nih.gov/condition/milroy-disease#inheritance |title=Milroy disease - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref><ref name="pmid16924388">{{cite journal |vauthors=Spiegel R, Ghalamkarpour A, Daniel-Spiegel E, Vikkula M, Shalev SA |title=Wide clinical spectrum in a family with hereditary lymphedema type I due to a novel missense mutation in VEGFR3 |journal=J. Hum. Genet. |volume=51 |issue=10 |pages=846–50 |date=2006 |pmid=16924388 |doi=10.1007/s10038-006-0031-3 |url=}}</ref><ref name="pmid2075326">{{cite journal |vauthors=Zbranca V, Aramă A, Mihăescu T, Covic M |title=[Hereditary lymphedema (Nonne-Milroy-Meige syndrome) associated with chylothorax. Comments on 2 cases] |language=Romanian |journal=Rev Med Chir Soc Med Nat Iasi |volume=94 |issue=1 |pages=189–92 |date=1990 |pmid=2075326 |doi= |url=}}</ref>
*# '''Primary hereditary lymphedema'''
*#* Chronic edema that can appear in any body part due to blockage or malfunctioning of lymphatic channels that may lead to recurrent infections and impairment.<ref name="pmid30071673">{{cite journal |vauthors=Nadarajah N, Schulte D, McConnell V, Martin-Almedina S, Karapouliou C, Mortimer PS, Jeffery S, Schulte-Merker S, Gordon K, Mansour S, Ostergaard P |title=A Novel Splice-Site Mutation in VEGFC Is Associated with Congenital Primary Lymphoedema of Gordon |journal=Int J Mol Sci |volume=19 |issue=8 |pages= |date=August 2018 |pmid=30071673 |pmc=6121331 |doi=10.3390/ijms19082259 |url=}}</ref><ref name="urlVEGFC gene - Genetics Home Reference - NIH">{{cite web |url=https://ghr.nlm.nih.gov/gene/VEGFC#conditions |title=VEGFC gene - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref>
*#* Results from mutations in VEGFC gene that encodes the ligand for the vascular endothelial growth factor receptor 3 (VEGFR3/FLT4). This gene plays an important role in lymphangiogenesis.<ref name="urlVEGFC gene - Genetics Home Reference - NIH">{{cite web |url=https://ghr.nlm.nih.gov/gene/VEGFC#conditions |title=VEGFC gene - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref><ref name="pmid30071673">{{cite journal |vauthors=Nadarajah N, Schulte D, McConnell V, Martin-Almedina S, Karapouliou C, Mortimer PS, Jeffery S, Schulte-Merker S, Gordon K, Mansour S, Ostergaard P |title=A Novel Splice-Site Mutation in VEGFC Is Associated with Congenital Primary Lymphoedema of Gordon |journal=Int J Mol Sci |volume=19 |issue=8 |pages= |date=August 2018 |pmid=30071673 |pmc=6121331 |doi=10.3390/ijms19082259 |url=}}</ref>
*# '''Primary hereditary lymphedema'''
*#* Edema typically first appears in legs and then progresses to involve the arms.<ref name="urlGJC2 gene - Genetics Home Reference - NIH">{{cite web |url=https://ghr.nlm.nih.gov/gene/GJC2#conditions |title=GJC2 gene - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref>
*#* Thought to be associated with muatation in GJC2 gene that encodes for connexin-47, a member of the gap junction connecxin family. Mutation in this gene has also been linked to Pelizaeus-Merzbacher-like disease type 1 and spastic paraplegia type 44.<ref name="urlGJC2 gene - Genetics Home Reference - NIH">{{cite web |url=https://ghr.nlm.nih.gov/gene/GJC2#conditions |title=GJC2 gene - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref><ref name="pmid23550541">{{cite journal |vauthors=Brice G, Ostergaard P, Jeffery S, Gordon K, Mortimer PS, Mansour S |title=A novel mutation in GJA1 causing oculodentodigital syndrome and primary lymphoedema in a three generation family |journal=Clin. Genet. |volume=84 |issue=4 |pages=378–81 |date=October 2013 |pmid=23550541 |doi=10.1111/cge.12158 |url=}}</ref>
*# '''Lymphedema-distichiasis'''
*#* A syndrome that is characterized by edema that typically manifests in lower limb and distichiasis that is an anomaly of eyelashes. Distichiasis appears earlier in life than lymphedema and manifests as extra eyelashes that typically arise from meibomian glands. This syndrome has been associated with congenital heart disease, varicose veins, cleft palate, ptosis, strabismus, renal abnormalities, spinal extradural cysts, and neck webbing.<ref name="pmid26759405">{{cite journal |vauthors=Marques NS, Miranda A, Barros S, Parreira S |title=Lymphoedema-distichiasis syndrome |journal=BMJ Case Rep |volume=2016 |issue= |pages= |date=January 2016 |pmid=26759405 |pmc=4716369 |doi=10.1136/bcr-2015-213651 |url=}}</ref><ref name="pmid17366583">{{cite journal |vauthors=Yabuki S, Kikuchi S, Ikegawa S |title=Spinal extradural arachnoid cysts associated with distichiasis and lymphedema |journal=Am. J. Med. Genet. A |volume=143A |issue=8 |pages=884–7 |date=April 2007 |pmid=17366583 |doi=10.1002/ajmg.a.31669 |url=}}</ref><ref name="pmid12114478">{{cite journal |vauthors=Brice G, Mansour S, Bell R, Collin JR, Child AH, Brady AF, Sarfarazi M, Burnand KG, Jeffery S, Mortimer P, Murday VA |title=Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24 |journal=J. Med. Genet. |volume=39 |issue=7 |pages=478–83 |date=July 2002 |pmid=12114478 |pmc=1735188 |doi= |url=}}</ref><ref name="pmid23806988">{{cite journal |vauthors=Sardesai VR, Mhatre MA, Patil RM |title=Lymphoedema - distichiasis syndrome with recurrent abortions |journal=Indian J Med Sci |volume=66 |issue=5-6 |pages=141–3 |date=2012 |pmid=23806988 |doi=10.4103/0019-5359.114202 |url=}}</ref><ref name="pmid28959174">{{cite journal |vauthors=Planinsek Rucigaj T, Rijavec M, Miljkovic J, Selb J, Korosec P |title=A Novel Mutation in the FOXC2 Gene: A Heterozygous Insertion of Adenosine (c.867insA) in a Family with Lymphoedema of Lower Limbs without Distichiasis |journal=Radiol Oncol |volume=51 |issue=3 |pages=363–368 |date=September 2017 |pmid=28959174 |pmc=5612002 |doi=10.1515/raon-2017-0026 |url=}}</ref><ref name="pmid29406328">{{cite journal |vauthors=De Niear MA, Breazzano MP, Mawn LA |title=Novel FOXC2 Mutation and Distichiasis in a Patient With Lymphedema-Distichiasis Syndrome |journal=Ophthalmic Plast Reconstr Surg |volume=34 |issue=3 |pages=e88–e90 |date=2018 |pmid=29406328 |doi=10.1097/IOP.0000000000001079 |url=}}</ref>
*#* Inherited in autosomal dominant pattern mutation in FOXC2 gene that encodes for transcription factors. Inheritance also shows variable expression.<ref name="pmid24984567">{{cite journal |vauthors=Zhu LL, Lv YN, Chen HD, Gao XH |title=A Chinese pedigree of lymphoedema-distichiasis syndrome with a novel mutation in the FOXC2 gene |journal=Clin. Exp. Dermatol. |volume=39 |issue=6 |pages=731–3 |date=August 2014 |pmid=24984567 |doi=10.1111/ced.12389 |url=}}</ref><ref name="pmid27570485">{{cite journal |vauthors=Zhang L, He J, Han B, Lu L, Fan J, Zhang H, Ge S, Zhou Y, Jia R, Fan X |title=Novel FOXC2 Mutation in Hereditary Distichiasis Impairs DNA-Binding Activity and Transcriptional Activation |journal=Int. J. Biol. Sci. |volume=12 |issue=9 |pages=1114–20 |date=2016 |pmid=27570485 |pmc=4997055 |doi=10.7150/ijbs.13774 |url=}}</ref><ref name="pmid28959174">{{cite journal |vauthors=Planinsek Rucigaj T, Rijavec M, Miljkovic J, Selb J, Korosec P |title=A Novel Mutation in the FOXC2 Gene: A Heterozygous Insertion of Adenosine (c.867insA) in a Family with Lymphoedema of Lower Limbs without Distichiasis |journal=Radiol Oncol |volume=51 |issue=3 |pages=363–368 |date=September 2017 |pmid=28959174 |pmc=5612002 |doi=10.1515/raon-2017-0026 |url=}}</ref>
*#* Diagnosis is clinical. Treatment for lymphedema is mainly conservative with management of complications such as cellulitis. Treatment for distichiasis consists of symptomatic management such as lubrication or definitive management such as surgery, cryotherapy, or electrolysis.<ref name="pmid26759405">{{cite journal |vauthors=Marques NS, Miranda A, Barros S, Parreira S |title=Lymphoedema-distichiasis syndrome |journal=BMJ Case Rep |volume=2016 |issue= |pages= |date=January 2016 |pmid=26759405 |pmc=4716369 |doi=10.1136/bcr-2015-213651 |url=}}</ref><ref name="pmid20301630">{{cite journal |vauthors=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Mansour S, Brice GW, Jeffery S, Mortimer P |title= |journal= |volume= |issue= |pages= |date= |pmid=20301630 |doi= |url=}}</ref>
*# '''Hypotrichosis-lymphedema-telangiectasia'''
*#* Characterized by less than normal body hair (hypotrichosis), chronic swelling of the body (lymphedema), and dilated blood vessels (telangiectasia). These usually appear at birth or early in life and then progressively worsen over time. Hypotrichosis may present as absent eyebrows, eyelashes and alopecia or may manifest as sparse body hair. Lymphedema typically has predilection for lower limbs and telangiectasia are more commonly seen on palms although plantar telangiectasia are also seen. This syndrome has also been associated with cutis marmorata, hydrocele, palpebral edema, ascites, dermal atrophy, small cutaneous papular vascular lesions, skin degeneration, hydrops fetalis, pleural effusion, renal defects, aortic dilation and abnormal nails.<ref>{{cite web |url=https://rarediseases.info.nih.gov/diseases/12827/hypotrichosis-lymphedema-telangiectasia-syndrome |title=Hypotrichosis-lymphedema-telangiectasia syndrome &#124; Genetic and Rare Diseases Information Center (GARD) – an NCATS Program |format= |work= |accessdate=}}</ref><ref>{{cite journal |vauthors=Wünnemann F, Kokta V, Leclerc S, Thibeault M, McCuaig C, Hatami A, Stheneur C, Grenier JC, Awadalla P, Mitchell GA, Andelfinger G, Preuss C |title=Aortic Dilatation Associated With a De Novo Mutation in the SOX18 Gene: Expanding the Clinical Spectrum of Hypotrichosis-Lymphedema-Telangiectasia Syndrome |journal=Can J Cardiol |volume=32 |issue=1 |pages=135.e1–7 |date=January 2016 |pmid=26148450 |doi=10.1016/j.cjca.2015.04.004 |url=}}</ref><ref>{{cite journal |vauthors=Moalem S, Brouillard P, Kuypers D, Legius E, Harvey E, Taylor G, Francois M, Vikkula M, Chitayat D |title=Hypotrichosis-lymphedema-telangiectasia-renal defect associated with a truncating mutation in the SOX18 gene |journal=Clin. Genet. |volume=87 |issue=4 |pages=378–82 |date=April 2015 |pmid=24697860 |doi=10.1111/cge.12388 |url=}}</ref><ref>{{cite journal |vauthors=Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M |title=Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia |journal=Am. J. Hum. Genet. |volume=72 |issue=6 |pages=1470–8 |date=June 2003 |pmid=12740761 |pmc=1180307 |doi=10.1086/375614 |url=}}</ref>
*#* Mutation in SOX18 gene that encodes for transcription factor SOX18 is thought to be the cause of this syndrome. This transcription factor is expressed widely in body tissues and that may explain the wide ranging manifestations of this syndrome. Inheritance can both be autosomal-dominant and autosomal-recessive.<ref>{{cite journal |vauthors=Valenzuela I, Fernández-Alvarez P, Plaja A, Ariceta G, Sabaté-Rotés A, García-Arumí E, Vendrell T, Tizzano E |title=Further delineation of the SOX18-related Hypotrichosis, Lymphedema, Telangiectasia syndrome (HTLS) |journal=Eur J Med Genet |volume=61 |issue=5 |pages=269–272 |date=May 2018 |pmid=29307792 |doi=10.1016/j.ejmg.2018.01.001 |url=}}</ref><ref>{{cite journal |vauthors=Bastaki F, Mohamed M, Nair P, Saif F, Tawfiq N, Al-Ali MT, Brandau O, Hamzeh AR |title=A novel SOX18 mutation uncovered in Jordanian patient with hypotrichosis-lymphedema-telangiectasia syndrome by Whole Exome Sequencing |journal=Mol. Cell. Probes |volume=30 |issue=1 |pages=18–21 |date=February 2016 |pmid=26631803 |doi=10.1016/j.mcp.2015.11.005 |url=}}</ref><ref>{{cite journal |vauthors=Wünnemann F, Kokta V, Leclerc S, Thibeault M, McCuaig C, Hatami A, Stheneur C, Grenier JC, Awadalla P, Mitchell GA, Andelfinger G, Preuss C |title=Aortic Dilatation Associated With a De Novo Mutation in the SOX18 Gene: Expanding the Clinical Spectrum of Hypotrichosis-Lymphedema-Telangiectasia Syndrome |journal=Can J Cardiol |volume=32 |issue=1 |pages=135.e1–7 |date=January 2016 |pmid=26148450 |doi=10.1016/j.cjca.2015.04.004 |url=}}</ref><ref>{{cite journal |vauthors=Moalem S, Brouillard P, Kuypers D, Legius E, Harvey E, Taylor G, Francois M, Vikkula M, Chitayat D |title=Hypotrichosis-lymphedema-telangiectasia-renal defect associated with a truncating mutation in the SOX18 gene |journal=Clin. Genet. |volume=87 |issue=4 |pages=378–82 |date=April 2015 |pmid=24697860 |doi=10.1111/cge.12388 |url=}}{{cite journal |vauthors=Downes M, François M, Ferguson C, Parton RG, Koopman P |title=Vascular defects in a mouse model of hypotrichosis-lymphedema-telangiectasia syndrome indicate a role for SOX18 in blood vessel maturation |journal=Hum. Mol. Genet. |volume=18 |issue=15 |pages=2839–50 |date=August 2009 |pmid=19429912 |doi=10.1093/hmg/ddp219 |url=}}</ref><ref>{{cite journal |vauthors=François M, Caprini A, Hosking B, Orsenigo F, Wilhelm D, Browne C, Paavonen K, Karnezis T, Shayan R, Downes M, Davidson T, Tutt D, Cheah KS, Stacker SA, Muscat GE, Achen MG, Dejana E, Koopman P |title=Sox18 induces development of the lymphatic vasculature in mice |journal=Nature |volume=456 |issue=7222 |pages=643–7 |date=December 2008 |pmid=18931657 |doi=10.1038/nature07391 |url=}}</ref><ref>{{cite journal |vauthors=Irrthum A, Devriendt K, Chitayat D, Matthijs G, Glade C, Steijlen PM, Fryns JP, Van Steensel MA, Vikkula M |title=Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia |journal=Am. J. Hum. Genet. |volume=72 |issue=6 |pages=1470–8 |date=June 2003 |pmid=12740761 |pmc=1180307 |doi=10.1086/375614 |url=}}</ref><ref>{{cite web |url=https://rarediseases.info.nih.gov/diseases/12827/hypotrichosis-lymphedema-telangiectasia-syndrome |title=Hypotrichosis-lymphedema-telangiectasia syndrome &#124; Genetic and Rare Diseases Information Center (GARD) – an NCATS Program |format= |work= |accessdate=}}</ref>
*#* There is no definitive treatment for this syndrome. Management is based on genetic counseling and symptomatic treatment.<ref>{{cite web |url=https://rarediseases.info.nih.gov/diseases/12827/hypotrichosis-lymphedema-telangiectasia-syndrome |title=Hypotrichosis-lymphedema-telangiectasia syndrome &#124; Genetic and Rare Diseases Information Center (GARD) – an NCATS Program |format= |work= |accessdate=}}</ref><ref>{{cite journal |vauthors=Valenzuela I, Fernández-Alvarez P, Plaja A, Ariceta G, Sabaté-Rotés A, García-Arumí E, Vendrell T, Tizzano E |title=Further delineation of the SOX18-related Hypotrichosis, Lymphedema, Telangiectasia syndrome (HTLS) |journal=Eur J Med Genet |volume=61 |issue=5 |pages=269–272 |date=May 2018 |pmid=29307792 |doi=10.1016/j.ejmg.2018.01.001 |url=}}</ref>
*# '''Primary lymphedema with myelodysplasia'''
*#* Also called Emberger syndrome, this anomaly presents with wide variety of phenotypes including congenital sensorineural deafness, lymphedema, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), hypotelorism, epicanthic folds, long tapering fingers and/or neck webbing, and generalized warts.. Lymphedema has predisposition for lower limbs. Patient may present with complication of these phenotypes such as infections, bleeding and recurrent cellulitis.<ref name="pmid26767875">{{cite journal |vauthors=Seo SK, Kim KY, Han SA, Yoon JS, Shin SY, Sohn SK, Moon JH |title=First Korean case of Emberger syndrome (primary lymphedema with myelodysplasia) with a novel GATA2 gene mutation |journal=Korean J. Intern. Med. |volume=31 |issue=1 |pages=188–90 |date=January 2016 |pmid=26767875 |pmc=4712426 |doi=10.3904/kjim.2016.31.1.188 |url=}}</ref><ref name="pmid21892158">{{cite journal |vauthors=Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, Dafou D, Kilo T, Smithson S, Lunt P, Murday VA, Hodgson S, Keenan R, Pilz DT, Martinez-Corral I, Makinen T, Mortimer PS, Jeffery S, Trembath RC, Mansour S |title=Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) |journal=Nat. Genet. |volume=43 |issue=10 |pages=929–31 |date=September 2011 |pmid=21892158 |doi=10.1038/ng.923 |url=}}</ref><ref name="pmid20803646">{{cite journal |vauthors=Mansour S, Connell F, Steward C, Ostergaard P, Brice G, Smithson S, Lunt P, Jeffery S, Dokal I, Vulliamy T, Gibson B, Hodgson S, Cottrell S, Kiely L, Tinworth L, Kalidas K, Mufti G, Cornish J, Keenan R, Mortimer P, Murday V |title=Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases |journal=Am. J. Med. Genet. A |volume=152A |issue=9 |pages=2287–96 |date=September 2010 |pmid=20803646 |doi=10.1002/ajmg.a.33445 |url=}}</ref><ref name="pmid29605372">{{cite journal |vauthors=Zawawi F, Sokolov M, Mawby T, Gordon KA, Papsin BC, Cushing SL |title=Emberger syndrome: A rare association with hearing loss |journal=Int. J. Pediatr. Otorhinolaryngol. |volume=108 |issue= |pages=82–84 |date=May 2018 |pmid=29605372 |doi=10.1016/j.ijporl.2018.02.014 |url=}}</ref>
*#* Deficiency of transcription factor GATA2 due to mutations in GATA2 gene is thought to play the critical role. Inheritance tends to follow autosomal-dominant pattern.<ref name="pmid26767875">{{cite journal |vauthors=Seo SK, Kim KY, Han SA, Yoon JS, Shin SY, Sohn SK, Moon JH |title=First Korean case of Emberger syndrome (primary lymphedema with myelodysplasia) with a novel GATA2 gene mutation |journal=Korean J. Intern. Med. |volume=31 |issue=1 |pages=188–90 |date=January 2016 |pmid=26767875 |pmc=4712426 |doi=10.3904/kjim.2016.31.1.188 |url=}}</ref><ref name="pmid21892158">{{cite journal |vauthors=Ostergaard P, Simpson MA, Connell FC, Steward CG, Brice G, Woollard WJ, Dafou D, Kilo T, Smithson S, Lunt P, Murday VA, Hodgson S, Keenan R, Pilz DT, Martinez-Corral I, Makinen T, Mortimer PS, Jeffery S, Trembath RC, Mansour S |title=Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) |journal=Nat. Genet. |volume=43 |issue=10 |pages=929–31 |date=September 2011 |pmid=21892158 |doi=10.1038/ng.923 |url=}}</ref><ref name="pmid20803646">{{cite journal |vauthors=Mansour S, Connell F, Steward C, Ostergaard P, Brice G, Smithson S, Lunt P, Jeffery S, Dokal I, Vulliamy T, Gibson B, Hodgson S, Cottrell S, Kiely L, Tinworth L, Kalidas K, Mufti G, Cornish J, Keenan R, Mortimer P, Murday V |title=Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases |journal=Am. J. Med. Genet. A |volume=152A |issue=9 |pages=2287–96 |date=September 2010 |pmid=20803646 |doi=10.1002/ajmg.a.33445 |url=}}</ref><ref name="pmid25397911">{{cite journal |vauthors=Hsu AP, McReynolds LJ, Holland SM |title=GATA2 deficiency |journal=Curr Opin Allergy Clin Immunol |volume=15 |issue=1 |pages=104–9 |date=February 2015 |pmid=25397911 |pmc=4342850 |doi=10.1097/ACI.0000000000000126 |url=}}</ref><ref name="pmid24345756">{{cite journal |vauthors=Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hämäläinen S, Seppänen M, Helbert M, Tholouli E, Gambineri E, Reykdal S, Gottfreðsson M, Thaventhiran JE, Morris E, Hirschfield G, Richter AG, Jolles S, Bacon CM, Hambleton S, Haniffa M, Bryceson Y, Allen C, Prchal JT, Dick JE, Bigley V, Collin M |title=The evolution of cellular deficiency in GATA2 mutation |journal=Blood |volume=123 |issue=6 |pages=863–74 |date=February 2014 |pmid=24345756 |pmc=3916878 |doi=10.1182/blood-2013-07-517151 |url=}}</ref><ref name="pmid29605372">{{cite journal |vauthors=Zawawi F, Sokolov M, Mawby T, Gordon KA, Papsin BC, Cushing SL |title=Emberger syndrome: A rare association with hearing loss |journal=Int. J. Pediatr. Otorhinolaryngol. |volume=108 |issue= |pages=82–84 |date=May 2018 |pmid=29605372 |doi=10.1016/j.ijporl.2018.02.014 |url=}}</ref>
*#* Screening for GATA2 muations is indicated in patients who present with lymphedema and hematological abnormalities. Children should be screened for hematological disorders if they present with lower limb lymphedema. Besides symptomatic treatment for lymphedema and standard treatment for deafness, primary stem cell transplant is indicated for hematological malignancies. <ref name="pmid20803646">{{cite journal |vauthors=Mansour S, Connell F, Steward C, Ostergaard P, Brice G, Smithson S, Lunt P, Jeffery S, Dokal I, Vulliamy T, Gibson B, Hodgson S, Cottrell S, Kiely L, Tinworth L, Kalidas K, Mufti G, Cornish J, Keenan R, Mortimer P, Murday V |title=Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases |journal=Am. J. Med. Genet. A |volume=152A |issue=9 |pages=2287–96 |date=September 2010 |pmid=20803646 |doi=10.1002/ajmg.a.33445 |url=}}</ref><ref name="pmid26767875">{{cite journal |vauthors=Seo SK, Kim KY, Han SA, Yoon JS, Shin SY, Sohn SK, Moon JH |title=First Korean case of Emberger syndrome (primary lymphedema with myelodysplasia) with a novel GATA2 gene mutation |journal=Korean J. Intern. Med. |volume=31 |issue=1 |pages=188–90 |date=January 2016 |pmid=26767875 |pmc=4712426 |doi=10.3904/kjim.2016.31.1.188 |url=}}</ref><ref name="pmid28643018">{{cite journal |vauthors=Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM |title=Heterogeneity of GATA2-related myeloid neoplasms |journal=Int. J. Hematol. |volume=106 |issue=2 |pages=175–182 |date=August 2017 |pmid=28643018 |doi=10.1007/s12185-017-2285-2 |url=}}</ref><ref name="pmid28179280">{{cite journal |vauthors=Crispino JD, Horwitz MS |title=GATA factor mutations in hematologic disease |journal=Blood |volume=129 |issue=15 |pages=2103–2110 |date=April 2017 |pmid=28179280 |pmc=5391620 |doi=10.1182/blood-2016-09-687889 |url=}}</ref>
*# '''Primary generalized lymphatic anomaly'''
*#* Also called Hennekam lymphangiectasia-lymphedema syndrome, this disorder is characterized by generalized lymphatic anomalies such as lymphangiectasia and lymphedema, typical dysmorphic features such as flat nasal bridge, hypertelorism, small mouth and variable intellectual disability that may present as developmental delay. Lymphangiectasias are typically found in intestines and can cause generalized body swelling due to loss of proteins but can also be found in other organs such as kidney, thyroid gland and pleura.<ref name="pmid25925991">{{cite journal |vauthors=Frosk P, Chodirker B, Simard L, El-Matary W, Hanlon-Dearman A, Schwartzentruber J, Majewski J, Rockman-Greenberg C |title=A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature |journal=BMC Med. Genet. |volume=16 |issue= |pages=28 |date=April 2015 |pmid=25925991 |pmc=4630843 |doi=10.1186/s12881-015-0175-0 |url=}}</ref><ref name="pmid12376947">{{cite journal |vauthors=Van Balkom ID, Alders M, Allanson J, Bellini C, Frank U, De Jong G, Kolbe I, Lacombe D, Rockson S, Rowe P, Wijburg F, Hennekam RC |title=Lymphedema-lymphangiectasia-mental retardation (Hennekam) syndrome: a review |journal=Am. J. Med. Genet. |volume=112 |issue=4 |pages=412–21 |date=November 2002 |pmid=12376947 |doi=10.1002/ajmg.10707 |url=}}</ref><ref name="pmid25616299">{{cite journal |vauthors=Deng XL, Yin F, Zhang GY, Duan YD |title=[A complicated case study: Hennekam syndrome] |language=Chinese |journal=Zhongguo Dang Dai Er Ke Za Zhi |volume=17 |issue=1 |pages=77–80 |date=January 2015 |pmid=25616299 |doi= |url=}}</ref>
*#* Mutations in CCBE1 gene are thought to be the main culprit although mutations in FAT4 gene has also be linked by some studies. CCBE1 encodes for Collagen- and calcium-binding EGF domain-containing protein 1 (CCBE1) that plays a crucial role in activation of vascular endothelial growth factor-C (VEGFC) through its collagen domain. Inheritance tends to follow autosomal-recessive pattern.<ref name="pmid25814692">{{cite journal |vauthors=Roukens MG, Peterson-Maduro J, Padberg Y, Jeltsch M, Leppänen VM, Bos FL, Alitalo K, Schulte-Merker S, Schulte D |title=Functional Dissection of the CCBE1 Protein: A Crucial Requirement for the Collagen Repeat Domain |journal=Circ. Res. |volume=116 |issue=10 |pages=1660–9 |date=May 2015 |pmid=25814692 |doi=10.1161/CIRCRESAHA.116.304949 |url=}}</ref><ref name="pmid25925991">{{cite journal |vauthors=Frosk P, Chodirker B, Simard L, El-Matary W, Hanlon-Dearman A, Schwartzentruber J, Majewski J, Rockman-Greenberg C |title=A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature |journal=BMC Med. Genet. |volume=16 |issue= |pages=28 |date=April 2015 |pmid=25925991 |pmc=4630843 |doi=10.1186/s12881-015-0175-0 |url=}}</ref><ref name="pmid25616299">{{cite journal |vauthors=Deng XL, Yin F, Zhang GY, Duan YD |title=[A complicated case study: Hennekam syndrome] |language=Chinese |journal=Zhongguo Dang Dai Er Ke Za Zhi |volume=17 |issue=1 |pages=77–80 |date=January 2015 |pmid=25616299 |doi= |url=}}</ref><ref name="pmid24552833">{{cite journal |vauthors=Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppänen VM, Holopainen T, Kivelä R, Ortega S, Kärpanen T, Alitalo K |title=CCBE1 enhances lymphangiogenesis via A disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation |journal=Circulation |volume=129 |issue=19 |pages=1962–71 |date=May 2014 |pmid=24552833 |doi=10.1161/CIRCULATIONAHA.113.002779 |url=}}</ref>
*#* Diagnosis depends on history and examination, lab findings, and genetic testing for associated mutations. Analysis for CCBE1 mutation should be considered in patients presenting with unexplained lymphatic anomalies, and/or unexplained intellectual disability. No definitive management is available at this point. Conservative measures for lymphedema and protein deficiency, and rehabilitation for intellectual disability is the mainstay of management.<ref name="pmid29560340">{{cite journal |vauthors=Lee YG, Kim SC, Park SB, Kim MJ |title=Hennekam Syndrome: A Case Report |journal=Ann Rehabil Med |volume=42 |issue=1 |pages=184–188 |date=February 2018 |pmid=29560340 |pmc=5852224 |doi=10.5535/arm.2018.42.1.184 |url=}}</ref><ref name="pmid25925991">{{cite journal |vauthors=Frosk P, Chodirker B, Simard L, El-Matary W, Hanlon-Dearman A, Schwartzentruber J, Majewski J, Rockman-Greenberg C |title=A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature |journal=BMC Med. Genet. |volume=16 |issue= |pages=28 |date=April 2015 |pmid=25925991 |pmc=4630843 |doi=10.1186/s12881-015-0175-0 |url=}}</ref><ref name="pmid25616299">{{cite journal |vauthors=Deng XL, Yin F, Zhang GY, Duan YD |title=[A complicated case study: Hennekam syndrome] |language=Chinese |journal=Zhongguo Dang Dai Er Ke Za Zhi |volume=17 |issue=1 |pages=77–80 |date=January 2015 |pmid=25616299 |doi= |url=}}</ref><ref name="pmid29560340">{{cite journal |vauthors=Lee YG, Kim SC, Park SB, Kim MJ |title=Hennekam Syndrome: A Case Report |journal=Ann Rehabil Med |volume=42 |issue=1 |pages=184–188 |date=February 2018 |pmid=29560340 |pmc=5852224 |doi=10.5535/arm.2018.42.1.184 |url=}}</ref>
*# '''Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome'''
*#* As name indicates, this syndrome is characterized by microcephaly that is often accompanied by intellectual disability, congenital lymphedema and ocular findings. Ocular defects, often because of chorioretinal dysplasia, may include peripheral retinal pigmentation, retinal folds, chorioretinopathy, widespread chorioretinal atrophy, hyperopia, small corneas, nystagmus and small optic nerves. Microcephaly can be variable and imaging often shows small size brain. Intellectual disability can also vary from normal developmental to severe mental retardation. Lymphedema most often involves lower limbs and may or may not resolve spontaneously. Facial features are distinct with broad nose, anteverted nares, upslanting palpebral fissures, a rounded nasal tip, a long philtrum, a pointed chin, a thin upper lip, prominent ears, and patient may also have atrial septal defects.<ref name="pmid25934493">{{cite journal |vauthors=Schlögel MJ, Mendola A, Fastré E, Vasudevan P, Devriendt K, de Ravel TJ, Van Esch H, Casteels I, Arroyo Carrera I, Cristofoli F, Fieggen K, Jones K, Lipson M, Balikova I, Singer A, Soller M, Mercedes Villanueva M, Revencu N, Boon LM, Brouillard P, Vikkula M |title=No evidence of locus heterogeneity in familial microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome |journal=Orphanet J Rare Dis |volume=10 |issue= |pages=52 |date=May 2015 |pmid=25934493 |pmc=4464120 |doi=10.1186/s13023-015-0271-4 |url=}}</ref><ref name="pmid5936364">{{cite journal |vauthors=McKusick VA, Stauffer M, Knox DL, Clark DB |title=Chorioretinopathy with hereditary microcephaly |journal=Arch. Ophthalmol. |volume=75 |issue=5 |pages=597–600 |date=May 1966 |pmid=5936364 |doi= |url=}}</ref><ref name="pmid15930898">{{cite journal |vauthors=Vasudevan PC, Garcia-Minaur S, Botella MP, Perez-Aytes A, Shannon NL, Quarrell OW |title=Microcephaly-lymphoedema-chorioretinal dysplasia: three cases to delineate the facial phenotype and review of the literature |journal=Clin. Dysmorphol. |volume=14 |issue=3 |pages=109–16 |date=July 2005 |pmid=15930898 |doi= |url=}}</ref><ref name="pmid19076985">{{cite journal |vauthors=Eventov-Friedman S, Singer A, Shinwell ES |title=Microcephaly, lymphedema, chorioretinopathy and atrial septal defect: a case report and review of the literature |journal=Acta Paediatr. |volume=98 |issue=4 |pages=758–9 |date=April 2009 |pmid=19076985 |doi=10.1111/j.1651-2227.2008.01161.x |url=}}</ref><ref name="pmid25115524">{{cite journal |vauthors=Mirzaa GM, Enyedi L, Parsons G, Collins S, Medne L, Adams C, Ward T, Davitt B, Bicknese A, Zackai E, Toriello H, Dobyns WB, Christian S |title=Congenital microcephaly and chorioretinopathy due to de novo heterozygous KIF11 mutations: five novel mutations and review of the literature |journal=Am. J. Med. Genet. A |volume=164A |issue=11 |pages=2879–86 |date=November 2014 |pmid=25115524 |pmc=4205200 |doi=10.1002/ajmg.a.36707 |url=}}</ref>
*#* Mutations in KIF11 gene that encodes for spindle motor protein of kinesin family, a protein that plays a role in mitosis, are thought to cause this syndrome. These mutations can be sporadic or hereditary, and when hereditary they follow autosomal-dominant pattern with variable expression and reduced penetrance.<ref name="pmid25934493">{{cite journal |vauthors=Schlögel MJ, Mendola A, Fastré E, Vasudevan P, Devriendt K, de Ravel TJ, Van Esch H, Casteels I, Arroyo Carrera I, Cristofoli F, Fieggen K, Jones K, Lipson M, Balikova I, Singer A, Soller M, Mercedes Villanueva M, Revencu N, Boon LM, Brouillard P, Vikkula M |title=No evidence of locus heterogeneity in familial microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome |journal=Orphanet J Rare Dis |volume=10 |issue= |pages=52 |date=May 2015 |pmid=25934493 |pmc=4464120 |doi=10.1186/s13023-015-0271-4 |url=}}</ref><ref name="pmid25764055">{{cite journal |vauthors=Mears K, Bakall B, Harney LA, Penticoff JA, Stone EM |title=Autosomal Dominant Microcephaly Associated With Congenital Lymphedema and Chorioretinopathy Due to a Novel Mutation in KIF11 |journal=JAMA Ophthalmol |volume=133 |issue=6 |pages=720–1 |date=June 2015 |pmid=25764055 |doi=10.1001/jamaophthalmol.2015.199 |url=}}</ref><ref name="pmid26472404">{{cite journal |vauthors=Hu H, Xiao X, Li S, Jia X, Guo X, Zhang Q |title=KIF11 mutations are a common cause of autosomal dominant familial exudative vitreoretinopathy |journal=Br J Ophthalmol |volume=100 |issue=2 |pages=278–83 |date=February 2016 |pmid=26472404 |doi=10.1136/bjophthalmol-2015-306878 |url=}}</ref><ref name="pmid25996076">{{cite journal |vauthors=Balikova I, Robson AG, Holder GE, Ostergaard P, Mansour S, Moore AT |title=Ocular manifestations of microcephaly with or without chorioretinopathy, lymphedema or intellectual disability (MCLID) syndrome associated with mutations in KIF11 |journal=Acta Ophthalmol |volume=94 |issue=1 |pages=92–8 |date=February 2016 |pmid=25996076 |doi=10.1111/aos.12759 |url=}}</ref><ref name="pmid24281367">{{cite journal |vauthors=Jones GE, Ostergaard P, Moore AT, Connell FC, Williams D, Quarrell O, Brady AF, Spier I, Hazan F, Moldovan O, Wieczorek D, Mikat B, Petit F, Coubes C, Saul RA, Brice G, Gordon K, Jeffery S, Mortimer PS, Vasudevan PC, Mansour S |title=Microcephaly with or without chorioretinopathy, lymphoedema, or mental retardation (MCLMR): review of phenotype associated with KIF11 mutations |journal=Eur. J. Hum. Genet. |volume=22 |issue=7 |pages=881–7 |date=July 2014 |pmid=24281367 |pmc=3938398 |doi=10.1038/ejhg.2013.263 |url=}}</ref>
*#* Diagnosis requires genetic testing in addition to clinical findings. Long term cardiac and ophthalmologic follow-ups are recommended.<ref name="pmid19076985">{{cite journal |vauthors=Eventov-Friedman S, Singer A, Shinwell ES |title=Microcephaly, lymphedema, chorioretinopathy and atrial septal defect: a case report and review of the literature |journal=Acta Paediatr. |volume=98 |issue=4 |pages=758–9 |date=April 2009 |pmid=19076985 |doi=10.1111/j.1651-2227.2008.01161.x |url=}}</ref><ref name="pmid24281367">{{cite journal |vauthors=Jones GE, Ostergaard P, Moore AT, Connell FC, Williams D, Quarrell O, Brady AF, Spier I, Hazan F, Moldovan O, Wieczorek D, Mikat B, Petit F, Coubes C, Saul RA, Brice G, Gordon K, Jeffery S, Mortimer PS, Vasudevan PC, Mansour S |title=Microcephaly with or without chorioretinopathy, lymphoedema, or mental retardation (MCLMR): review of phenotype associated with KIF11 mutations |journal=Eur. J. Hum. Genet. |volume=22 |issue=7 |pages=881–7 |date=July 2014 |pmid=24281367 |pmc=3938398 |doi=10.1038/ejhg.2013.263 |url=}}</ref>
*# '''Lymphedema-choanal atresia'''
*#* A very rare syndrome described in 1982 in a Middle Eastern family when individuals in the family presented with bilateral posterior choanal atresia with other developmental abnormalities such as high arched palate, hypoplastic nipples, pericardial effusion, and pectus excavatum. Follow up detected lymphedema in five individuals with choanal atresia in the family later in 1991.<ref name="pmid20826270">{{cite journal |vauthors=Au AC, Hernandez PA, Lieber E, Nadroo AM, Shen YM, Kelley KA, Gelb BD, Diaz GA |title=Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans |journal=Am. J. Hum. Genet. |volume=87 |issue=3 |pages=436–44 |date=September 2010 |pmid=20826270 |pmc=2933336 |doi=10.1016/j.ajhg.2010.08.008 |url=}}</ref>
*#* Deletion in PTPN14 gene that appeared to follow autosomal-recessive pattern are thought to be the cause. This gene encodes for a protein that is thought to be involved in cell-signaling pathways and regulation of cellular functions.<ref name="pmid20826270">{{cite journal |vauthors=Au AC, Hernandez PA, Lieber E, Nadroo AM, Shen YM, Kelley KA, Gelb BD, Diaz GA |title=Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans |journal=Am. J. Hum. Genet. |volume=87 |issue=3 |pages=436–44 |date=September 2010 |pmid=20826270 |pmc=2933336 |doi=10.1016/j.ajhg.2010.08.008 |url=}}</ref>
====Venous malformations (VM)====
=====Common VM=====
* Localized defects characterized by dilated venous channels. Microscopically they consist of thin endothelial cells lined by fewer, disorganized smooth muscle cells and extracellular matrix. Patient may present with deforming lesions, bleeding, thrombosis, significant acute or chronic pain, and pressure symptoms. Located on skin and mucosa for majority of the times, lesions often are present at birth.<ref name="pmid26319232">{{cite journal |vauthors=Nätynki M, Kangas J, Miinalainen I, Sormunen R, Pietilä R, Soblet J, Boon LM, Vikkula M, Limaye N, Eklund L |title=Common and specific effects of TIE2 mutations causing venous malformations |journal=Hum. Mol. Genet. |volume=24 |issue=22 |pages=6374–89 |date=November 2015 |pmid=26319232 |pmc=4614705 |doi=10.1093/hmg/ddv349 |url=}}</ref><ref name="pmid27030595">{{cite journal |vauthors=Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VE, Chivite I, Milà-Guasch M, Pearce W, Solomon I, Angulo-Urarte A, Figueiredo AM, Dewhurst RE, Knox RG, Clark GR, Scudamore CL, Badar A, Kalber TL, Foster J, Stuckey DJ, David AL, Phillips WA, Lythgoe MF, Wilson V, Semple RK, Sebire NJ, Kinsler VA, Graupera M, Vanhaesebroeck B |title=Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans |journal=Sci Transl Med |volume=8 |issue=332 |pages=332ra43 |date=March 2016 |pmid=27030595 |pmc=5973268 |doi=10.1126/scitranslmed.aad9982 |url=}}</ref><ref name="pmid26637981">{{cite journal |vauthors=Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, Eklund L, Boon LM, Vikkula M |title=Somatic Activating PIK3CA Mutations Cause Venous Malformation |journal=Am. J. Hum. Genet. |volume=97 |issue=6 |pages=914–21 |date=December 2015 |pmid=26637981 |pmc=4678782 |doi=10.1016/j.ajhg.2015.11.011 |url=}}</ref>
* Sporadic mutations in the TEK gene, that encodes the tyrosine kinase receptor TIE2 that functions to regulate cellular growth and proliferation are found in half of the patients with sporadic venous malformations.<ref name="pmid26319232">{{cite journal |vauthors=Nätynki M, Kangas J, Miinalainen I, Sormunen R, Pietilä R, Soblet J, Boon LM, Vikkula M, Limaye N, Eklund L |title=Common and specific effects of TIE2 mutations causing venous malformations |journal=Hum. Mol. Genet. |volume=24 |issue=22 |pages=6374–89 |date=November 2015 |pmid=26319232 |pmc=4614705 |doi=10.1093/hmg/ddv349 |url=}}</ref><ref name="pmid27030595">{{cite journal |vauthors=Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VE, Chivite I, Milà-Guasch M, Pearce W, Solomon I, Angulo-Urarte A, Figueiredo AM, Dewhurst RE, Knox RG, Clark GR, Scudamore CL, Badar A, Kalber TL, Foster J, Stuckey DJ, David AL, Phillips WA, Lythgoe MF, Wilson V, Semple RK, Sebire NJ, Kinsler VA, Graupera M, Vanhaesebroeck B |title=Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans |journal=Sci Transl Med |volume=8 |issue=332 |pages=332ra43 |date=March 2016 |pmid=27030595 |pmc=5973268 |doi=10.1126/scitranslmed.aad9982 |url=}}</ref><ref name="pmid26637981">{{cite journal |vauthors=Limaye N, Kangas J, Mendola A, Godfraind C, Schlögel MJ, Helaers R, Eklund L, Boon LM, Vikkula M |title=Somatic Activating PIK3CA Mutations Cause Venous Malformation |journal=Am. J. Hum. Genet. |volume=97 |issue=6 |pages=914–21 |date=December 2015 |pmid=26637981 |pmc=4678782 |doi=10.1016/j.ajhg.2015.11.011 |url=}}</ref>
* Diagnosis is clinical. Current treatment options include sclerotherapy and surgery, alone or in combination but inaccessible lesions and high recurrence rate remains a problem. mTOR inhibitor rapamycin has been used in some studies with success.<ref name="pmid27030595">{{cite journal| author=Castillo SD, Tzouanacou E, Zaw-Thin M, Berenjeno IM, Parker VE, Chivite I et al.| title=Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans. | journal=Sci Transl Med | year= 2016 | volume= 8 | issue= 332 | pages= 332ra43 | pmid=27030595 | doi=10.1126/scitranslmed.aad9982 | pmc=5973268 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27030595  }}</ref>
=====Familial VM cutaneo-mucosal (VMCM)=====
* Venous malformations that appear both on skin and mucous membranes.  Present at birth, they may not be apparent early in life and can appear after trauma and during pregnancy and puberty because of rapid growth. Patient may present with sequela of these malformations such as cosmetic deformation, pain, bleeding.<ref name="pmid28316284">{{cite journal |vauthors=Brahami N, Subramaniam S, Al-Ddafari MS, Elkaim C, Harmand PO, Sari BE, Lefranc G, Aribi M |title=Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src |journal=J Negat Results Biomed |volume=16 |issue=1 |pages=9 |date=March 2017 |pmid=28316284 |pmc=5357811 |doi=10.1186/s12952-017-0072-5 |url=}}</ref>
* Associated with mutation in TEK/TIE2 receptor tyrosine kinase that plays critical role in development of vessels and cardiovascular system.<ref name="pmid28316284">{{cite journal |vauthors=Brahami N, Subramaniam S, Al-Ddafari MS, Elkaim C, Harmand PO, Sari BE, Lefranc G, Aribi M |title=Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src |journal=J Negat Results Biomed |volume=16 |issue=1 |pages=9 |date=March 2017 |pmid=28316284 |pmc=5357811 |doi=10.1186/s12952-017-0072-5 |url=}}</ref><ref name="pmid19888299">{{cite journal |vauthors=Wouters V, Limaye N, Uebelhoer M, Irrthum A, Boon LM, Mulliken JB, Enjolras O, Baselga E, Berg J, Dompmartin A, Ivarsson SA, Kangesu L, Lacassie Y, Murphy J, Teebi AS, Penington A, Rieu P, Vikkula M |title=Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects |journal=Eur. J. Hum. Genet. |volume=18 |issue=4 |pages=414–20 |date=April 2010 |pmid=19888299 |pmc=2841708 |doi=10.1038/ejhg.2009.193 |url=}}</ref>
=====Blue rubber bleb nevus (Bean) syndrome VM=====
* Also called Bean's syndrome and diffuse angiomatosis, venous malformations in this disorder involve the skin, oral cavity and internal organs, most typically the gastrointestinal tract. Cutaneous malformations are bluish in color, generally smaller than 1-2 cm, often hyperkeratotic, compressible and often found at palms and soles. Anomalies on the skin are usually asymptomatic but GI malformations can cause hemorrhage that can lead to anemia, most frequent presentation in patient population. Other manifestation can include GI infarction, telescoping or twisting of GI tract leading to intussusception and volvulus.<ref name="pmid29515720">{{cite journal |vauthors=El Bakkaly A, Ettayebi F, Oubeja H, Erraji M, Zerhouni H |title=[Bean's syndrome in children: about two cases] |language=French |journal=Pan Afr Med J |volume=28 |issue= |pages=102 |date=2017 |pmid=29515720 |pmc=5837144 |doi=10.11604/pamj.2017.28.102.11109 |url=}}</ref><ref name="pmid27519652">{{cite journal |vauthors=Soblet J, Kangas J, Nätynki M, Mendola A, Helaers R, Uebelhoer M, Kaakinen M, Cordisco M, Dompmartin A, Enjolras O, Holden S, Irvine AD, Kangesu L, Léauté-Labrèze C, Lanoel A, Lokmic Z, Maas S, McAleer MA, Penington A, Rieu P, Syed S, van der Vleuten C, Watson R, Fishman SJ, Mulliken JB, Eklund L, Limaye N, Boon LM, Vikkula M |title=Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations |journal=J. Invest. Dermatol. |volume=137 |issue=1 |pages=207–216 |date=January 2017 |pmid=27519652 |doi=10.1016/j.jid.2016.07.034 |url=}}</ref><ref name="pmid23272612">{{cite journal |vauthors=Akutko K, Krzesiek E, Iwańczak B |title=[Blue rubber bleb naevus syndrome] |language=Polish |journal=Pol. Merkur. Lekarski |volume=33 |issue=196 |pages=226–8 |date=October 2012 |pmid=23272612 |doi= |url=}}</ref>
* Thought to be caused by somatic double (cis) muatations in TEK gene although autosomal-dominant inheritance has also been described in some cases. The gene that encodes TIE2, receptor tyrosine kinase involved in cell-signaling.<ref name="pmid24003209">{{cite journal |vauthors=Jeltsch M, Leppänen VM, Saharinen P, Alitalo K |title=Receptor tyrosine kinase-mediated angiogenesis |journal=Cold Spring Harb Perspect Biol |volume=5 |issue=9 |pages= |date=September 2013 |pmid=24003209 |pmc=3753715 |doi=10.1101/cshperspect.a009183 |url=}}</ref><ref name="pmid23272612">{{cite journal |vauthors=Akutko K, Krzesiek E, Iwańczak B |title=[Blue rubber bleb naevus syndrome] |language=Polish |journal=Pol. Merkur. Lekarski |volume=33 |issue=196 |pages=226–8 |date=October 2012 |pmid=23272612 |doi= |url=}}</ref><ref name="pmid29537205">{{cite journal |vauthors=Gawlikowska-Sroka A, Glura B, Mokrzycka M, Ociepa T |title=[Bean Syndrome (blue rubber bleb nevus syndrome)] |language=Polish |journal=Pomeranian J Life Sci |volume=62 |issue=2 |pages=5–7 |date=2016 |pmid=29537205 |doi= |url=}}</ref><ref name="pmid27519652">{{cite journal |vauthors=Soblet J, Kangas J, Nätynki M, Mendola A, Helaers R, Uebelhoer M, Kaakinen M, Cordisco M, Dompmartin A, Enjolras O, Holden S, Irvine AD, Kangesu L, Léauté-Labrèze C, Lanoel A, Lokmic Z, Maas S, McAleer MA, Penington A, Rieu P, Syed S, van der Vleuten C, Watson R, Fishman SJ, Mulliken JB, Eklund L, Limaye N, Boon LM, Vikkula M |title=Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations |journal=J. Invest. Dermatol. |volume=137 |issue=1 |pages=207–216 |date=January 2017 |pmid=27519652 |doi=10.1016/j.jid.2016.07.034 |url=}}</ref>
* The documentation of gastrointestinal lesions by endoscopy, colonoscopy, CT scan or MRI is considered pathognomonic. Sclerotherapy and surgery such as enterotomy remain the mainstay of treatment along with symptomatic management such as long term iron supplementation and/or blood transfusions.<ref name="pmid27519652">{{cite journal |vauthors=Soblet J, Kangas J, Nätynki M, Mendola A, Helaers R, Uebelhoer M, Kaakinen M, Cordisco M, Dompmartin A, Enjolras O, Holden S, Irvine AD, Kangesu L, Léauté-Labrèze C, Lanoel A, Lokmic Z, Maas S, McAleer MA, Penington A, Rieu P, Syed S, van der Vleuten C, Watson R, Fishman SJ, Mulliken JB, Eklund L, Limaye N, Boon LM, Vikkula M |title=Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations |journal=J. Invest. Dermatol. |volume=137 |issue=1 |pages=207–216 |date=January 2017 |pmid=27519652 |doi=10.1016/j.jid.2016.07.034 |url=}}</ref><ref name="pmid29515720">{{cite journal |vauthors=El Bakkaly A, Ettayebi F, Oubeja H, Erraji M, Zerhouni H |title=[Bean's syndrome in children: about two cases] |language=French |journal=Pan Afr Med J |volume=28 |issue= |pages=102 |date=2017 |pmid=29515720 |pmc=5837144 |doi=10.11604/pamj.2017.28.102.11109 |url=}}</ref><ref name="pmid24133559">{{cite journal |vauthors=Lindsey SF, Reiders B, Mechaber HF |title=Life-threatening pharyngeal edema after sclerotherapy of oral venous malformations in a patient with blue rubber bleb nevus syndrome |journal=J Dermatol Case Rep |volume=7 |issue=3 |pages=74–6 |date=2013 |pmid=24133559 |pmc=3797012 |doi=10.3315/jdcr.2013.1145 |url=}}</ref>
=====Glomuvenous malformation (GVM)=====
* Defined by presence of glomus cells in in smooth muscle layer of the vessels, these mesynchymal vascular anomaly arises from glomus bodies, arteriovenous anastomosis that help regulate temperature via shunting of blood through its unique neuromyoarterial structure. Classically found in digits, they can occur anywhere but widespread lesions are not common. Clinical presentation varies from asymptomatic bluish to reddish plaques and nodules that are often partially compressible and are tender to painful disfiguring lesions.<ref name="pmid28683898">{{cite journal |vauthors=Wortsman X, Millard F, Aranibar L |title=Color Doppler Ultrasound Study of Glomuvenous Malformations with its Clinical and Histologic Correlations |journal=Actas Dermosifiliogr |volume=109 |issue=3 |pages=e17–e21 |date=April 2018 |pmid=28683898 |doi=10.1016/j.ad.2017.04.013 |url=}}</ref><ref name="pmid28163461">{{cite journal |vauthors=Jha A, Khunger N, Malarvizhi K, Ramesh V, Singh A |title=Familial Disseminated Cutaneous Glomuvenous Malformation: Treatment with Polidocanol Sclerotherapy |journal=J Cutan Aesthet Surg |volume=9 |issue=4 |pages=266–269 |date=2016 |pmid=28163461 |pmc=5227083 |doi=10.4103/0974-2077.197083 |url=}}</ref><ref name="pmid27065433">{{cite journal |vauthors=Whipple KM, Godfrey KJ, Solomon JP, Lin JH, Korn BS, Kikkawa DO |title=Glomuvenous Malformation: A Rare Periorbital Lesion of the Thermoregulatory Apparatus |journal=Ophthalmic Plast Reconstr Surg |volume=33 |issue=2 |pages=e36–e37 |date=2017 |pmid=27065433 |pmc=5118188 |doi=10.1097/IOP.0000000000000695 |url=}}</ref><ref name="pmid25382523">{{cite journal |vauthors=Jha A, Ramesh V, Singh A |title=Disseminated cutaneous glomuvenous malformation |journal=Indian J Dermatol Venereol Leprol |volume=80 |issue=6 |pages=556–8 |date=2014 |pmid=25382523 |doi=10.4103/0378-6323.144200 |url=}}</ref>
* Mutations in glomulin (GLMN) gene that leads to defective GLMN protein is thought to be the cause. GMLN protein binds Rbx1 and inhibits its E3 ubiquitin ligase activity. If GMLN is defective then it leads to increased activity of Rbx1 causing decreased levels of Fbw7 and thus increased levels of Cyclin E and c-Myc because Fbw7 facilitates the ubiquitination and degradation Cyclin E and c-Myc.Mutations are inherited in autosomal-dominant pattern with incomplete pattern and variable expression although sporadic cases have been reported.<ref name="pmid24345188">{{cite journal |vauthors=Borroni RG, Grassi S, Concardi M, Puccio I, Giordano C, Agozzino M, Caspani C, Grasso M, Diegoli M, Arbustini E |title=Glomuvenous malformations with smooth muscle and eccrine glands: unusual histopathologic features in a familial setting |journal=J. Cutan. Pathol. |volume=41 |issue=3 |pages=308–15 |date=March 2014 |pmid=24345188 |doi=10.1111/cup.12283 |url=}}</ref><ref name="pmid23801931">{{cite journal |vauthors=Brouillard P, Boon LM, Revencu N, Berg J, Dompmartin A, Dubois J, Garzon M, Holden S, Kangesu L, Labrèze C, Lynch SA, McKeown C, Meskauskas R, Quere I, Syed S, Vabres P, Wassef M, Mulliken JB, Vikkula M |title=Genotypes and phenotypes of 162 families with a glomulin mutation |journal=Mol Syndromol |volume=4 |issue=4 |pages=157–64 |date=April 2013 |pmid=23801931 |pmc=3666456 |doi=10.1159/000348675 |url=}}</ref><ref name="pmid22405651">{{cite journal |vauthors=Tron AE, Arai T, Duda DM, Kuwabara H, Olszewski JL, Fujiwara Y, Bahamon BN, Signoretti S, Schulman BA, DeCaprio JA |title=The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7 |journal=Mol. Cell |volume=46 |issue=1 |pages=67–78 |date=April 2012 |pmid=22405651 |pmc=3336104 |doi=10.1016/j.molcel.2012.02.005 |url=}}</ref><ref name="pmid15689436">{{cite journal |vauthors=Brouillard P, Ghassibé M, Penington A, Boon LM, Dompmartin A, Temple IK, Cordisco M, Adams D, Piette F, Harper JI, Syed S, Boralevi F, Taïeb A, Danda S, Baselga E, Enjolras O, Mulliken JB, Vikkula M |title=Four common glomulin mutations cause two thirds of glomuvenous malformations ("familial glomangiomas"): evidence for a founder effect |journal=J. Med. Genet. |volume=42 |issue=2 |pages=e13 |date=February 2005 |pmid=15689436 |pmc=1735996 |doi=10.1136/jmg.2004.024174 |url=}}</ref>
* Imaging such as MRI and CT scan and ultrasound can localize and define the extent of disease but definitive diagnosis requires biopsy following by histopathological studies demonstrating  proliferation of glomus cells and venous malformations. Current treatment modalities include surgical excision and sclerotherapy although recurrence is common. Recently electron beam radiation and Nd:YAG laser have been used with success.<ref name="pmid28683898">{{cite journal |vauthors=Wortsman X, Millard F, Aranibar L |title=Color Doppler Ultrasound Study of Glomuvenous Malformations with its Clinical and Histologic Correlations |journal=Actas Dermosifiliogr |volume=109 |issue=3 |pages=e17–e21 |date=April 2018 |pmid=28683898 |doi=10.1016/j.ad.2017.04.013 |url=}}</ref><ref name="pmid28163461">{{cite journal |vauthors=Jha A, Khunger N, Malarvizhi K, Ramesh V, Singh A |title=Familial Disseminated Cutaneous Glomuvenous Malformation: Treatment with Polidocanol Sclerotherapy |journal=J Cutan Aesthet Surg |volume=9 |issue=4 |pages=266–269 |date=2016 |pmid=28163461 |pmc=5227083 |doi=10.4103/0974-2077.197083 |url=}}</ref><ref name="pmid27065433">{{cite journal |vauthors=Whipple KM, Godfrey KJ, Solomon JP, Lin JH, Korn BS, Kikkawa DO |title=Glomuvenous Malformation: A Rare Periorbital Lesion of the Thermoregulatory Apparatus |journal=Ophthalmic Plast Reconstr Surg |volume=33 |issue=2 |pages=e36–e37 |date=2017 |pmid=27065433 |pmc=5118188 |doi=10.1097/IOP.0000000000000695 |url=}}</ref><ref name="pmid26177926">{{cite journal |vauthors=Rivers JK, Rivers CA, Li MK, Martinka M |title=Laser Therapy for an Acquired Glomuvenous Malformation (Glomus Tumour): A Nonsurgical Approach |journal=J Cutan Med Surg |volume=20 |issue=1 |pages=80–3 |date=January 2016 |pmid=26177926 |doi=10.1177/1203475415596121 |url=}}</ref><ref name="pmid25933083">{{cite journal |vauthors=Phillips CB, Guerrero C, Theos A |title=Nd:YAG laser offers promising treatment option for familial glomuvenous malformation |journal=Dermatol. Online J. |volume=21 |issue=4 |pages= |date=April 2015 |pmid=25933083 |doi= |url=}}</ref><ref name="pmid24996811">{{cite journal |vauthors=Flors L, Norton PT, Hagspiel KD |title=Glomuvenous malformation: magnetic resonance imaging findings |journal=Pediatr Radiol |volume=45 |issue=2 |pages=286–90 |date=February 2015 |pmid=24996811 |doi=10.1007/s00247-014-3086-x |url=}}</ref><ref name="pmid17511950">{{cite journal |vauthors=Henning JS, Kovich OI, Schaffer JV |title=Glomuvenous malformations |journal=Dermatol. Online J. |volume=13 |issue=1 |pages=17 |date=January 2007 |pmid=17511950 |doi= |url=}}</ref>
=====Cerebral cavernous malformation (CCM)=====
* Characterized by clusters of malformed endothelial channels forming densely arranged sinusoids that possess little to no intervening brain tissues. Because they lack smooth muscles and connective tissue and are malformed, they are prone to leakage causing micro-hemorrhages and thrombosis leading to hemosiderin deposits and gliosis around them. They can remain asymptomatic throughout life making them incidental finding but can cause symptoms associated with hemorrhage and pressure effects such as  headaches, seizures, stroke, and focal neurologic deficits.<ref name="pmid24481819">{{cite journal |vauthors=Draheim KM, Fisher OS, Boggon TJ, Calderwood DA |title=Cerebral cavernous malformation proteins at a glance |journal=J. Cell. Sci. |volume=127 |issue=Pt 4 |pages=701–7 |date=February 2014 |pmid=24481819 |pmc=3924200 |doi=10.1242/jcs.138388 |url=}}</ref><ref name="pmid30252265">{{cite journal |vauthors=Zyck S, Gould GC |title= |journal= |volume= |issue= |pages= |date= |pmid=30252265 |doi= |url=}}</ref><ref name="pmid25896717">{{cite journal |vauthors=Trapani E, Retta SF |title=Cerebral cavernous malformation (CCM) disease: from monogenic forms to genetic susceptibility factors |journal=J Neurosurg Sci |volume=59 |issue=3 |pages=201–9 |date=September 2015 |pmid=25896717 |doi= |url=}}</ref>
* Mutations in CCM1 Krev interaction trapped protein 1 (KRIT1), CCM2 Malcavernin, and CCM3 Programmed cell death protein 10 (PDCD10) are thought to be the cause of familial cases that tend to be inherited in autosomal-dominant pattern with incomplete penetrance, and variable expression. These proteins interact with cytoskeleton and endothelial tight junctions during vascular development in neural tissues to help maintain endothelial barrier function. they can occur due to sporadic mutations, usually presenting as single cavernous malformation while familial cases typically present as multiple cavernous malformations.<ref name="pmid24481819">{{cite journal |vauthors=Draheim KM, Fisher OS, Boggon TJ, Calderwood DA |title=Cerebral cavernous malformation proteins at a glance |journal=J. Cell. Sci. |volume=127 |issue=Pt 4 |pages=701–7 |date=February 2014 |pmid=24481819 |pmc=3924200 |doi=10.1242/jcs.138388 |url=}}</ref><ref name="pmid30252265">{{cite journal |vauthors=Zyck S, Gould GC |title= |journal= |volume= |issue= |pages= |date= |pmid=30252265 |doi= |url=}}</ref><ref name="pmid30252535">{{cite journal |vauthors=Wang Y, Li Y, Zou J, Polster SP, Lightle R, Moore T, Dimaano M, He TC, Weber CR, Awad IA, Shen L |title=The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation |journal=FASEB J. |volume= |issue= |pages=fj201800343R |date=September 2018 |pmid=30252535 |doi=10.1096/fj.201800343R |url=}}</ref><ref name="pmid30161288">{{cite journal |vauthors=Nardella G, Visci G, Guarnieri V, Castellana S, Biagini T, Bisceglia L, Palumbo O, Trivisano M, Vaira C, Scerrati M, Debrasi D, D'Angelo V, Carella M, Merla G, Mazza T, Castori M, D'Agruma L, Fusco C |title=A single-center study on 140 patients with cerebral cavernous malformations: 28 new pathogenic variants and functional characterization of a PDCD10 large deletion |journal=Hum. Mutat. |volume= |issue= |pages= |date=August 2018 |pmid=30161288 |doi=10.1002/humu.23629 |url=}}</ref>
* Magnetic resonance (MR) imaging techniques are diagnostic modality of choice. Current treatment options depend on clinical history and location of the malformations. Surgery is usually preferred for symptomatic lesions in easily accessible locations and by some, for refractory epilepsy. If asymptomatic, observation is recommended but in case of single accessible asymptomatic malformation, surgical resection can be done. Surgery is also not recommended for malformations located in brain-stem due to significant mortality and morbidity associated with surgery while some recommend surgery after a second symptomatic bleed. Guidelines for symptomatic lesions located deep vary. Radiosurgery can be an alternative modality for single, symptomatic lesion if risks associated with surgery are unacceptable.<ref name="pmid30252265">{{cite journal |vauthors=Zyck S, Gould GC |title= |journal= |volume= |issue= |pages= |date= |pmid=30252265 |doi= |url=}}</ref><ref name="pmid25629087">{{cite journal |vauthors=Mouchtouris N, Chalouhi N, Chitale A, Starke RM, Tjoumakaris SI, Rosenwasser RH, Jabbour PM |title=Management of cerebral cavernous malformations: from diagnosis to treatment |journal=ScientificWorldJournal |volume=2015 |issue= |pages=808314 |date=2015 |pmid=25629087 |pmc=4300037 |doi=10.1155/2015/808314 |url=}}</ref><ref name="pmid26923303">{{cite journal |vauthors=Kim J |title=Introduction to cerebral cavernous malformation: a brief review |journal=BMB Rep |volume=49 |issue=5 |pages=255–62 |date=May 2016 |pmid=26923303 |pmc=5070704 |doi= |url=}}</ref><ref name="pmid15987569">{{cite journal |vauthors=Wurm G, Schnizer M, Fellner FA |title=Cerebral cavernous malformations associated with venous anomalies: surgical considerations |journal=Neurosurgery |volume=57 |issue=1 Suppl |pages=42–58; discussion 42–58 |date=July 2005 |pmid=15987569 |doi= |url=}}</ref><ref name="pmid20809765">{{cite journal |vauthors=Washington CW, McCoy KE, Zipfel GJ |title=Update on the natural history of cavernous malformations and factors predicting aggressive clinical presentation |journal=Neurosurg Focus |volume=29 |issue=3 |pages=E7 |date=September 2010 |pmid=20809765 |doi=10.3171/2010.5.FOCUS10149 |url=}}</ref>
=====Familial intraosseous vascular malformation (VMOS)=====
* Described as enlargement and expansion of malformed blood vessels that is severe and progressive, typically in skull, face, and vertebral column. Another typical finding is mid-line abnormalities such as diastasis recti, supraumbilical raphe, and hiatus hernia. Clinical presentation can vary but increasing intracranial pressure and hemorrhage after any surgical procedure such as extraction of tooth are of major concern. Other common findings include pain, enlarging tissues such as expanding jaw, bluish mass/swelling, loose tooth, spontaneous bleeding, and ulceration.<ref name="pmid27476657">{{cite journal |vauthors=Cetinkaya A, Xiong JR, Vargel İ, Kösemehmetoğlu K, Canter Hİ, Gerdan ÖF, Longo N, Alzahrani A, Camps MP, Taskiran EZ, Laupheimer S, Botto LD, Paramalingam E, Gormez Z, Uz E, Yuksel B, Ruacan Ş, Sağıroğlu MŞ, Takahashi T, Reversade B, Akarsu NA |title=Loss-of-Function Mutations in ELMO2 Cause Intraosseous Vascular Malformation by Impeding RAC1 Signaling |journal=Am. J. Hum. Genet. |volume=99 |issue=2 |pages=299–317 |date=August 2016 |pmid=27476657 |pmc=4974086 |doi=10.1016/j.ajhg.2016.06.008 |url=}}</ref><ref name="pmid11932989">{{cite journal |vauthors=Vargel I, Cil BE, Er N, Ruacan S, Akarsu AN, Erk Y |title=Hereditary intraosseous vascular malformation of the craniofacial region: an apparently novel disorder |journal=Am. J. Med. Genet. |volume=109 |issue=1 |pages=22–35 |date=April 2002 |pmid=11932989 |doi= |url=}}</ref><ref name="pmid24701461">{{cite journal |vauthors=Handa H, Naidu GS, Dara BG, Deshpande A, Raghavendra R |title=Diverse imaging characteristics of a mandibular intraosseous vascular lesion |journal=Imaging Sci Dent |volume=44 |issue=1 |pages=67–73 |date=March 2014 |pmid=24701461 |pmc=3972408 |doi=10.5624/isd.2014.44.1.67 |url=}}</ref>
* Mutations in ELMO2 gene encoding engulfment and cell motility protein 2 (ELMO2) are thought to be the cause of these malformations. This protein s involved cell-signaling cascade through its attachment to cell membrane. Majority of the cases are sporadic but recently some familial cases with autosomal-recessive inheritance have been described.<ref name="pmid27476657">{{cite journal |vauthors=Cetinkaya A, Xiong JR, Vargel İ, Kösemehmetoğlu K, Canter Hİ, Gerdan ÖF, Longo N, Alzahrani A, Camps MP, Taskiran EZ, Laupheimer S, Botto LD, Paramalingam E, Gormez Z, Uz E, Yuksel B, Ruacan Ş, Sağıroğlu MŞ, Takahashi T, Reversade B, Akarsu NA |title=Loss-of-Function Mutations in ELMO2 Cause Intraosseous Vascular Malformation by Impeding RAC1 Signaling |journal=Am. J. Hum. Genet. |volume=99 |issue=2 |pages=299–317 |date=August 2016 |pmid=27476657 |pmc=4974086 |doi=10.1016/j.ajhg.2016.06.008 |url=}}</ref><ref name="pmid27539661">{{cite journal |vauthors=Peotter JL, Phillips J, Tong T, Dimeo K, Gonzalez JM, Peters DM |title=Involvement of Tiam1, RhoG and ELMO2/ILK in Rac1-mediated phagocytosis in human trabecular meshwork cells |journal=Exp. Cell Res. |volume=347 |issue=2 |pages=301–11 |date=October 2016 |pmid=27539661 |pmc=5333770 |doi=10.1016/j.yexcr.2016.08.009 |url=}}</ref>
* CT angiography and magnetic resonance techniques are the preferred diagnostic modalities and may show widening of neurovascular canal on CTA, hyperintense signal on MRI. Honeycomb and sunburst radiographic appearances have been described as well. Management options include embolization, sclerotherapy, and surgical extirpation.<ref name="pmid27476657">{{cite journal |vauthors=Cetinkaya A, Xiong JR, Vargel İ, Kösemehmetoğlu K, Canter Hİ, Gerdan ÖF, Longo N, Alzahrani A, Camps MP, Taskiran EZ, Laupheimer S, Botto LD, Paramalingam E, Gormez Z, Uz E, Yuksel B, Ruacan Ş, Sağıroğlu MŞ, Takahashi T, Reversade B, Akarsu NA |title=Loss-of-Function Mutations in ELMO2 Cause Intraosseous Vascular Malformation by Impeding RAC1 Signaling |journal=Am. J. Hum. Genet. |volume=99 |issue=2 |pages=299–317 |date=August 2016 |pmid=27476657 |pmc=4974086 |doi=10.1016/j.ajhg.2016.06.008 |url=}}</ref><ref name="pmid24701461">{{cite journal |vauthors=Handa H, Naidu GS, Dara BG, Deshpande A, Raghavendra R |title=Diverse imaging characteristics of a mandibular intraosseous vascular lesion |journal=Imaging Sci Dent |volume=44 |issue=1 |pages=67–73 |date=March 2014 |pmid=24701461 |pmc=3972408 |doi=10.5624/isd.2014.44.1.67 |url=}}</ref><ref name="pmid29670739">{{cite journal |vauthors=Cariati P, Marín-Fernández AB, Julia-Martínez MÁ, Pérez-de Perceval-Tara M, Sánchez-López D, Martínez-Lara I |title=Endovascular treatment of an intraosseous arteriovenous malformation of the mandible in a child. A case Report |journal=J Clin Exp Dent |volume=10 |issue=2 |pages=e189–e191 |date=February 2018 |pmid=29670739 |pmc=5899801 |doi=10.4317/jced.54550 |url=}}</ref>
=====Verrucous venous malformation=====
* Formerly verrucous hemangioma, this rare congenital malformation is characterized by dilated blood vessels reaching out from papillary layer of dermis into subcutaneous tissue. Earlier presentation is bluish lesion that develops warty surface later on. Painful enlarging mass is the typical complain in symptomatic patients.<ref name="pmid28761841">{{cite journal |vauthors=Singh J, Sharma P, Tandon S, Sinha S |title=Multiple Verrucous Hemangiomas: A Case Report with New Therapeutic Insight |journal=Indian Dermatol Online J |volume=8 |issue=4 |pages=254–256 |date=2017 |pmid=28761841 |pmc=5518576 |doi=10.4103/idoj.IDOJ_313_16 |url=}}</ref><ref name="pmid30156622">{{cite journal |vauthors=Oppermann K, Boff AL, Bonamigo RR |title=Verrucous hemangioma and histopathological differential diagnosis with angiokeratoma circumscriptum neviforme |journal=An Bras Dermatol |volume=93 |issue=5 |pages=712–715 |date=2018 |pmid=30156622 |pmc=6106676 |doi=10.1590/abd1806-4841.20187259 |url=}}</ref>
* Somatic mutation in MAP3K3 mitogen-activated protein kinase kinase kinase 3 are thought to be the cause.<ref name="pmid25728774">{{cite journal |vauthors=Couto JA, Vivero MP, Kozakewich HP, Taghinia AH, Mulliken JB, Warman ML, Greene AK |title=A somatic MAP3K3 mutation is associated with verrucous venous malformation |journal=Am. J. Hum. Genet. |volume=96 |issue=3 |pages=480–6 |date=March 2015 |pmid=25728774 |pmc=4375628 |doi=10.1016/j.ajhg.2015.01.007 |url=}}</ref>
* MRI is the diagnostic modality of choice but histopathological confirmation is gold standard for accurate diagnosis because of its close resemblance with angiokeratoma. Superficial ablation, surgical excision are treatment choices. Recently sirolimus has been used in some studies.<ref name="pmid28761841">{{cite journal |vauthors=Singh J, Sharma P, Tandon S, Sinha S |title=Multiple Verrucous Hemangiomas: A Case Report with New Therapeutic Insight |journal=Indian Dermatol Online J |volume=8 |issue=4 |pages=254–256 |date=2017 |pmid=28761841 |pmc=5518576 |doi=10.4103/idoj.IDOJ_313_16 |url=}}</ref><ref name="pmid30156622">{{cite journal |vauthors=Oppermann K, Boff AL, Bonamigo RR |title=Verrucous hemangioma and histopathological differential diagnosis with angiokeratoma circumscriptum neviforme |journal=An Bras Dermatol |volume=93 |issue=5 |pages=712–715 |date=2018 |pmid=30156622 |pmc=6106676 |doi=10.1590/abd1806-4841.20187259 |url=}}</ref><ref name="pmid30048660">{{cite journal |vauthors=Zhang G, Chen H, Zhen Z, Chen J, Zhang S, Qin Q, Liu X |title=Sirolimus for treatment of verrucous venous malformation: A retrospective cohort study |journal=J. Am. Acad. Dermatol. |volume= |issue= |pages= |date=July 2018 |pmid=30048660 |doi=10.1016/j.jaad.2018.07.014 |url=}}</ref>
==Provisionally unclassified vascular anomalies==
===Intramuscular hemangioma===
* Characterized by benign proliferation of vascular channels. Majority of lesions occur in subcutaneous adipose tissues, followed by muscles. Thigh and calf are most common sites of occurrence. Majority of the lesions are asymptomatic. Typical clinical presentation includes chronic pain and swelling that both may increase with exercise of affected muscle due to increased blood flow. Other clinical manifestations may include pulsations, discoloration over the lesion, lesion enlargement when in dependent position, increased temperature, muscle contracture, tenderness, and muscle weakness and fatigue.<ref name="pmid24427416">{{cite journal |vauthors=Wierzbicki JM, Henderson JH, Scarborough MT, Bush CH, Reith JD, Clugston JR |title=Intramuscular hemangiomas |journal=Sports Health |volume=5 |issue=5 |pages=448–54 |date=September 2013 |pmid=24427416 |pmc=3752185 |doi=10.1177/1941738112470910 |url=}}</ref><ref name="pmid15155443">{{cite journal |vauthors=Brown RA, Crichton K, Malouf GM |title=Intramuscular haemangioma of the thigh in a basketball player |journal=Br J Sports Med |volume=38 |issue=3 |pages=346–8 |date=June 2004 |pmid=15155443 |pmc=1724833 |doi= |url=}}</ref>
* Intramuscular hemangiomas may be associated with Kasabach-Merritt syndrome characterized by thrombocytopenia and/or consumptive coagulopathy. This lesion may also lead to functional impairment, congestive cardiac failure due to AV shunting, pressure symptoms, skin necrosis and may also erode bone.<ref name="pmid15155443"></ref><ref name="pmid28507959">{{cite journal |vauthors=Patnaik S, Kumar P, Nayak B, Mohapatra N |title=Intramuscular Arteriovenous Hemangioma of Thigh: A Case Report and Review of Literature |journal=J Orthop Case Rep |volume=6 |issue=5 |pages=20–23 |date=2016 |pmid=28507959 |pmc=5404154 |doi=10.13107/jocr.2250-0685.612 |url=}}</ref>
* Etiology and pathophysiology are not clearly defined but majority of the lesions are congenital while a one fifth may be associated with trauma.<ref name="pmid24427416"></ref>
* MRI is the diagnostic study of choice although X-RAY and ultrasound may be used as initial studies. Treatment is generally not indicated for asymptomatic lesions. Management options for symptomatic, complicated and for cosmetic reasons may include laser ablation, systemic corticosteroids, cryotherapy, embolization, radiation, compression sclerotherapy, and surgical excision although surgical excision is usually treatment of choice in majority of the cases.<ref name="pmid24427416"></ref><ref name="pmid15155443"></ref><ref name="pmid28507959"></ref><ref name="pmid12011711">{{cite journal |vauthors=Tang P, Hornicek FJ, Gebhardt MC, Cates J, Mankin HJ |title=Surgical treatment of hemangiomas of soft tissue |journal=Clin. Orthop. Relat. Res. |volume= |issue=399 |pages=205–10 |date=June 2002 |pmid=12011711 |doi= |url=}}</ref><ref name="pmid17596677">{{cite journal |vauthors=Kim DH, Hwang M, Kang YK, Kim IJ, Park YK |title=Intramuscular hemangioma mimicking myofascial pain syndrome: a case report |journal=J. Korean Med. Sci. |volume=22 |issue=3 |pages=580–2 |date=June 2007 |pmid=17596677 |pmc=2693661 |doi=10.3346/jkms.2007.22.3.580 |url=}}</ref><ref name="pmid25198963">{{cite journal |vauthors=Babu D, Bhamre R, Katna R, Pai P |title=Intramuscular haemangioma of the tongue |journal=Ann R Coll Surg Engl |volume=96 |issue=6 |pages=e15–7 |date=September 2014 |pmid=25198963 |pmc=4474220 |doi=10.1308/003588414X13946184903126 |url=}}</ref>
===Angiokeratoma===
* A muco-cutaneous vascular lesion with wart-like papular appearance characterized by dilated capillaries in the dermis and hyperkeratotis of the overlying epidermis. Clinically it may manifest as solitary or multiple hyperkeratotic papules that may be localized or generalized, most typically on scrotum, thighs, lower extremity, abdomen, trunk, tongue, penis and labia majora. Majority of the lesions are asymptomatic but some may ulcerate and/or bleed.<ref name="pmid25100920">{{cite journal |vauthors=Hussein RS, Kfoury H, Al-Faky YH |title=Eyelid angiokeratoma |journal=Middle East Afr J Ophthalmol |volume=21 |issue=3 |pages=287–8 |date=2014 |pmid=25100920 |pmc=4123288 |doi=10.4103/0974-9233.134702 |url=}}</ref><ref name="pmid16988295">{{cite journal |vauthors=Trickett R, Dowd H |title=Angiokeratoma of the scrotum: a case of scrotal bleeding |journal=Emerg Med J |volume=23 |issue=10 |pages=e57 |date=October 2006 |pmid=16988295 |pmc=2579622 |doi=10.1136/emj.2006.038745 |url=}}</ref>
* It may be classified into following entities:<ref name="pmid26155544">{{cite journal |vauthors=Chowdappa V, Narasimha A, Bhat A, Masamatti SS |title=Solitary Angiokeratoma: Report of Two Uncommon Cases |journal=J Clin Diagn Res |volume=9 |issue=5 |pages=WD01–2 |date=May 2015 |pmid=26155544 |pmc=4484136 |doi=10.7860/JCDR/2015/12163.5946 |url=}}</ref>
** Fordyce’s angiokeratoma (arising on the genitals)
** Mibelli’s angiokeratoma (dorsum of toes and fingers)
** Angiokeratoma circumscriptum naeviforme (unilateral large keratotic plaques)
** Angiokeratoma corporis diffusum (ACD) (generalized lesions between umbilicus and the knee)
* Angiokeratomas are more prevalent among males as compared to females. Increased venous pressure and radiation therapy have been cited as possible causes. Angiokeratomas have been associated with enzyme deficiencies such as  alpha-galactosidase A (Fabry disease), α-fucosidase (fucosidosis), neuraminidase (sialodosis), aspartyl glycosaminase (aspartyl glucosaminuria), β-mannosidase (β- mannosidosis), α-N-acetyl galactosaminidase (Kansaki disease), and β-galactosidase (adult onset GM1 gangliosidosis).<ref name="pmid25100920"></ref><ref name="pmid16988295"></ref><ref name="pmid26155544">{{cite journal |vauthors=Chowdappa V, Narasimha A, Bhat A, Masamatti SS |title=Solitary Angiokeratoma: Report of Two Uncommon Cases |journal=J Clin Diagn Res |volume=9 |issue=5 |pages=WD01–2 |date=May 2015 |pmid=26155544 |pmc=4484136 |doi=10.7860/JCDR/2015/12163.5946 |url=}}</ref><ref name="pmid19468654">{{cite journal |vauthors=Rees R, Freeman A, Malone P, Garaffa G, Muneer A, Minhas S |title=Case study: the surgical management of angiokeratoma resulting from radiotherapy for penile cancer |journal=ScientificWorldJournal |volume=9 |issue= |pages=339–42 |date=May 2009 |pmid=19468654 |pmc=5823195 |doi=10.1100/tsw.2009.23 |url=}}</ref>
* The diagnosis is mainly clinical but biopsy may be required. Associated enzyme deficiencies and systemic disorders must be ruled out. Treatment is generally not indicated but if so required then excision, electrocautery, cryotherapy, or laser ablations are the options.<ref name="pmid25100920"></ref><ref name="pmid19468654"></ref><ref name="pmid26155544"></ref><ref name="pmid29644211">{{cite journal |vauthors=Jha AK, Sonthalia S, Jakhar D |title=Dermoscopy of Angiokeratoma |journal=Indian Dermatol Online J |volume=9 |issue=2 |pages=141–142 |date=2018 |pmid=29644211 |pmc=5885630 |doi=10.4103/idoj.IDOJ_278_17 |url=}}</ref>
===Sinusoidal hemangioma===
* A variant of cavernous hemangioma characterized histopathologically by presence of dilated thin-walled vascular channels, that vary in size, exhibiting nodular proliferation with sinusoidal arrangement.  Pseudopapillary structures may also be present. Clinically majority of the lesions manifest in female adults as single, well-defined, painless, subcutaneous nodule with bluish color. Most frequent locations are trunk, extremities and breasts. Painless swelling is the most common patient complaint.<ref name="pmid22148063">{{cite journal |vauthors=Song BH, Youn SH, Park EJ, Kwon IH, Kim KH, Kim KJ |title=A case of sinusoidal hemangioma with lipoma |journal=Ann Dermatol |volume=23 |issue=Suppl 2 |pages=S250–3 |date=October 2011 |pmid=22148063 |pmc=3229078 |doi=10.5021/ad.2011.23.S2.S250 |url=}}</ref><ref name="pmid21892538">{{cite journal |vauthors=Ciurea M, Ciurea R, Popa D, Pârvănescu H, Marinescu D, Vrabete M |title=Sinusoidal hemangioma of the arm: case report and review of literature |journal=Rom J Morphol Embryol |volume=52 |issue=3 |pages=915–8 |date=2011 |pmid=21892538 |doi= |url=}}</ref><ref name="pmid26729822">{{cite journal |vauthors=Konda P, Bavle RM, Makarla S, Muniswamappa S |title=Intramuscular sinusoidal haemangioma with secondary Masson's phenomenon |journal=BMJ Case Rep |volume=2016 |issue= |pages= |date=January 2016 |pmid=26729822 |pmc=4716435 |doi=10.1136/bcr-2013-201457 |url=}}</ref>
* Abnormalities of vasculogenesis and angiogenesis have been proposed as pathogenesis but it is not well-established.<ref name="pmid21892538"></ref>
* Combination of clinical manifestations and histopathological features is used for diagnosis. Surgery (wide excision of tumor) is the treatment of choice if treatment is required.<ref name="pmid21892538"></ref><ref name="pmid26729822"></ref><ref name="pmid28210560">{{cite journal |vauthors=Salemis NS |title=Sinusoidal hemangioma of the breast: diagnostic evaluation management and literature review |journal=Gland Surg |volume=6 |issue=1 |pages=105–109 |date=February 2017 |pmid=28210560 |pmc=5293651 |doi=10.21037/gs.2016.11.06 |url=}}</ref>
===Acral arteriovenous "tumour"===
* Congenital or acquired lesion manifesting clinically as asymptomatic mass or may present with pulsatile swelling, headache, localized throbbing pain, tinnitus and bleeding. Histopathologically they are characterized by arterio-venous connection without connecting capillary with or without intracranial component. The lesion derived its name from its acral distribution.<ref name="pmid25624933">{{cite journal |vauthors=Gupta R, Kayal A |title=Scalp arteriovenous malformations in young |journal=J Pediatr Neurosci |volume=9 |issue=3 |pages=263–6 |date=2014 |pmid=25624933 |pmc=4302550 |doi=10.4103/1817-1745.147587 |url=}}</ref><ref name="pmid29492122">{{cite journal |vauthors=Özkara E, Özbek Z, Özdemir AÖ, Arslantaş A |title=Misdiagnosed Case of Scalp Arteriovenous Malformation |journal=Asian J Neurosurg |volume=13 |issue=1 |pages=59–61 |date=2018 |pmid=29492122 |pmc=5820896 |doi=10.4103/1793-5482.181137 |url=}}</ref>
* Etiology can be classified as following: Congenital, traumatic, infection and inflammation and familial.<ref name="pmid25624933"></ref><ref name="pmid4682507">{{cite journal |vauthors=Khodadad G |title=Arteriovenous malformations of the scalp |journal=Ann. Surg. |volume=177 |issue=1 |pages=79–85 |date=January 1973 |pmid=4682507 |pmc=1355509 |doi= |url=}}</ref>
* Although diagnosis can be made clinically, angiography is the gold standard diagnostic modality to diagnose and define the extent of the lesion. Management regimen may include surgical excision, ligation of the supplying arteries, embolization, and intralesional sclerosing injection.<ref name="pmid29492122"></ref><ref name="pmid23960313">{{cite journal |vauthors=Chowdhury FH, Haque MR, Kawsar KA, Sarker MH, Momtazul Haque AF |title=Surgical management of scalp arterio-venous malformation and scalp venous malformation: An experience of eleven cases |journal=Indian J Plast Surg |volume=46 |issue=1 |pages=98–107 |date=January 2013 |pmid=23960313 |pmc=3745130 |doi=10.4103/0970-0358.113723 |url=}}</ref><ref name="pmid23559986">{{cite journal |vauthors=El Shazly AA, Saoud KM |title=Results of surgical excision of cirsoid aneurysm of the scalp without preoperative interventions |journal=Asian J Neurosurg |volume=7 |issue=4 |pages=191–6 |date=October 2012 |pmid=23559986 |pmc=3613641 |doi=10.4103/1793-5482.106651 |url=}}</ref><ref name="pmid1271098">{{cite journal |vauthors=Kasdon DL, Altemus LR, Stein BM |title=Embolization of a traumatic arteriovenous fistula of the scalp with radiopaque Gelfoam pledgets. Case report and technical note |journal=J. Neurosurg. |volume=44 |issue=6 |pages=753–6 |date=June 1976 |pmid=1271098 |doi=10.3171/jns.1976.44.6.0753 |url=}}</ref><ref name="pmid8956889">{{cite journal |vauthors=Hendrix LE, Meyer GA, Erickson SJ |title=Cirsoid aneurysm treatment by percutaneous injection of sodium tetradecyl sulfate |journal=Surg Neurol |volume=46 |issue=6 |pages=557–60; discussion 560–1 |date=December 1996 |pmid=8956889 |doi= |url=}}</ref>
===Multifocal lymphangioendotheliomatosis with thrombocytopenia / cutaneovisceral angiomatosis with thrombocytopenia (MLT/CAT)===
* Rare congenital disorder characterized by proliferation of vascular channels in multiple organs associated with thrombocytopenia of variable degree. Lesions may manifest themselves on skin, gastrointestinal tract, lungs, brain, bone, liver, spleen and muscles. Majority of cutaneous lesions present as multiple red to blue papules, plaques, nodules on trunk and extremities. Gastrointestinal bleeding due to multiple hemorrhagic lesions is the cause of mortality in majority of the patients. Similar lesions in brain and lungs may cause severe cerebral edema and pulmonary hemorrhage.<ref name="pmid26148948">{{cite journal |vauthors=Droitcourt C, Boccara O, Fraitag S, Favrais G, Dupuy A, Maruani A |title=Multifocal Lymphangioendotheliomatosis With Thrombocytopenia: Clinical Features and Response to Sirolimus |journal=Pediatrics |volume=136 |issue=2 |pages=e517–22 |date=August 2015 |pmid=26148948 |doi=10.1542/peds.2014-2410 |url=}}</ref><ref name="pmid25088066">{{cite journal |vauthors=Uller W, Kozakewich HP, Trenor CC, O'Hare M, Alomari AI |title=Cutaneovisceral angiomatosis with thrombocytopenia without cutaneous involvement |journal=J. Pediatr. |volume=165 |issue=4 |pages=876–876.e1 |date=October 2014 |pmid=25088066 |doi=10.1016/j.jpeds.2014.06.042 |url=}}</ref>
* Disease may manifest without cutaneous involvement or thrombocytopenia. Biopsy typically reveals proliferation of well differentiated vascular channels with intravascular papillary structure and thrombi, sometimes with hobnail appearance of lining endothelial cells.<ref name="pmid26148948"></ref><ref name="pmid22565464">{{cite journal |vauthors=Zegpi MS, Zavala A, del Puerto C, Cárdenas C, González S |title=Newborn with multifocal lymphangioendotheliomatosis with thrombocytopenia |journal=Indian J Dermatol Venereol Leprol |volume=78 |issue=3 |pages=409 |date=2012 |pmid=22565464 |doi=10.4103/0378-6323.95494 |url=}}</ref>
* Biopsy followed by histopathological and immunohistochemical are required for diagnosis. Management is not well-established and disorder has a poor prognosis with high mortality. Recently sirolimus and bevacizumab have been used to treat this diorder with some success.<ref name="pmid26148948"></ref><ref name="pmid22074937">{{cite journal |vauthors=Takahashi H, Nagatoshi Y, Kato M, Koh K, Kishimoto H, Kawai M, Fukuzawa R, Hanada R |title=Multifocal skin lesions and melena with thrombocytopenia in an infant |journal=J. Pediatr. |volume=160 |issue=3 |pages=524–524.e1 |date=March 2012 |pmid=22074937 |doi=10.1016/j.jpeds.2011.09.034 |url=}}</ref><ref name="pmid19101995">{{cite journal |vauthors=Kline RM, Buck LM |title=Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia |journal=Pediatr Blood Cancer |volume=52 |issue=4 |pages=534–6 |date=April 2009 |pmid=19101995 |doi=10.1002/pbc.21860 |url=}}</ref>


==References==
==References==
{{reflist|2}}

Latest revision as of 19:30, 22 February 2019

Abbreviations

ACTH: Adrenocorticotropic hormone, ARR: Aldosterone-renin ratio, CAM: Cellular adhesion molecules, ERCP: Endoscopic retrograde cholangiopancreatography, ESR: Erythrocyte sedimentation rate, CT: Computerized tomography, Fluorescence in situ hybridization, FDG: Fluorodeoxyglucose, FSH: Follicle stimulating hormone, GI: Gastrointestinal, H&E stain: Hematoxylin and eosin stain, LCA: Leukocyte common antigen, LDH: Lactate dehydrogenase, LH: Luteinizing hormone, MEN: Multiple endocrine neoplasia, MRCP: Magnetic resonance cholangiopancreatography, MRI: Magnetic resonance imaging, N/A: Not applicable/Not available, N/L: Normal, PAS stain: Periodic acid–Schiff stain, PET: Position emission tomography, PGP: Protein gene product 9.5, TB: Tuberculosis, U/S: Ultrasound, ZF: Zona fasciculata, ZG: Zona granulosa, ZR: Zona reticularis.

Adrenal Cortex Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Adrenal Adenoma Aldosterone
[1][2][3][4]
  • Iso and low FDG uptake compared with liver
  • Hyperintense on in-phase and hypointense on oppose-phase
Cortisol
[1][5][6][7]
  • Iso and low FDG uptake compared with liver
  • Hyperintense on in-phase and hypointense on oppose-phase
Androgens
[4][8][9][10]
  • Well-defined
  • Solid mass
  • N/A
  • Hyperintense on in-phase and hypointense on oppose-phase
Non-functional
[1][11][12][13]
  • Solid, well defined mass
  • High lipid content and adjacent compression
  • N/A
  • Hyperintense on in-phase and hypointense on oppose-phase
Adrenal Carcinoma
[12][14][15][16][17]
  • N/A
  • Heterogeneous enhancement
  • Heterogeneous mass with intense FDG uptake greater than liver
  • Heterogenous hyper-intensity (T2-weighted) and hypo-intensity on (T1-weighted)
Adrenal Hyperplasia
[2][5][4][8][9][15][18][19]
  • N/A
  • Unilateral or bilateral adrenal enlargement or thickening
  • Signaling is same as that of normal adrenal gland
Medulla Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Pheochromocytoma
[20][21][22][23][24]
  • N/A
Neuroblastoma
[15][25][26][27]
  • Large mass
  • May cross midline
  • N/A
Stains positive for:
Ganglioneuroma
[15][28][29][30]
  • N/A
  • N/A
  • Hypointense (T1-weighted)
  • Varied signal (T2-weighted)

Stains positive for:

Stroma Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Lipoma/Myolipoma
[15][31][32][33]
  • N/A
  • N/L
  • N/A
  • High signal
Others Product Clinical manifestations Diagnosis Other features
Symptoms Signs Blood & Urine Histopathological Others Ultrasound CT scan FDG PET/CT MRI
Tuberculosis
[34][35][36][37][38]
  • N/A
  • Variable
Histoplasmosis
[39][40][41][42][43]
  • N/A
Cysts
[15][44][45][46]
  • N/A
  • Gold standard
  • Circumscribed anechoic or hypoechoic mass
  • N/A
  • High signal
Hematoma
[15][47][48][49]
  • N/A
  • Variable
  • N/A
  • Majority of the cases in neonantal peiod
  • Majority of the cases caused by trauma
Hemangioma
[15][50][51][52]
  • N/A
  • Hyperintensity (T2) hypointensity (T1)
  • Peripheral spotty and centripetal enhancement
  • Majority of the cases diagnosed incidentally
  • Majority of the lesions are non-functional with female pre-dominance
Lymphoma
[15][53][54][55]
  • N/A
  • N/A
Cystic Lymphangioma
[15][56][57][58]
  • N/A
  • N/L
  • N/A
  • T1 hypointense & T2 hyperintense
Teratoma
[15][59][60][61]
  • N/A
  • N/L
  • Heterogeneous
  • Mixed echo (U/S)
  • Heterogeneous
  • Mixed density elements
  • Egg-shell calcification
  • Mild enhancement
  • N/A
  • Mild enhancement
  • Mixed signals (MRI)
Metastases
[15][62][63][64][65]
  • Related to the primary tumor
  • N/A
  • Low signal on T1-weighed MRI and high signal on T2-weighed MRI

OR

  • Isointense on T1- and T2-weighed MRI

References

  1. 1.0 1.1 1.2 Park JJ, Park BK, Kim CK (June 2016). "Adrenal imaging for adenoma characterization: imaging features, diagnostic accuracies and differential diagnoses". Br J Radiol. 89 (1062): 20151018. doi:10.1259/bjr.20151018. PMC 5258164. PMID 26867466.
  2. 2.0 2.1 Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P (August 2015). "Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas". Mol. Cell. Endocrinol. 411: 146–54. doi:10.1016/j.mce.2015.04.022. PMC 4474471. PMID 25958045.
  3. Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (May 2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.
  4. 4.0 4.1 4.2 Guerrisi A, Marin D, Baski M, Guerrisi P, Capozza F, Catalano C (2013). "Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging". J Clin Imaging Sci. 3: 61. doi:10.4103/2156-7514.124088. PMC 3935261. PMID 24605256.
  5. 5.0 5.1 Stratakis CA (2008). "Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)". Endocr Dev. 13: 117–32. doi:10.1159/000134829. PMC 3132884. PMID 18493137.
  6. Zilbermint M, Stratakis CA (June 2015). "Protein kinase A defects and cortisol-producing adrenal tumors". Curr Opin Endocrinol Diabetes Obes. 22 (3): 157–62. doi:10.1097/MED.0000000000000149. PMC 4560837. PMID 25871963.
  7. Wei J, Li S, Liu Q, Zhu Y, Wu N, Tang Y, Li Q, Ren K, Zhang Q, Yu Y, An Z, Chen J, Li J (April 2018). "ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures". BMC Endocr Disord. 18 (1): 22. doi:10.1186/s12902-018-0250-6. PMC 5913873. PMID 29685132.
  8. 8.0 8.1 Arnold DT, Reed JB, Burt K (January 2003). "Evaluation and management of the incidental adrenal mass". Proc (Bayl Univ Med Cent). 16 (1): 7–12. PMC 1200803. PMID 16278716.
  9. 9.0 9.1 Rodríguez-Gutiérrez R, Bautista-Medina MA, Teniente-Sanchez AE, Zapata-Rivera MA, Montes-Villarreal J (2013). "Pure androgen-secreting adrenal adenoma associated with resistant hypertension". Case Rep Endocrinol. 2013: 356086. doi:10.1155/2013/356086. PMC 3681270. PMID 23819074.
  10. Zhou WB, Chen N, Li CJ (January 2019). "A rare case of pure testosterone-secreting adrenal adenoma in a postmenopausal elderly woman". BMC Endocr Disord. 19 (1): 14. doi:10.1186/s12902-019-0342-y. PMC 6343319. PMID 30674304.
  11. Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, Vaidya A (October 2016). ""Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study". Ann. Intern. Med. 165 (8): 533–542. doi:10.7326/M16-0547. PMC 5453639. PMID 27479926.
  12. 12.0 12.1 Nieman LK (September 2010). "Approach to the patient with an adrenal incidentaloma". J. Clin. Endocrinol. Metab. 95 (9): 4106–13. doi:10.1210/jc.2010-0457. PMC 2936073. PMID 20823463.
  13. Li B, Guo Q, Yang H, Guan J (January 2013). "Giant non-functional adrenal adenoma: A case report". Oncol Lett. 5 (1): 378–380. doi:10.3892/ol.2012.978. PMC 3525484. PMID 23255953.
  14. Libé R (2015). "Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment". Front Cell Dev Biol. 3: 45. doi:10.3389/fcell.2015.00045. PMC 4490795. PMID 26191527.
  15. 15.00 15.01 15.02 15.03 15.04 15.05 15.06 15.07 15.08 15.09 15.10 15.11 Wang F, Liu J, Zhang R, Bai Y, Li C, Li B, Liu H, Zhang T (September 2018). "CT and MRI of adrenal gland pathologies". Quant Imaging Med Surg. 8 (8): 853–875. doi:10.21037/qims.2018.09.13. PMC 6177362. PMID 30306064.
  16. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ, Hammer GD (April 2014). "Adrenocortical carcinoma". Endocr. Rev. 35 (2): 282–326. doi:10.1210/er.2013-1029. PMC 3963263. PMID 24423978.
  17. Wang C, Sun Y, Wu H, Zhao D, Chen J (March 2014). "Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers". Histopathology. 64 (4): 567–76. doi:10.1111/his.12283. PMC 4282325. PMID 24102952.
  18. Michelle M A, Jensen CT, Habra MA, Menias CO, Shaaban AM, Wagner-Bartak NA, Roman-Colon AM, Elsayes KM (November 2017). "Adrenal cortical hyperplasia: diagnostic workup, subtypes, imaging features and mimics". Br J Radiol. 90 (1079): 20170330. doi:10.1259/bjr.20170330. PMC 5963387. PMID 28707538. Vancouver style error: name (help)
  19. Zhang Y, Li H (2015). "Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease". Int J Clin Exp Med. 8 (10): 19311–7. PMC 4694469. PMID 26770569.
  20. Martucci VL, Pacak K (2014). "Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment". Curr Probl Cancer. 38 (1): 7–41. doi:10.1016/j.currproblcancer.2014.01.001. PMC 3992879. PMID 24636754.
  21. Kantorovich V, Pacak K (2010). "Pheochromocytoma and paraganglioma". Prog. Brain Res. 182: 343–73. doi:10.1016/S0079-6123(10)82015-1. PMC 4714594. PMID 20541673.
  22. Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV (November 2009). "Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus)". Vet. Pathol. 46 (6): 1221–9. doi:10.1354/vp.09-VP-0022-M-FL. PMID 19605896.
  23. Kantorovich V, Eisenhofer G, Pacak K (December 2008). "Pheochromocytoma: an endocrine stress mimicking disorder". Ann. N. Y. Acad. Sci. 1148: 462–8. doi:10.1196/annals.1410.081. PMC 2693284. PMID 19120142.
  24. Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
  25. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG (October 2014). "Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project". J. Clin. Oncol. 32 (28): 3169–76. doi:10.1200/JCO.2014.56.1621. PMC 4171360. PMID 25154816.
  26. Bordbar M, Tasbihi M, Kamfiroozi R, Haghpanah S (2014). "Epidemiological and clinical characteristics of neuroblastoma in southern iran". Iran J Ped Hematol Oncol. 4 (3): 89–96. PMC 4173027. PMID 25254086.
  27. Skoura E, Oikonomopoulos G, Vasileiou S, Kyprianou D, Koumakis G, Datseris IE (2014). "(18)F-FDG-PET/CT, (123)I-MIBG and (99m)Tc-MDP whole-body scans, in detecting recurrence of an adult adrenal neuroblastoma". Hell J Nucl Med. 17 (1): 58–61. doi:10.1967/s002449910116. PMID 24563879.
  28. Mylonas KS, Schizas D, Economopoulos KP (October 2017). "Adrenal ganglioneuroma: What you need to know". World J Clin Cases. 5 (10): 373–377. doi:10.12998/wjcc.v5.i10.373. PMC 5648998. PMID 29085827.
  29. Adas M, Koc B, Adas G, Ozulker F, Aydin T (April 2014). "Ganglioneuroma presenting as an adrenal incidentaloma: a case report". J Med Case Rep. 8: 131. doi:10.1186/1752-1947-8-131. PMC 4031973. PMID 24779851.
  30. Li J, Yang CH, Li LM (April 2013). "Diagnosis and treatment of 29 cases of adrenal ganglioneuroma". Eur Rev Med Pharmacol Sci. 17 (8): 1110–3. PMID 23661526.
  31. Lam KY, Lo CY (September 2001). "Adrenal lipomatous tumours: a 30 year clinicopathological experience at a single institution". J. Clin. Pathol. 54 (9): 707–12. PMC 1731508. PMID 11533079.
  32. Gershuni VM, Bittner JG, Moley JF, Brunt LM (January 2014). "Adrenal myelolipoma: operative indications and outcomes". J Laparoendosc Adv Surg Tech A. 24 (1): 8–12. doi:10.1089/lap.2013.0411. PMC 3931430. PMID 24328509.
  33. Luo J, Chen L, Wen Q, Xu L, Chu S, Wang W, Alnemah MM, Fan S (2015). "Lipoadenoma of the adrenal gland: report of a rare entity and review of literature". Int J Clin Exp Pathol. 8 (8): 9693–7. PMC 4583971. PMID 26464739.
  34. Rodríguez-Gutiérrez R, Rendon A, Barrera-Sánchez M, Carlos-Reyna KE, Álvarez-Villalobos NA, González-Saldivar G, González-González JG (2016). "Multidrug-Resistant Tuberculosis and Its Association with Adrenal Insufficiency: Assessment with the Low-Dose ACTH Stimulation Test". Int J Endocrinol. 2016: 9051865. doi:10.1155/2016/9051865. PMC 4781954. PMID 27006656.
  35. Haddara WM, van Uum SH (September 2004). "TB and adrenal insufficiency". CMAJ. 171 (7): 710, author reply 710–1. doi:10.1503/cmaj.1041046. PMC 517840. PMID 15451821.
  36. Huang YC, Tang YL, Zhang XM, Zeng NL, Li R, Chen TW (October 2015). "Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status". World J Radiol. 7 (10): 336–42. doi:10.4329/wjr.v7.i10.336. PMC 4620114. PMID 26516430.
  37. Vinnard C, Blumberg EA (January 2017). "Endocrine and Metabolic Aspects of Tuberculosis". Microbiol Spectr. 5 (1). doi:10.1128/microbiolspec.TNMI7-0035-2016. PMID 28233510.
  38. Rajasekharan C, Ajithkumar S, Anto V, Parvathy R (May 2013). "Extrapulmonary disseminated tuberculosis with tuberculous adrenalitis: a stitch in time saves nine". BMJ Case Rep. 2013. doi:10.1136/bcr-2012-008011. PMID 23687365.
  39. Rog CJ, Rosen DG, Gannon FH (December 2016). "Bilateral adrenal histoplasmosis in an immunocompetent man from Texas". Med Mycol Case Rep. 14: 4–7. doi:10.1016/j.mmcr.2016.11.006. PMC 5154969. PMID 27995051.
  40. Wahab NA, Mohd R, Zainudin S, Kamaruddin NA (2013). "Adrenal involvement in histoplasmosis". EXCLI J. 12: 1–4. PMC 4817423. PMID 27047312.
  41. May D, Khaled D, Gills J (July 2018). "Unilateral adrenal histoplasmosis". Urol Case Rep. 19: 54–56. doi:10.1016/j.eucr.2018.03.010. PMC 5991316. PMID 29888193.
  42. Gupta RK, Majumdar K, Srivastava S, Varakanahalli S, Saran RK (2018). "Endoscopic Ultrasound-guided Cytodiagnosis of Adrenal Histoplasmosis with Reversible CD4 T-Lymphocytopenia and Jejunal Lymphangiectasia". J Cytol. 35 (2): 110–113. doi:10.4103/JOC.JOC_234_15. PMC 5885598. PMID 29643659.
  43. Padma S, Sreehar S (May 2014). "18F FDG PET/CT identifies unsuspected bilateral adrenal histoplasmosis in an elderly immuno compromised patient". Indian J. Med. Res. 139 (5): 786–7. PMC 4140048. PMID 25027093.
  44. Carsote M, Ghemigian A, Terzea D, Gheorghisan-Galateanu AA, Valea A (2017). "Cystic adrenal lesions: focus on pediatric population (a review)". Clujul Med. 90 (1): 5–12. doi:10.15386/cjmed-677. PMID 28246490.
  45. Słapa RZ, Jakubowski WS, Dobruch-Sobczak K, Kasperlik-Załuska AA (December 2015). "Standards of ultrasound imaging of the adrenal glands". J Ultrason. 15 (63): 377–87. doi:10.15557/JoU.2015.0035. PMC 4710689. PMID 26807295.
  46. Olaoye IO, Adesina MD, Afolayan EA (June 2018). "A giant adrenal cyst with an uncertain preoperative diagnosis causing a dilemma in management". Clin Case Rep. 6 (6): 1074–1076. doi:10.1002/ccr3.1519. PMC 5986023. PMID 29881567.
  47. Hamilton D, Harris MD, Foweraker J, Gresham GA (February 2004). "Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection". J. Clin. Pathol. 57 (2): 208–9. PMC 1770213. PMID 14747454.
  48. Di Serafino M, Severino R, Coppola V, Gioioso M, Rocca R, Lisanti F, Scarano E (September 2017). "Nontraumatic adrenal hemorrhage: the adrenal stress". Radiol Case Rep. 12 (3): 483–487. doi:10.1016/j.radcr.2017.03.020. PMC 5551907. PMID 28828107.
  49. Ierardi AM, Petrillo M, Patella F, Biondetti P, Fumarola EM, Angileri SA, Pesapane F, Pinto A, Dionigi G, Carrafiello G (April 2018). "Interventional radiology of the adrenal glands: current status". Gland Surg. 7 (2): 147–165. doi:10.21037/gs.2018.01.04. PMC 5938278. PMID 29770310.
  50. Alhajri K, Alhasan I, Alzerwi N, Abudaff N (April 2011). "Adrenal haemangioma". BMJ Case Rep. 2011. doi:10.1136/bcr.12.2010.3604. PMC 3079485. PMID 22701011.
  51. Iwamoto G, Shimokihara K, Kawahara T, Takamoto D, Yao M, Teranishi JI, Otani M, Uemura H (2018). "Adrenal Hemangioma: A Case of Retroperitoneal Tumor". Case Rep Med. 2018: 8796327. doi:10.1155/2018/8796327. PMC 5836307. PMID 29560018.
  52. Tarchouli M, Boudhas A, Ratbi MB, Essarghini M, Njoumi N, Sair K, Zentar A (2015). "Giant adrenal hemangioma: Unusual cause of huge abdominal mass". Can Urol Assoc J. 9 (11–12): E834–6. doi:10.5489/cuaj.2967. PMC 4639440. PMID 26600897.
  53. Harada K, Kimura K, Iwamuro M, Terasaka T, Hanayama Y, Kondo E, Hayashi E, Yoshino T, Otsuka F (September 2017). "The Clinical and Hormonal Characteristics of Primary Adrenal Lymphomas: The Necessity of Early Detection of Adrenal Insufficiency". Intern. Med. 56 (17): 2261–2269. doi:10.2169/internalmedicine.8216-16. PMC 5635296. PMID 28794358.
  54. Laurent C, Casasnovas O, Martin L, Chauchet A, Ghesquieres H, Aussedat G, Fornecker LM, Bologna S, Borot S, Laurent K, Bouillet B, Verges B, Petit JM (February 2017). "Adrenal lymphoma: presentation, management and prognosis". QJM. 110 (2): 103–109. doi:10.1093/qjmed/hcw174. PMID 27795295.
  55. Karimi F (October 2017). "Primary Adrenal Lymphoma Presenting with Adrenal Failure: A Case Report and Review of the Literature". Int J Endocrinol Metab. 15 (4): e12014. doi:10.5812/ijem.12014. PMC 5750783. PMID 29344029.
  56. Michalopoulos N, Laskou S, Karayannopoulou G, Pavlidis L, Kanellos I (December 2015). "Adrenal Gland Lymphangiomas". Indian J Surg. 77 (Suppl 3): 1334–42. doi:10.1007/s12262-015-1206-y. PMC 4775622. PMID 27011561.
  57. Zhao M, Gu Q, Li C, Yu J, Qi H (2014). "Cystic lymphangioma of adrenal gland: a clinicopathological study of 3 cases and review of literature". Int J Clin Exp Pathol. 7 (8): 5051–6. PMC 4152068. PMID 25197378.
  58. Joliat GR, Melloul E, Djafarrian R, Schmidt S, Fontanella S, Yan P, Demartines N, Halkic N (February 2015). "Cystic lymphangioma of the adrenal gland: report of a case and review of the literature". World J Surg Oncol. 13: 58. doi:10.1186/s12957-015-0490-0. PMC 4335415. PMID 25889625.
  59. Ramakant P, Rana C, Singh KR, Mishra A (2018). "Primary adrenal teratoma: An unusual tumor - Challenges in diagnosis and surgical management". J Postgrad Med. 64 (2): 112–114. doi:10.4103/jpgm.JPGM_588_16. PMC 5954807. PMID 29067922.
  60. Li S, Li H, Ji Z, Yan W, Zhang Y (November 2015). "Primary adrenal teratoma: Clinical characteristics and retroperitoneal laparoscopic resection in five adults". Oncol Lett. 10 (5): 2865–2870. doi:10.3892/ol.2015.3701. PMC 4665718. PMID 26722254.
  61. Zhou L, Pan X, He T, Lai Y, Li W, Hu Y, Ni L, Yang S, Chen Y, Lai Y (October 2018). "Primary adrenal teratoma: A case series and review of the literature". Mol Clin Oncol. 9 (4): 437–442. doi:10.3892/mco.2018.1687. PMC 6125700. PMID 30214733.
  62. Karanikiotis C, Tentes AA, Markakidis S, Vafiadis K (November 2004). "Large bilateral adrenal metastases in non-small cell lung cancer". World J Surg Oncol. 2: 37. doi:10.1186/1477-7819-2-37. PMC 535544. PMID 15541184.
  63. ABRAMS HL, SPIRO R, GOLDSTEIN N (January 1950). "Metastases in carcinoma; analysis of 1000 autopsied cases". Cancer. 3 (1): 74–85. PMID 15405683.
  64. Gerber E, Dinlenc C, Wagner JR (2004). "Laparoscopic adrenalectomy for isolated adrenal metastasis". JSLS. 8 (4): 314–9. PMC 3016821. PMID 15554272.
  65. Vaughan ED (September 1998). "Diagnosis and management of surgical adrenal disorders". Int. J. Urol. 5 (5): 401–17. PMID 9781426.